0001144204-15-028236.txt : 20150507 0001144204-15-028236.hdr.sgml : 20150507 20150507122351 ACCESSION NUMBER: 0001144204-15-028236 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150331 FILED AS OF DATE: 20150507 DATE AS OF CHANGE: 20150507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPROS THERAPEUTICS INC. CENTRAL INDEX KEY: 0000897075 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 760233274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-15281 FILM NUMBER: 15840429 BUSINESS ADDRESS: STREET 1: 2408 TIMBERLOCH PL STREET 2: SUITE B-7 CITY: WOODLANDS STATE: TX ZIP: 77380 BUSINESS PHONE: 2817193400 MAIL ADDRESS: STREET 1: 2408 TIMBERLOCH PLACE B-7 CITY: THE WOODLANDS STATE: TX ZIP: 77380 FORMER COMPANY: FORMER CONFORMED NAME: REPROS THERAPEUTICS INC DATE OF NAME CHANGE: 20060503 FORMER COMPANY: FORMER CONFORMED NAME: ZONAGEN INC DATE OF NAME CHANGE: 19930208 10-Q 1 v408247_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2015

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission file number: 001-15281

REPROS THERAPEUTICS INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	2408 Timberloch Place, Suite B-7	76-0233274
(State or other jurisdiction of	The Woodlands, Texas 77380	(IRS Employer
incorporation or	(Address of principal executive offices	Identification No.)
organization)	and zip code)

	(281) 719-3400
	(Registrant's telephone number,
	including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or smaller reporting company. See definition of "accelerated filer", "large accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨ Accelerated filer x Non-accelerated filer ¨ Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of May 1, 2015, there were outstanding 24,276,173 shares of Common Stock, par value $.001 per share, of the Registrant.

REPROS THERAPEUTICS INC.

For the Quarter Ended March 31, 2015

INDEX

		Page
FACTORS AFFECTING FORWARD-LOOKING STATEMENTS		3

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements (unaudited)	4

Unaudited Condensed Consolidated Balance Sheets as of March 31, 2015 and December 31, 2014		5
Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2015 and 2014		6
Unaudited Condensed Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2015 and 2014		7
Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2015 and 2014		8
Notes to Unaudited Condensed Consolidated Financial Statements		9
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24
Item 4.	Controls and Procedures	24

PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	25
Item 1A.	Risk Factors	25
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25
Item 3.	Defaults Upon Senior Securities	25
Item 4.	Mine Safety Disclosures	25
Item 5.	Other Information	25
Item 6.	Exhibits	25

SIGNATURES		27

FACTORS AFFECTING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "may," "anticipate," "believe," "expect," "estimate," "project," "suggest," "intend" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, expected, estimated, projected, suggested or intended. These risks and uncertainties include risks associated with the progress of the Company’s New Drug Application, or NDA, for its enclomiphene product candidate and the review of the NDA by the Food and Drug Administration, or FDA; the success of the clinical trials for Proellex®; uncertainty related to the Company's ability to obtain approval of the Company's products by the FDA and regulatory bodies in other jurisdictions; uncertainty relating to the Company's patent portfolio; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission. For additional discussion of such risks, uncertainties and assumptions, see "Part I. Financial Information - Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources" included elsewhere in this quarterly report on Form 10-Q and “Item 1A. Risk Factors” to Part I of Form 10-K for the fiscal year ended December 31, 2014.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

The following unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (which include only normal recurring adjustments) considered necessary for a fair statement of the interim periods presented have been included. The year-end balance sheet data was derived from audited financial statements, but does not include all the disclosures required by accounting principles generally accepted in the United States of America. Operating results for the three month period ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. For further information, refer to the financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited and in thousands except share and per share amounts)

	March 31,			December 31,
	2015			2014

ASSETS

Current Assets
Cash and cash equivalents	$	37,875		$	46,620
Prepaid expenses and other current assets		569			289
Total current assets		38,444			46,909
Fixed assets, net		22			32
Total assets	$	38,466		$	46,941

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities
Accounts payable	$	1,159		$	2,090
Accrued expenses		793			834
Total current liabilities		1,952			2,924

Commitments & Contingencies (note 6)

Stockholders' Equity
Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding		-			-
Common Stock, $.001 par value, 75,000,000 shares authorized, 24,388,523 shares issued; 24,276,173 shares outstanding		24			24
Additional paid-in capital		319,459			318,437
Cost of treasury stock, 112,350 shares		(1,380	)		(1,380	)
Accumulated deficit		(281,589	)		(273,064	)
Total stockholders' equity		36,514			44,017
Total liabilities and stockholders' equity	$	38,466		$	46,941

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited and in thousands except per share amounts)

	Three Months Ended March 31,
	2015			2014

Revenues and other income
Interest income	$	1		$	2
Total revenues and other income		1			2
Expenses
Research and development		7,321			7,569
General and administrative		1,205			1,226
Total expenses		8,526			8,795
Net loss	$	(8,525	)	$	(8,793	)

Loss per share - basic and diluted	$	(0.35	)	$	(0.38	)

Shares used in loss per share calculation:
Basic		24,276			23,033
Diluted		24,276			23,033

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(unaudited and in thousands except share and per share amounts)



					Additional										Total
	Common Stock				Paid-in		Treasury Stock					Accumulated			Stockholders'
	Shares		Amount		Capital		Shares		Amount			Deficit			Equity
Balance at December 31, 2014		24,388,523	$	24	$	318,437		112,350	$	(1,380	)	$	(273,064	)	$	44,017
Stock based compensation		-		-		1,022		-		-			-			1,022
Net loss		-		-		-		-		-			(8,525	)		(8,525	)
Balance at March 31, 2015		24,388,523	$	24	$	319,459		112,350	$	(1,380	)	$	(281,589	)	$	36,514

Balance at December 31, 2013		23,125,565	$	23	$	314,405		112,350	$	(1,380	)	$	(240,529	)	$	72,519
Stock based compensation		-		-		920		-		-			-			920
Issuance of 69,197 shares of common stock for the cashless exercise of 91,664 stock options		69,197		-		-		-		-			-			-
Exercise of stock options to purchase common stock stock for cash ($1.56 to $9.60 per share)		15,000		-		104		-		-			-			104
Net loss		-		-		-		-		-			(8,793	)		(8,793	)
Balance at March 31, 2014		23,209,762	$	23	$	315,429		112,350	$	(1,380	)	$	(249,322	)	$	64,750

The accompanying notes are an integral part of these consolidated financial statements.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited and in thousands)

	Three Months Ended March 31,
	2015			2014

Cash Flows from Operating Activities
Net loss	$	(8,525	)	$	(8,793	)
Depreciation		10			11
Noncash stock-based compensation		1,022			920
(Increase) decrease in prepaid expenses and other current assets		(382	)		(393	)
Increase (decrease) in accounts payable and accrued expenses		(972	)		356
Net cash used in operating activities		(8,847	)		(7,899	)

Cash Flows from Investing Activities
Capital expenditures		-			-
Net cash used in investing activities		-			-

Cash Flows from Financing Activities
Exercise of stock options & warrants		-			104
Proceeds from a shareholder transaction		102			-
Net cash provided by financing activities		102			104
Net decrease in cash and cash equivalents		(8,745	)		(7,795	)
Cash and cash equivalents at beginning of period		46,620			75,807
Cash and cash equivalents at end of period	$	37,875		$	68,012

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2015

(Unaudited)

NOTE 1 — Organization, Operations and Liquidity

Repros Therapeutics Inc. (the “Company,” “RPRX,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

Our enclomiphene product candidate, formerly known as Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. We expect to rename this product candidate in the near future. We are developing enclomiphene for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. Enclomiphene is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism. The Company believes that secondary hypogonadism due to being overweight or obese is the single greatest cause of hypogonadism in general. On February 2, 2015, we announced that we electronically submitted our New Drug Application (“NDA”) to the Food and Drug Administration (“FDA”) for enclomiphene. Subsequently, we announced that the NDA was accepted by the FDA and the FDA assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of November 30, 2015. In addition, the FDA has informed the Company that they plan to hold an advisory committee meeting during the review.

Our product development pipeline, with dates as expected as of the date of this report, is summarized in the table below:

Product Candidate (Indication) Enclomiphene	Status	Next Expected Milestone(s)
Secondary Hypogonadism	NDA accepted and under review	PDUFA date of November 30, 2015
Proellex®
Uterine Fibroids	Phase 2	Complete first course of treatment in a Phase 2B study (oral delivery) (YE 2015) Complete first course of treatment in a Phase 2B study (vaginal delivery) (YE 2015)
Endometriosis	Phase 2	Fully enroll Phase 2 study (oral delivery) (YE 2015)

As of March 31, 2015, we had accumulated losses of $281.6 million, approximately $37.9 million in cash and cash equivalents, and accounts payable and accrued expenses of approximately $2.0 million, in the aggregate. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates into the second half of 2016. We continue to explore potential corporate partnering opportunities for assistance in the clinical development funding and commercialization of our products, as appropriate; however, there can be no assurance that an acceptable corporate partnering opportunity will be successfully completed or that our current liquidity will be sufficient to fund all of our product development needs.

NOTE 2 — Revision of Prior Years’ Financial Statements

While preparing its financial statements for the year ended December 31, 2014, the Company identified a prior period error related to the accounting for patent costs. As disclosed in its prior filings, historically the Company had capitalized patent related costs associated with its drug candidates, enclomiphene and Proellex®. However, the Company has now concluded that these costs should have been expensed as research and development costs since the related products were, at the time the costs were incurred, in the development phase and had not been approved by the FDA. The Company concluded this error was not material individually or in the aggregate to any of the prior reporting periods, and therefore, no restatements of previously issued financial statements were necessary. However, if the entire correction had been recorded in the fourth quarter of 2014, the cumulative impact would have been material to the fourth quarter of 2014, and would have impacted the comparability to prior periods. As such, revisions for the prior periods are reflected in the financial statements herein. The quarter ended March 31, 2015 was not affected.

At December 31, 2013, accumulated deficit and shareholders’ equity were reported as ($237,623) and $75,425, respectively, and were revised to ($240,529) and $72,519, respectively.

The effects of the error correction on the consolidated statements of operations for the three month period ended March 31, 2014 are as follows (in thousands):

	Three months ended March 31, 2014
	As previously reported			Correction			As revised
Research and development	$	7,325		$	244		$	7,569
Total expenses		8,551			244			8,795
Net loss		(8,549	)		(244	)		(8,793	)
Loss per share – basic and diluted		(0.37	)		(0.01	)		(0.38	)

The effects of the error correction on the consolidated statements of cash flows for the three month period ended March 31, 2014 are as follows (in thousands):

	Three months ended March 31, 2014
	As previously reported			Correction			As revised
Net cash used in operating activities	$	(7,614	)	$	(285	)	$	(7,899	)
Net cash used in investing activities		(285	)		285			(0	)

NOTE 3 — Accrued Expenses

Accrued expenses consist of the following (in thousands):

	March 31, 2015		December 31, 2014

Research and development costs	$	654	$	284
Personnel related costs		63		458
Other		76		92
Total	$	793	$	834

NOTE 4 — Loss Per Share

Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed using the average share price for the period and applying the treasury stock method to potentially dilutive outstanding options. In all applicable periods, all potential common stock equivalents were anti-dilutive and, accordingly, were not included in the computation of diluted loss per share.

The following table presents information necessary to calculate loss per share for the three month periods ended March 31, 2015 and 2014 (in thousands, except per share amounts):

	Three Months Ended March 31,
	2015			2014

Net loss	$	(8,525	)	$	(8,793	)
Average common shares outstanding		24,276			23,033
Basic and diluted loss per share	$	(0.35	)	$	(0.38	)

Potential common stock of 3,274,157 and 4,086,885 common shares underlying stock options and warrants for the periods ended March 31, 2015 and 2014, respectively, were excluded from the above calculation of diluted loss per share because they were anti-dilutive. Other potential common stock at March 31, 2015 includes Series A Warrants to purchase 39,595 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 429,704 shares of our common stock at an exercise price of $2.49 issued in our February 8, 2011 public offering. Other potential common stock at March 31, 2014 includes Series A Warrants to purchase 877,137 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 809,805 shares of our common stock at an exercise price of $2.49 issued in our February 8, 2011 public offering.

NOTE 5 – Stock-Based Compensation

During the three month period ended March 31, 2015, the Compensation Committee of the Company’s Board of Directors approved grants of options to purchase 369,000 shares of our common stock to certain employees and directors under the 2011 Equity Incentive Plan. All of these options vest in equal annual installments on the first three year anniversaries of the date of grant. Additionally, during the three month period ended March 31, 2015, 5,000 options either expired or were forfeited.

NOTE 6 — Commitments and Contingencies

Therapeutic uses of our enclomiphene product candidate are covered in the United States by nine issued U.S. patents and nine pending patent applications. Foreign coverage of therapeutic uses of our enclomiphene product candidate includes 76 issued foreign patents and 99 foreign pending patent applications. The issued patents and pending applications relate to methods for treating certain conditions including the treatment of testosterone deficiency in men, the treatment of diabetes mellitus Type 2, the treatment of metabolic syndrome and conditions associated therewith, and the treatment of infertility in hypogonadal men. Enclomiphene (the trans-isomer of clomiphene) is purified from clomiphene citrate. A third party individual holds two issued patents related to the use of anti-estrogen such as clomiphene citrate and others for use in the treatment of androgen deficiency and disorders related thereto. We requested re-examination of one of these patents by the U.S. Patent and Trademark Office (“PTO”) based on prior art. The patent holder amended the claims in the re-examination proceedings, which led the PTO to determine that the amended claims were patentable in view of those publications under consideration and a re-examination certificate was issued. We subsequently filed a second request for re-examination by the PTO in light of a number of additional publications. The request was granted and all of the claims were finally rejected by the PTO in the re-examination. The patent holder appealed the rejections to the PTO Board of Patent Appeals and Interferences (the “PTO Board”) which ultimately reversed the rejections of several dependent claims in view of those publications under consideration. The patent holder filed a Notice of Appeal to the Federal Circuit on September 28, 2010 contesting the rejections maintained by the PTO Board. A decision was rendered by the Court of Appeals for the Federal Circuit on December 12, 2011, affirming the rejection of the appealed claims. The PTO issued an Ex Parte Reexamination Certificate on April 29, 2013, canceling the rejected claims and confirming the patentability of the remaining claims. Nevertheless, we believe that our development of enclomiphene does not infringe any of the remaining claims and that all of the remaining claims are invalid on various grounds including additional prior art publications. We also believe that the second of these two patents is invalid in view of published prior art not considered by the PTO. If necessary, we intend to vigorously defend any and all claims that may be brought by the holder of such patents in a court of competent jurisdiction in order to develop enclomiphene further. Adverse determinations in litigation proceedings could require us to seek licenses which may not be available on commercially reasonable terms, or at all, or subject us to significant liabilities, in which case we may not be able to successfully commercialize or out-license enclomiphene until such patents expire or are otherwise no longer in force.

On July 19, 2013, we received a letter from Dr. Harry Fisch threatening to file a lawsuit against us and two of our executive officers (Joseph S. Podolski, President and Chief Executive Officer and Ron Wiehle, Executive Vice President), seeking addition of Dr. Harry Fisch as an inventor on three of our patents, U.S. Patent Nos. 7,173,064, 7,737,185 and 7,759,360, covering therapeutic uses of enclomiphene. We believe that these allegations are without merit and on August 2, 2013, we commenced a lawsuit against Dr. Fisch in the U.S. District Court for the Southern District of Texas seeking a declaratory judgment that he should not be added as inventor to any of these patents. On October 2, 2013, Dr. Fisch filed counterclaims to our complaint seeking correction of inventorship of the three patents at issue to name Dr. Fisch as a co-inventor of the applications leading to these patents. Dr. Fisch subsequently stipulated that he does not claim to be a co-inventor of U.S. Patent No. 7,173,064. The court granted summary judgment in favor of the Company on separate equitable and legal grounds, and entered judgment on December 23, 2014. Our request for attorney’s fees was denied. On February 9, 2015, Dr. Fisch filed a notice of appeal of the summary judgment rulings to the United States Court of Appeals for the Federal Circuit.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") that involve risk and uncertainties. Any statements contained in this quarterly report that are not statements of historical fact may be forward-looking statements. When we use the words "may," "anticipates," "believes," "plans," "expects" and similar expressions, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. The following discussion of financial condition should be read in conjunction with the accompanying consolidated financial statements and related notes.

Repros Therapeutics Inc.

The Company was organized on August 20, 1987. We are a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

We are developing enclomiphene, formerly known as Androxal®, a single isomer of clomiphene citrate which is an orally active proprietary small molecule compound. The Food and Drug Administration (the “FDA”) rejected the proprietary name of Androxal® because it evokes the word “androgen”, which is a male sex hormone and enclomiphene is not an androgen. The Company expects to rename this product candidate in the near future. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. Enclomiphene is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism. The Company believes that secondary hypogonadism due to being overweight or obese is the single greatest cause of hypogonadism in general. As of 2013, sales of preparations for the treatment of low testosterone have exceeded $2 billion in the U.S. and first tier pharmaceutical companies have entered the low testosterone marketplace.

In December 2011, we completed a Phase 2B study of enclomiphene in men with secondary hypogonadism, but naïve to testosterone treatment, at the recommendation of the FDA. Top line results of this study demonstrated that enclomiphene was generally well tolerated compared to placebo and that there were no drug related serious adverse events that led to discontinuation. We met with the FDA in May 2012 to discuss the design of pivotal Phase 3 efficacy studies for enclomiphene as well as the components of the overall drug development program required for a New Drug Application (“NDA”) submission and agreed on registration requirements for enclomiphene oral therapy for the treatment of secondary hypogonadism. In July 2012, we announced that we reached an agreement with the FDA for the design of the pivotal efficacy studies for enclomiphene for the treatment of secondary hypogonadism. The pivotal studies were conducted under a Special Protocol Assessment (“SPA”). We have completed both Phase 3 pivotal efficacy studies. On March 27, 2013, we announced that the top-line results from our first pivotal Phase 3 study, ZA-301, met both co-primary endpoints mandated by the FDA, and we announced on September 16, 2013, that we met both co-primary endpoints in the second pivotal study, ZA-302. Additionally, on September 16, 2013, we announced the results from ZA-300, a six-month safety study. This study identified no new safety issues. On October 22, 2013, we announced that we received guidance from the FDA instructing the Company to request a meeting to discuss the adequacy of studies ZA-301 and ZA-302. In addition to this guidance, the FDA further noted that they would allow us to run head-to-head studies against approved testosterone replacement products. These head-to-head studies, ZA-304 and ZA-305, were initiated in January 2014 and subsequently completed in September and August 2014, respectively. Both of these head-to-head studies achieved superiority for both co-primary endpoints and most secondary endpoints as compared to the approved testosterone replacement product. On October 21, 2014, we announced the results from ZA-303, a 52 week, single-blind, placebo-controlled Phase 3 study to evaluate the effects on bone mineral density. In this study, no new safety signals were identified, including no evidence of negative effects on bone mineral density. On February 2, 2015, we announced that we electronically submitted our NDA to the FDA for enclomiphene. Subsequently, we announced that the NDA was accepted by the FDA and the FDA assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of November 30, 2015. In addition, the FDA has informed the Company that they plan to hold an advisory committee meeting during the review. In conjunction with the review process and the advisory committee meeting, we plan to respond to any questions or issues raised by the FDA. The NDA includes a collection of data on safety and efficacy from over 20 studies, including four Phase 3 efficacy studies. Regardless of the outcome of the advisory committee meeting, there can be no assurance that the FDA will approve our enclomiphene product candidate.

We are also developing Proellex®, an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Uterine fibroids and endometriosis affect millions of women of reproductive age. Proellex® has shown statistically significant results in previous Phase 2 studies for endometriosis and uterine fibroids. We completed a low dose escalating study as permitted by the FDA in late 2011, to determine both signals of efficacy and safety for low oral doses of the drug. There was no evidence of elevations of liver enzymes over baseline, suggesting these lower doses avoid the type of adverse events seen at much higher doses in earlier studies. On October 8, 2012, we announced that the FDA has agreed to a reclassification of the full clinical hold to a partial clinical hold on low dose oral Proellex® to allow us to conduct a Phase 2 study in the treatment of endometriosis. We initiated this study in November 2012. To date, we have experienced difficulty enrolling subjects into this study due to changes in the current treatment of this disorder. We believe we can have this study full enrolled in 2015.

On October 31, 2013, the Company held a meeting with the FDA to discuss the clinical development plan for low dose oral Proellex® in the treatment of uterine fibroids. During the meeting, the FDA provided guidance for endpoints it believed acceptable for the treatment of uterine fibroids in an efficacy study and instructed the Company to submit a request for lifting the full clinical hold. The Company has followed the FDA’s recommendations and submitted the study protocol and the request for the full hold lift. Additionally, on March 17, 2014, we announced that the FDA indicated that we may proceed to conduct Phase 1 and Phase 2 studies of low dose oral Proellex® for endometriosis and uterine fibroids while remaining on partial clinical hold. This guidance indicated that the highest allowed dose will be 12 mg daily. On December 29, 2014, we announced that we have initiated a Phase 2B study for low dose oral Proellex® in the treatment of uterine fibroids.

The Company has an active IND for the vaginal delivery of Proellex® for the treatment of uterine fibroids. Since the clinical hold relates only to oral delivery of Proellex®, this IND has no clinical hold issues. In the first quarter of 2012, we initiated a Phase 2 vaginal administration study for the treatment of uterine fibroids, and reported final study results in January 2013. We held an end of Phase 2 meeting with the FDA in May 2013, to discuss a Phase 3 study design for the vaginally delivered Proellex as a treatment for uterine fibroids. The FDA recommended that a Phase 2B study should be conducted prior to commencing a Phase 3 program. On December 29, 2014, we announced that we have initiated a Phase 2B study for vaginally delivered Proellex® in the treatment of uterine fibroids.

Our Research and Development Program

Our product development pipeline, with milestone dates as expected as of the date of this report, is summarized in the table below:

Product Candidate (Indication) Enclomiphene	Status	Next Expected Milestone(s)
Secondary Hypogonadism	NDA accepted and under review	PDUFA date of November 30, 2015
Proellex®
Uterine Fibroids	Phase 2	Complete first course of treatment in a Phase 2B study (oral delivery) (YE 2015) Complete first course of treatment in a Phase 2B study (vaginal delivery) (YE 2015)
Endometriosis	Phase 2	Fully enroll Phase 2 study (oral delivery) (YE 2015)

Enclomiphene

Product Overview

We are developing enclomiphene, formerly known as Androxal®, a single isomer of clomiphene citrate which is an orally active proprietary small molecule compound. The FDA rejected the proprietary name of Androxal® because it evokes the word “androgen”, which is a male sex hormone and enclomiphene is not an androgen. The Company expects to rename this product candidate in the near future. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. Enclomiphene is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism. The Company believes that secondary hypogonadism due to being overweight or obese is the single greatest cause of hypogonadism in general.

Testosterone is an important male hormone. Testosterone deficiency in men is linked to several negative physical and mental conditions, including loss of muscle tone, reduced sexual desire and deterioration of memory and certain other cognitive functions. Testosterone production normally decreases as men age and this decline can be accelerated by obesity, sometimes leading to testosterone deficiency. The leading therapy for low testosterone is AndroGel®, a commercially available testosterone replacement cream marketed by Abbott Laboratories (“Abbott”) for the treatment of low testosterone, which we believe has had and continues to have significant sales in North America.

Based on our own clinical trial screening data, we believe over 70% of men that have low testosterone suffer from secondary hypogonadism, a pituitary defect which is characterized by suboptimal levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone). LH and FSH are the pituitary hormones that stimulate testicular testosterone and sperm production, respectively. Men with secondary hypogonadism can be readily distinguished from those that have primary testicular failure via assessment of the levels of secretions of pituitary hormones, as men with primary testicular failure experience elevated secretions of pituitary hormones. In secondary hypogonadism, the low levels of LH and FSH fail to provide adequate hormone signaling to the testes, causing testosterone levels to drop to a level where we believe pituitary secretions fall under the influence of estrogen, which is enhanced in obese men, thus further suppressing the testicular stimulation from the pituitary.

Enclomiphene acts centrally to restore testicular function and, hence, normal testosterone in the body. The administration of exogenous testosterone can restore serum testosterone levels, but does not restore testicular function and thereby generally leads to the cessation of, or significant reduction in, sperm production. Enclomiphene, by contrast, restores levels of both LH and FSH, which stimulate testicular testosterone and sperm production, respectively.

Enclomiphene is in the midst of a full regulatory approval process, including pivotal Phase 3 trials, long-term open label safety studies and a dual-energy X-ray absorptiometry (DEXA) study, as well as other requirements. Enclomiphene is closely related chemically to the drug, Clomid®, which is approved for use in women to treat certain infertility disorders. Clomid® contains both the trans and cis isomers of clomiphene citrate; enclomiphene contains only the trans isomer. The FDA has indicated that testicular tumors, gynecomastia and adverse ophthalmologic events, which have been reported in males taking Clomid®, are potential risks that should be included in informed consent forms for our enclomiphene clinical trials. We do not believe that enclomiphene will present with the same adverse events given its reduced half-life and lack of cis isomer as compared to Clomid®. In our preclinical studies and our clinical trials to date, we have observed no evidence of any of these events except for certain ophthalmologic events in our preclinical dog study at doses significantly higher than those administered in the clinical trials. All clinical trial results are subject to review by the FDA and the FDA may disagree with our conclusions about safety and efficacy.

Treatment for Secondary Hypogonadism in Men Wishing to Preserve Testicular Function (Reproductive Status)

On November 8, 2010, we held a Type B meeting with the FDA to discuss whether the FDA would review our protocols for a Phase 3 trial of enclomiphene in men with secondary hypogonadism under an SPA. In the meeting, the FDA recommended that a Phase 2B study in men with secondary hypogonadism but naïve to testosterone treatment be conducted if we desired the protocols to be reviewed under an SPA. The FDA further opined that such Phase 2B study would provide for a more solid data base for design of Phase 3 studies and eventual approval of such studies under an SPA.

We completed the Phase 2B trial which consisted of four arms; placebo, two doses of enclomiphene and topical testosterone. In this study, at baseline the men exhibited morning testosterone less than 250 ng/dl and there was no statistical difference between the groups in testosterone at baseline. At the end of the three month dosing period, median morning testosterone levels were placebo (196 ng/dl), 12.5 mg enclomiphene (432 ng/dl), 25 mg enclomiphene (416 ng/dl) and Testim® (393 ng/dl). A comparison of final median morning testosterone in all three of the active arms to placebo showed them to be highly statistically different and there was no statistical difference observed between these active arms. This trial also showed that enclomiphene was able to maintain sperm counts in men being treated for their low testosterone levels, whereas Testim® resulted in suppressed sperm levels.

On July 9, 2012, we announced that we reached an agreement with the FDA for the design of the pivotal efficacy studies for enclomiphene for the treatment of secondary hypogonadism. The pivotal studies were conducted under an SPA. On March 27, 2013, we announced that the top-line results from our first pivotal Phase 3 study, ZA-301, met both co-primary endpoints mandated by the FDA and we announced on September 16, 2013, that we met both co-primary endpoints in the second pivotal study, ZA-302.

The 500 subject, six month, open label safety study, ZA-300, completed enrollment in February 2013 at 28 U.S. clinical sites. On September 16, 2013, we reported top-line results of this study. Additionally, we completed enrollment into a one year, 150 subject DEXA study, ZA-303, in January 2013 at 10 U.S. clinical sites. On October 21, 2014, we announced that this study identified no new safety signals, including no evidence of negative effects on bone mineral density.

On October 22, 2013, we announced that we received guidance from the FDA instructing the Company to request a meeting to discuss the adequacy of studies ZA-301 and ZA-302. In addition to this guidance, the FDA further noted they would allow us to run head-to-head studies against approved testosterone replacement products. These head-to-head studies, ZA-304 and ZA-305, were initiated in January 2014 and subsequently completed in September and August 2014, respectively. Both of these head-to-head studies achieved superiority for both co-primary endpoints and most secondary endpoints as compared to the approved testosterone replacement product.

On February 2, 2015, we announced that we electronically submitted our NDA to the FDA for enclomiphene. Subsequently, we announced that the NDA was accepted by the FDA and the FDA assigned a PDUFA goal date of November 30, 2015. In addition, the FDA has informed the Company that they plan to hold an advisory committee meeting during the review. In conjunction with the review process and advisory committee meeting, we plan to respond to any questions or issues raised by the FDA. The NDA includes a collection of data on safety and efficacy from over 20 studies, including four Phase 3 efficacy studies. Regardless of the outcome of the advisory committee meeting, there can be no assurance that the FDA will approve our enclomiphene product candidate.

Unlike testosterone replacement therapies, enclomiphene maintains the normal daily rhythm of testosterone peaks and valleys. We previously conducted three studies in which 24 hour testosterone levels were obtained and, unlike topical testosterone, morning testosterone was the maximum concentration observed, consistent with the normal circadian rhythm in men. These studies provide evidence that one assessment of testosterone between 8 a.m. and 10 a.m. correlates to the maximum value of testosterone for a given subject on a given day. Additionally, we conducted one additional 24-hour study which showed that enclomiphene’s action in maintaining the normal rhythm is both predictable and dose-dependent.

In addition, the Company continues to consider the potential for use of enclomiphene as an adjuvant therapy in hypogonadal men with Type 2 diabetes. The Company has an active IND open with the Division of Endocrine and Metabolic Products at the FDA for this indication. We believe there may be an association between the restoration of normal pituitary function and improvement of metabolic conditions such as Type 2 diabetes. Research has been published which demonstrates that increased insulin resistance, a characteristic implicated in Type 2 diabetes, is associated with the onset of secondary hypogonadism. Based on our own clinical trial screening data from our previously conducted Phase 2 study, we have found hypogonadism, obesity and Type 2 diabetes to be co-morbid conditions in a significant number of men. The results from this Phase 2 study indicated that the enclomiphene treated subjects showed statistically significant improvement in HbA1c and insulin, as well as HOMA-IR compared to placebo in men less than 65 years of age.

We believe the advantages of oral delivery, maintenance of testicular function and additional metabolic benefits, as an adjunct therapy to a program of diet and exercise, will be important differentiating factors for enclomiphene, should it be approved. There can be no assurance, however, that we will be successful in implementing this strategy or that the FDA will approve our drug for commercial use.

Proellex®

Product Overview

Proellex®, our product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. There are currently no FDA-approved orally administered drug treatments for the long-term treatment of either uterine fibroids or endometriosis. The National Uterine Fibroids Foundation estimates that 80% of all women in the U.S. have uterine fibroids, and one in four of these women have symptoms severe enough to require treatment. According to the Endometriosis Association, endometriosis affects 6.3 million women in the U.S. and Canada and millions more worldwide.

The current standards of care for uterine fibroids and endometriosis consist of surgery or short-term treatment with gonadotropin-releasing hormone (“GnRH”) agonists drugs, such as Lupron®. GnRH agonists induce a low estrogen, menopausal-like state and promote bone loss and are not recommended for use for more than six months.

We have conducted numerous studies with Proellex® dosing approximately 700 women with the drug. All Proellex® studies completed to date exhibited strong efficacy signals, whether in uterine fibroids or endometriosis. In a 120 patient study of Proellex® as a treatment of uterine fibroids conducted in the United States (roughly 40 subjects per arm), both a 12.5 and 25 mg dose of Proellex® were compared to placebo. In this study each of the 12.5 and 25 mg doses achieved highly statistically significant results when compared to placebo when menstrual bleeding was assessed (p<0.0001). The two doses also achieved highly statistically significant improvement in quality of life measures using the Uterine Fibroid Symptom Quality of Life questionnaire developed and validated by Georgetown University and used in the development of device like treatments of uterine fibroids such as uterine artery embolization. There was no statistical difference in efficacy measures between the two doses. Importantly, in the Phase 2 U.S. trial a significant percentage of women stopped menstruating. Proellex® resulted in the induction of amenorrhea (cessation of menses), which we believe is a strong surrogate signal of efficacy. Over 80% of women on both the 12.5 and 25 mg doses exhibited no menses during the three month trial, whereas all women on placebo exhibited at least one menses.

Up until the summer of 2009, all side effects exhibited in the studies were considered manageable and the benefit of Proellex® far outweighed the risk. However, in Phase 3 efficacy and larger Phase 3 safety studies in diverse populations, a small number of subjects exhibited serious adverse effects associated with elevated liver enzymes. As a result of these findings, we elected to stop the trials and the FDA subsequently placed Proellex® on full clinical hold. All women that experienced elevated liver enzymes and returned for follow-up visits returned to baseline conditions with no overnight hospitalization necessary. An analysis of all the subjects that experienced such serious adverse effects showed that the effect only occurred in a small percentage of subjects that were exposed to the 50 mg dose of the drug for any period of time. Based on these findings, we petitioned the FDA to allow us to conduct a low dose study to demonstrate both safety and signals of efficacy in low oral doses of Proellex®, up to 12 mg administered per day. The FDA upgraded the full clinical hold to a partial hold to allow the low dose study to be conducted. In addition, we are exploring vaginal delivery as an alternative administrative route to bypass first-pass liver effects and reduce systemic exposure, which is currently in a Phase 2 study.

Low Dose Oral

Pursuant to the terms of the partial clinical hold currently in place as a result of the liver toxicity exhibited by Proellex®, the FDA allowed us to run a single study to test low oral doses of Proellex® for signals of safety and efficacy. The study tested five different doses of Proellex® (1, 3, 6, 9 and 12 mg), with 1 mg being the first dose tested. Each dose was then compared to placebo with weekly assessments of liver function during both the placebo and drug period. Subjects were dosed with the active drug for 10 weeks, which allowed for adequate time to determine the impact of a given dose on trends in liver function. Each dose was tested in up to 12 different subjects and assessment of pharmacokinetic parameters was obtained at the start of dosing and the end of the dosing period to determine overall and maximum drug exposure for a given dose. We also monitored changes in menstrual bleeding patterns and ovulation as well as changes in endometrial thickness. The FDA required that an independent Drug Safety Monitoring Board be established and that the informed consent clearly state the liver toxicity previously experienced with Proellex®. We have completed this study and have announced that there was no evidence of elevations of liver enzymes over baseline, suggesting these lower doses avoid the type of adverse events seen at much higher doses in earlier studies.

On July 16, 2012, we announced that we held a teleconference with the FDA to discuss the development of low dose oral Proellex® as a treatment for endometriosis. Subsequently, on October 8, 2012, we announced that the FDA has agreed to reclassify the full clinical hold to a partial clinical hold on low dose oral Proellex® to allow us to conduct a Phase 2 study in the treatment of endometriosis. We initiated this 60 subject, four month active dosing study in November 2012. To date, we have experienced difficulty enrolling subjects into this study due to changes in the current treatment of this disorder. We believe we can have this study fully enrolled in 2015.

Vaginal Administration

We are assessing vaginal administration of Proellex® to avoid first pass liver effects and achieve higher reproductive tract concentrations of the drug while minimizing systemic exposure. We reported results from two in vivo animal studies which confirmed reduced maximum circulating concentrations of the drug when administered vaginally, as well as efficacy signals at substantially lower doses than oral administration. The Company has an active IND for the vaginal delivery of Proellex® for the treatment of uterine fibroids. Since the clinical hold relates only to the oral delivery of Proellex®, this IND has no clinical hold issues. In the first quarter of 2012, we initiated a Phase 2 vaginal administration study for the treatment of uterine fibroids. In January 2013, we reported the final study results which indicated the 12 mg dose achieved statistically significant improvement in menstrual bleeding, uterine fibroid symptoms and reduction in fibroid volume even with the low number of subjects enrolled into the study (n=12 @ 12 mg). Based on these findings, the Company believes the 12 mg dose is appropriate for further development. We held an end of Phase 2 meeting with the FDA in May 2013, to discuss a Phase 3 study design for the vaginally delivered Proellex as a treatment for uterine fibroids. The FDA recommended that a Phase 2B study should be conducted prior to commencing a Phase 3 program. On December 29, 2014, we announced that we have initiated a Phase 2B study for vaginally delivered Proellex® in the treatment of uterine fibroids.

Other Products

VASOMAX® has been on partial clinical hold in the U.S. since 1998, and no further development activities are planned.

Business Strategy

We plan to focus our clinical program on (i) conducting a Phase 2B study for low dose oral Proellex® in the treatment of uterine fibroids, (ii) conducting a Phase 2B vaginal administration study for Proellex® in the treatment of uterine fibroids and (iii) conducting a Phase 2 study for low dose oral Proellex® for the treatment of endometriosis. With respect to enclomiphene, on February 2, 2015, we reported that the NDA was electronically submitted to the FDA. Subsequently, we announced that the NDA was accepted by the FDA and the FDA assigned a PDUFA goal date of November 30, 2015. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates into the second half of 2016. Should we undertake additional strategies, such as commercialization, we will require additional capital prior to the time anticipated. In the normal course of business we continue to explore potential corporate partnering opportunities for assistance in the clinical development funding and commercialization of our products, as appropriate; however, there can be no assurance that an acceptable corporate partnering opportunity will be successfully completed or that our current liquidity will be sufficient to fund all of our product development needs.

Corporate Information

We were organized as a Delaware corporation in August 1987. Our principal executive offices are located at 2408 Timberloch Place, Suite B-7, The Woodlands, Texas, 77380, and our telephone number is (281) 719-3400. We maintain an internet website at www.reprosrx.com. The information on our website or any other website is not incorporated by reference into this quarterly report and does not constitute a part of this quarterly report. Our Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and all amendments to such reports are made available free of charge through the Investor Relations section of our website as soon as reasonably practicable after they have been filed or furnished with the Securities and Exchange Commission.

General

We have 26 full-time employees. We utilize the services of contract research organizations, contract manufacturers and various consultants to assist us in performing clinical and regulatory services for the clinical development of our products. We are substantially dependent on our various contract groups to adequately perform the activities required to obtain regulatory approval of our products.

We have accumulated net operating losses through March 31, 2015 and the value of the tax asset associated with these accumulated net operating losses may be substantially diminished in value due to various tax regulations, including change in control provisions in the tax code. Additionally, during 2013, the Company completed an analysis of its section 382 limit. Based on this analysis, the Company concluded that the amount of net operating loss (“NOL”) carryforwards and the credits available to offset taxable income is limited under section 382. See “Critical Accounting Policies and the Use of Estimates – Income Taxes,” below.

Losses have resulted principally from costs incurred in conducting clinical trials for our product candidates, in research and development activities related to efforts to develop our products and from the associated administrative costs required to support those efforts. There can be no assurance that we will be able to successfully complete the transition from a development stage company to the successful introduction of commercially viable products. Our ability to achieve profitability will depend on, among other things, successfully completing the clinical development of our products in a reasonable time frame and at a reasonable cost, obtaining regulatory approvals, establishing marketing, sales and manufacturing capabilities or collaborative arrangements with others that possess such capabilities, and, if applicable, continuing to raise sufficient funds to finance our activities. There can be no assurance that we will be able to achieve profitability.

Critical Accounting Policies and the Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Accrued Expenses

We estimate accrued expenses as part of our process of preparing financial statements. Examples of areas in which subjective judgments may be required include costs associated with services provided by contract organizations for clinical trials, preclinical development and manufacturing of clinical materials. We accrue for costs incurred as the services are being provided by monitoring the status of the trials or services provided and the invoices received from our external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the projected cost to treat a patient in our trials, and we recognize this cost over the estimated term of the study based on the number of patients enrolled in the trial on an ongoing basis, beginning with patient enrollment. As actual costs become known to us, we adjust our accruals. To date, our estimates have not differed significantly from the actual costs incurred. However, subsequent changes in estimates may result in a material change in our accruals, which could also materially affect our balance sheet and results of operations.

Research and Development Expenses

Research and development, or R&D, expenses include salaries and related employee expenses, contracted regulatory affairs activities, insurance coverage for clinical trials and prior product sales, contracted research and consulting fees, facility costs and internal research and development supplies. We expense research and development costs in the period they are incurred. These costs consist of direct and indirect costs associated with specific projects as well as fees paid to various entities that perform research on our behalf.

Stock-Based Compensation

We had one stock-based compensation plan at March 31, 2015, the 2011 Equity Incentive Plan. Accounting for stock-based compensation generally requires the recognition of the cost of employee services for stock-based compensation based on the grant date fair value of the equity or liability instruments issued. We use the Black-Scholes option pricing model to estimate the fair value of our stock options. Expected volatility is determined using historical volatilities based on historical stock prices for a period equal to the expected term. The expected volatility assumption is adjusted if future volatility is expected to vary from historical experience. The expected term of options represents the period of time that options granted are expected to be outstanding and falls between the options' vesting and contractual expiration dates. The risk-free interest rate is based on the yield at the date of grant of a zero-coupon U.S. Treasury bond whose maturity period equals the option's expected term.

Income Taxes

Our losses from inception to date have resulted principally from costs incurred in conducting clinical trials and in research and development activities related to efforts to develop our products and from the associated administrative costs required to support those efforts. We have recorded a deferred tax asset for our NOLs; however, as the Company has incurred losses since inception, and since there is no certainty of future profits, a valuation allowance has been provided in full on our deferred tax assets in the accompanying consolidated financial statements. Additionally, during 2013, the Company completed an analysis of its section 382 limit. Based on this analysis, the Company concluded that the amount of NOL carryforwards and the credits available to offset taxable income is limited under section 382. Accordingly, if the Company generates taxable income in any year in excess of its then annual limitation, the Company may be required to pay federal income taxes even though it has unexpired NOL carryforwards. Additionally, because U.S. tax laws limit the time during which NOLs and tax credit carryforwards may be applied against future taxable income and tax liabilities, the Company may not be able to take full advantage of its NOLs and tax credit carryforwards for federal income tax purposes. Future public and private stock placements may create additional limitations on the Company’s NOLs, credits and other tax attributes.

Recent Accounting Pronouncements

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, “Presentation of Financial Statements - Going Concern.” The new standard requires management to evaluate whether there are conditions or events that raise substantial doubt about an entity's ability to continue as a going concern for both annual and interim reporting periods. This guidance is effective for us for the fiscal year beginning January 1, 2016 and interim periods thereafter. The guidance is not expected to have a material impact on our consolidated financial statements.

In June 2014, the FASB issued Accounting Standards Update 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.” The guidance eliminates the definition of a development stage entity thereby removing the incremental financial reporting requirements from U.S. Generally Accepted Accounting Principles for development stage entities, primarily presentation of inception to date financial information. The provisions of the amendment is effective for annual reporting periods beginning after December 15, 2015. We elected to adopt ASU 2014-10 early and as an early adopter, we are no longer providing inception-to-date financial information in our consolidated financial statements.

In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to a customer at an amount reflecting the consideration it expects to receive in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. Additionally, this guidance requires improved disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. This standard was initially released as effective for fiscal years beginning after December 15, 2016; however, on April 1, 2015, the FASB proposed a deferral of the effective date of ASU 2014-09 by one year. The proposed deferral would result in ASU 2014-09 being effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company is currently monitoring the deferral and assessing the impact of the new standard on our consolidated financial statements.

Results of Operations

Comparison of the three month periods ended March 31, 2015 and 2014

Revenues and Other Income

Total revenues and other income decreased to $1,000 for the three month period ended March 31, 2015 as compared to $2,000 for the same period in the prior year. The decrease for the three month period ended March 31, 2015 as compared to the same period in the prior year was primarily due to decreased cash balances, resulting in decreased interest income.

Research and Development Expenses

R&D expenses include contracted services relating to our clinical product development activities which include preclinical studies, clinical trials, expenses associated with our patent portfolio, regulatory affairs, including FDA filing fees, and bulk manufacturing scale-up activities and bulk active ingredient purchases for preclinical and clinical trials primarily relating to our two products in clinical development, which are enclomiphene and Proellex®. Research and development expenses also include internal operating expenses relating to our general research and development activities. R&D expenses decreased 3%, or $248,000, to $7.3 million for the three month period ended March 31, 2015, as compared to $7.6 million for the same period in the prior year. Our primary R&D expenses for the three month periods ended March 31, 2015 and 2014 are shown in the following table (in thousands):

	Three months ended March 31,
Research and Development	2015		2014		Variance			Change (%)
Enclomiphene clinical development	$	4,070	$	4,999	$	(929	)		(19	)%
Proellex® clinical development		820		477		343			72	%
Payroll and benefits		1,292		1,065		227			21	%
Operating and occupancy		1,139		1,028		111			11	%
Total	$	7,321	$	7,569	$	(248	)		(3	)%

Operating and occupancy expense for the three month period ended March 31, 2014 has been revised. For a further description of the revisions, see Note 2 – “Revision of Prior Years’ Financial Statements” of the Notes to Condensed Consolidated Financial Statements.

R&D expenses related to the clinical development of enclomiphene decreased 19%, or approximately $929,000, for the three month period ended March 31, 2015 as compared to the prior year period, primarily due to the completion of all Phase 3 clinical trials, partially offset by the payment of $2.3 million to the FDA associated with the submission of our NDA for the product candidate. R&D expenses related to the clinical development of Proellex® increased 72%, or approximately $343,000, from the 2014 period to the 2015 period, due to increased expenses associated with our Phase 2B clinical trials for the treatment of uterine fibroids.

Payroll and benefits expenses increased 21%, or approximately $227,000, to $1.3 million for the three month period ended March 31, 2015 as compared to $1.1 million for the same period in the prior year. Included in payroll and benefits expense is a charge for non-cash stock-based compensation of $574,000 for the three month period ended March 31, 2015 as compared to $479,000 for the same period in the prior year. Additionally, salaries for the three month period ended March 31, 2015 were $579,000 as compared to $480,000 for the same period in the prior year.

Operating and occupancy expenses increased 11%, or approximately $111,000, to $1.1 million for the three month period ended March 31, 2015 as compared to $1.0 million for the same period in the prior year, primarily due to increased legal expenses.

To date through March 31, 2015 we have incurred approximately $64.4 million for the development of enclomiphene and approximately $63.6 million for the development of Proellex®. These accumulated costs exclude any internal operating expenses.

General and Administrative Expenses

General and administrative (“G&A”) expenses decreased 2%, or approximately $21,000, to $1.2 million for the three month period ended March 31, 2015 as compared to $1.2 million for the same period in the prior year. Our primary G&A expenses for the three month periods ended March 31, 2015 and 2014 are shown in the following table (in thousands):

	Three months ended March 31,
General and Administrative	2015		2014		Variance			Change (%)
Payroll and benefits	$	743	$	736	$	7			1	%
Operating and occupancy		462		490		(28	)		(6	)%
Total	$	1,205	$	1,226	$	(21	)		(2	)%

G&A payroll and benefits expenses include salaries, bonuses, non-cash stock-based compensation expense and fringe benefits. Included in payroll and benefits expense is a charge for non-cash stock-based compensation of $448,000 for the three month period ended March 31, 2015 as compared to $441,000 for the same period in the prior year. Additionally, salaries for the three month period ended March 31, 2015 were $255,000 as compared to $247,000 for the same period in the prior year.

G&A operating and occupancy expenses, which include expenses to operate as a public company, decreased 6%, or approximately $28,000, to $462,000 for the three month period ended March 31, 2015 as compared to $490,000 for the same period in the prior year primarily due to a decrease in legal expenses.

Off-Balance Sheet Arrangements

As of March 31, 2015, we did not have any off-balance sheet arrangements.

Liquidity and Capital Resources

Since our inception, we have financed our operations primarily with proceeds from private placements and public offerings of equity securities and with funds received under collaborative agreements.

Our primary use of cash to date has been in operating activities to fund research and development, including preclinical studies and clinical trials, and general and administrative expenses. We had cash and cash equivalents of approximately $37.9 million as of March 31, 2015 as compared to $46.6 million as of December 31, 2014. All cash and cash equivalents as of March 31, 2015 and December 31, 2014 were held in an account backed by U.S. government securities.

Net cash of approximately $8.8 million and $7.9 million was used in operating activities during the three month periods ended March 31, 2015 and 2014, respectively. The major use of cash for operating activities for the three month period ended March 31, 2015 was to fund our clinical development programs and associated administrative costs. No cash was used in investing activities during the three month period ended March 31, 2015. Cash provided by financing activities during the three month period ended March 31, 2015 was approximately $102,000 due to the receipt of that amount from a former 10% shareholder of the Company in accordance with Section 16(a) under the Securities Exchange Act of 1934, as amended.

We have experienced negative cash flows from operations since inception. We will require substantial funds for R&D, including preclinical studies and clinical trials of our product candidates, and to commence sales and marketing efforts, if appropriate, if the FDA or other regulatory approvals are obtained. Based on our current and planned clinical activities, we believe that our current liquidity will be sufficient to continue the development of our product candidates into the second half of 2016. It is possible that our clinical trial activities will be more costly and take longer than we anticipate; accordingly, there can be no assurance that additional capital will not be necessary prior to the time anticipated. Our capital requirements will depend on many factors, which are discussed in detail in “Item 1A. Risk Factors” to Part I of Form 10-K for the fiscal year ended December 31, 2014. Additionally, as discussed in Note 6 to the financial statements included in the Quarterly Report on form 10-Q, there is a third party individual patent holder that claims priority over our patent application for enclomiphene.

Our results of operations may vary significantly from quarter to quarter and year to year, and depend on, among other factors, our ability to raise additional capital on acceptable terms or at all, our ability to be successful in our clinical trials, the regulatory approval process in the United States and other foreign jurisdictions and the ability to complete strategic licenses and product development agreements. The timing of our revenues may not match the timing of our associated product development expenses. To date, R&D expenses have usually exceeded revenue in any particular period and/or fiscal year.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk. We had cash and cash equivalents of approximately $37.9 million at March 31, 2015 which is held in an account backed by U.S. government securities. Although this cash account is subject to fluctuations in interest rates and market conditions, no significant gain or loss on this account is expected to be recognized in earnings. We do not invest in derivative securities.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e)) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), were effective as of March 31, 2015.

Changes in Internal Control over Financial Reporting

In connection with the evaluation described above, we identified no change in internal control over financial reporting that occurred during the quarter ended March 31, 2015 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

See Note 6 of the Notes to the Condensed Consolidated Financial Statements.

Item 1A. Risk Factors

There were no material changes from the risk factors previously disclosed in the registrant’s Form 10-K for the fiscal year ended December 31, 2014 in response to “Item 1A. Risk Factors” to Part I of Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

None

Item 5. Other Information

None

Item 6. Exhibits

31.1*

Certification Pursuant to Rule 13(a)-14(a) or 15(d)-14(a) of the Exchange Act, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Principal Executive Officer).

31.2*

Certification Pursuant to Rule 13(a)-14(a) or 15(d)-14(a) of the Exchange Act, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Principal Financial Officer).

32.1**

Certification Furnished Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Principal Executive Officer) (This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)

32.2**

Certification Furnished Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Principal Financial Officer) (This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)

101.INS*

XBRL Instance Document

101.SCH*

XBRL Taxonomy Extension Schema Document

101.CAL*

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*

XBRL Taxonomy Extension Label Linkbase Document

101.PRE*

XBRL Taxonomy Extension Presentation Linkbase Document

Filed herewith.

Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	REPROS THERAPEUTICS INC.

Date: May 7, 2015
	By:	/s/ Joseph S. Podolski
		Joseph S. Podolski
		President and Chief Executive Officer
		(Principal Executive Officer)

Date: May 7, 2015
	By:	/s/ Katherine A. Anderson
		Katherine A. Anderson
		Chief Financial Officer
		(Principal Financial Officer)

EX-31.1 2 v408247_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

I, Joseph S. Podolski, certify that:

1. I have reviewed this quarterly report of Repros Therapeutics Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: May 7, 2015	By: /s/ Joseph S. Podolski
	Joseph S. Podolski
	President and Chief Executive Officer
	Repros Therapeutics Inc.
	(Principal Executive Officer)

EX-31.2 3 v408247_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

I, Katherine A. Anderson, certify that:

1. I have reviewed this quarterly report of Repros Therapeutics Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: May 7, 2015	By: /s/ Katherine A. Anderson
	Katherine A. Anderson
	Chief Financial Officer
	Repros Therapeutics Inc.
	(Principal Financial Officer)

EX-32.1 4 v408247_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repros Therapeutics Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Joseph S. Podolski, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 7, 2015	By: /s/ Joseph S. Podolski
	Joseph S. Podolski
	President and Chief Executive Officer
	Repros Therapeutics Inc.
	(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to Repros and will be retained by Repros and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 v408247_ex32-2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repros Therapeutics Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Katherine A. Anderson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 7, 2015	By: /s/ Katherine A. Anderson
	Katherine A. Anderson
	Chief Financial Officer
	Repros Therapeutics Inc.
	(Principal Financial Officer)

EX-101.INS 6 rprx-20150331.xml XBRL INSTANCE DOCUMENT 0000897075 2014-01-01 2014-03-31 0000897075 2015-01-01 2015-03-31 0000897075 2015-03-31 0000897075 2015-05-01 0000897075 2013-12-31 0000897075 2014-12-31 0000897075 2014-03-31 0000897075 rprx:EnclomipheneMember rprx:SecondaryHypogonadismMember 2015-01-01 2015-03-31 0000897075 rprx:ProellexMember rprx:UterineFibroids1Member 2015-01-01 2015-03-31 0000897075 rprx:ProellexMember rprx:EndometriosisMember 2015-01-01 2015-03-31 0000897075 us-gaap:MaximumMember 2014-03-31 0000897075 rprx:SeriesWarrantMember 2014-03-31 0000897075 rprx:SeriesBWarrantMember 2014-03-31 0000897075 us-gaap:MaximumMember 2015-03-31 0000897075 rprx:SeriesWarrantMember 2015-03-31 0000897075 rprx:SeriesBWarrantMember 2015-03-31 0000897075 rprx:TwoThousandAndElevenEquityIncentivePlanMember 2015-01-01 2015-03-31 0000897075 rprx:DomesticMember 2015-01-01 2015-03-31 0000897075 rprx:ForeignMember 2015-01-01 2015-03-31 0000897075 rprx:ThirdPartyMember 2015-01-01 2015-03-31 0000897075 rprx:UndesignatedPreferredStockMember 2015-03-31 0000897075 rprx:UndesignatedPreferredStockMember 2014-12-31 0000897075 us-gaap:CommonStockMember 2013-12-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000897075 us-gaap:TreasuryStockMember 2013-12-31 0000897075 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2013-12-31 0000897075 us-gaap:CommonStockMember 2014-12-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000897075 us-gaap:TreasuryStockMember 2014-12-31 0000897075 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2014-12-31 0000897075 us-gaap:CommonStockMember 2014-01-01 2014-03-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-03-31 0000897075 us-gaap:TreasuryStockMember 2014-01-01 2014-03-31 0000897075 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2014-01-01 2014-03-31 0000897075 us-gaap:CommonStockMember 2015-01-01 2015-03-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-03-31 0000897075 us-gaap:TreasuryStockMember 2015-01-01 2015-03-31 0000897075 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2015-01-01 2015-03-31 0000897075 us-gaap:CommonStockMember 2014-03-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2014-03-31 0000897075 us-gaap:TreasuryStockMember 2014-03-31 0000897075 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2014-03-31 0000897075 us-gaap:CommonStockMember 2015-03-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2015-03-31 0000897075 us-gaap:TreasuryStockMember 2015-03-31 0000897075 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2015-03-31 0000897075 us-gaap:ScenarioPreviouslyReportedMember 2013-12-31 0000897075 us-gaap:MinimumMember 2014-01-01 2014-03-31 0000897075 us-gaap:MaximumMember 2014-01-01 2014-03-31 0000897075 us-gaap:ScenarioPreviouslyReportedMember 2014-01-01 2014-03-31 0000897075 us-gaap:RestatementAdjustmentMember 2014-01-01 2014-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Accrued expenses consist of the following (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>March 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>December 31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Research and development costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>654</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>284</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Personnel related costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>63</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>458</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>76</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>92</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>793</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>834</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

NDA accepted and under review Phase 2 Phase 2 PDUFA date of November 30, 2015 Complete first course of treatment in a Phase 2B study (oral delivery) (YE 2015) Complete first course of treatment in a Phase 2B study (vaginal delivery) (YE 2015) Fully enroll Phase 2 study (oral delivery) (YE 2015)

281600000

37875000

46620000

569000

289000

38444000

46909000

22000

32000

38466000

46941000

1159000

2090000

793000

834000

1952000

2924000

24000

319459000

318437000

1380000

-281589000

-273064000

36514000

44017000

38466000

46941000

654000 284000 63000 458000

76000

92000

-8793000

-8525000

23033000

24276000

-0.38

-0.35

4086885

877137

809805

3274157

39595

429704

0.01

2.49

0.01

2.49

369000

5000

0.001

5000000

0.001

75000000

24388523

24276173

112350

2000

1000

2000

1000

7569000

7321000

1226000

1205000

8795000

8526000

23033000

24276000

23033000

24276000

72519000

23000

314405000

-1380000

-240529000

24000

318437000

-1380000

-273064000

23125565

112350

24388523

112350

920000

1022000

69197

104000

15000

-8793000

-8525000

64750000

23000

315429000

-1380000

-249322000

24000

319459000

-1380000

-281589000

112350

23209762

24388523

112350

69197

11000

10000

920000

1022000

393000

382000

356000

-972000

-7899000

-8847000

104000

102000

104000

102000

-7795000

-8745000

75807000

68012000

2000000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong>NOTE 2  Revision of Prior Years’ Financial Statements</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">While preparing its financial statements for the year ended December 31, 2014, the Company identified a prior period error related to the accounting for patent costs. As disclosed in its prior filings, historically the Company had capitalized patent related costs associated with its drug candidates, enclomiphene and Proellex®. However, the Company has now concluded that these costs should have been expensed as research and development costs since the related products were, at the time the costs were incurred, in the development phase and had not been approved by the FDA.  The Company concluded this error was not material individually or in the aggregate to any of the prior reporting periods, and therefore, no restatements of previously issued financial statements were necessary.  <font style="BACKGROUND-COLOR: transparent">However, if the entire correction had been recorded in the fourth quarter of 2014, the cumulative impact would have been material to the fourth quarter of 2014, and would have impacted the comparability to prior periods.  As such, revisions for the prior periods are reflected in the financial statements herein. The quarter ended March 31, 2015 was not affected. </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">At December 31, 2013, accumulated deficit and shareholders’ equity were reported as ($237,623) and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,425</font>, respectively, and were revised to ($240,529) and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">72,519</font>, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The effects of the error correction on the consolidated statements of operations for the three month period ended March 31, 2014 are as follows (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="38%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div style="CLEAR:both;CLEAR: both"> Three months ended March 31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="38%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">As previously <br/> reported</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Correction</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">As revised</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div style="CLEAR:both;CLEAR: both">Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,325</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">244</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,569</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div style="CLEAR:both;CLEAR: both">Total expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8,551</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">244</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8,795</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div style="CLEAR:both;CLEAR: both">Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(8,549)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(244)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(8,793)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div style="CLEAR:both;CLEAR: both">Loss per share  basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(0.37)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(0.01)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(0.38)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The effects of the error correction on the consolidated statements of cash flows for the three month period ended March 31, 2014 are as follows (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="38%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div style="CLEAR:both;CLEAR: both"> Three months ended March 31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="38%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">As previously<br/> reported</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Correction</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">As revised</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div style="CLEAR:both;CLEAR: both">Net cash used in operating activities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(7,614)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(285)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(7,899)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div style="CLEAR:both;CLEAR: both">Net cash used in investing activities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(285)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">285</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(0)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The effects of the error correction on the consolidated statements of operations for the three month period ended March 31, 2014 are as follows (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="38%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div style="CLEAR:both;CLEAR: both"> Three months ended March 31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="38%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">As previously <br/> reported</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Correction</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">As revised</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div style="CLEAR:both;CLEAR: both">Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,325</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">244</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,569</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div style="CLEAR:both;CLEAR: both">Total expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8,551</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">244</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8,795</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div style="CLEAR:both;CLEAR: both">Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(8,549)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(244)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(8,793)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div style="CLEAR:both;CLEAR: both">Loss per share  basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(0.37)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(0.01)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(0.38)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

75425000

1.56 9.60

-237623000

-240529000

7325000

244000

8551000

244000

-8549000

-244000

-0.37

-0.01

-7614000

-285000

285000

10-Q false 2015-03-31 2015 Q1 REPROS THERAPEUTICS INC. 0000897075 --12-31 Accelerated Filer RPRX 24276173 91664

EX-101.SCH 7 rprx-20150331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Organization, Operations and Liquidity link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Revision of Prior Years' Financial Statements link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Loss Per Share link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 113 - Statement - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Organization, Operations and Liquidity (Tables) link:presentationLink link:definitionLink link:calculationLink 115 - Statement - Revision of Prior Years' Financial Statements (Tables) link:presentationLink link:definitionLink link:calculationLink 116 - Statement - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Organization, Operations and Liquidity (Product Development Pipeline) (Details) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Organization, Operations and Liquidity (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Revision of Prior Years' Financial Statements (Details) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Revision of Prior Years' Financial Statements (Details 1) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Revision of Prior Years' Financial Statements (Additional information) (Details) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Loss Per Share (Calculation of Loss Per Share) (Details) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Loss Per Share (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Stock-Based Compensation (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Commitments and Contingencies (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 rprx-20150331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 rprx-20150331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 rprx-20150331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Accrued Expenses [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Earnings Per Share [Abstract] Earnings Per Share [Text Block] Loss Per Share Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Product Information [Table Text Block] Product Development Pipeline Schedule Of Accrued Liabilities Table [Text Block] Accrued Expenses Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Calculation of Loss Per Share Schedule of Product Information [Table] Products and Services [Axis] Products and Services [Domain] Enclomiphene [Member] Proellex [Member] Products Or Services Secondary Categorization [Axis] Products Or Services Secondary Categorization [Domain] Secondary Hypogonadism [Member] Uterine Fibroids 1 [Member] UterineFibroids 2 [Member] Uterine Fibroids 2 [Member] Endometriosis [Member] Product Information [Line Items] Product Information [Line Items] Product Status Status Product Status Product Next Expected Milestone Next Expected Milestone(s) Product Next Expected Milestone Legal Entity [Axis] Entity [Domain] Subsidiary, Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] IPO [Member] Development Stage Enterprise, Deficit Accumulated During Development Stage Deficit accumulated during the development stage Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Statement Of Financial Position [Abstract] Statement [Table] Statement [Line Items] Assets [Abstract] ASSETS Assets Current [Abstract] Current Assets Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current, Total Total current assets Property, Plant and Equipment, Net, Total Fixed assets, net Net Fixed Assets Assets, Total Total assets Total assets Liabilities and Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Current [Abstract] Current Liabilities Accounts Payable Current Accounts payable Accrued Expenses Accrued expenses Total Liabilities, Current, Total Total current liabilities Commitments and Contingencies Commitments & Contingencies (note 6) Stockholders Equity [Abstract] Stockholders' Equity Preferred Stock Value Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding Common Stock Value Common Stock, $.001 par value, 75,000,000 shares authorized, 24,388,523 shares issued; 24,276,173 shares outstanding Additional Paid in Capital, Total Additional paid-in capital Treasury Stock Value Cost of treasury stock, 112,350 shares Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders Equity Attributable to Parent, Total Total stockholders' equity Beginning Balance Shareholders’ Equity Ending Balance Total stockholders’ equity Liabilities and Equity, Total Total liabilities and stockholders' equity Schedule Of Accrued Liabilities [Table] Schedule of Accrued Liabilities [Table] Schedule Of Accrued Liabilities [Line Items] Schedule of Accrued Liabilities [Line Items] Accrued Research and Development Expense Current Research and development costs Accrued Research and Development Expense, Current Accrued Personnel Expense Current Personnel related costs Accrued Personnel Expense Current Other Accrued Liabilities Current Other Net Income (Loss) Attributable to Parent, Total Net loss Net loss Net loss Weighted Average Number Of Shares Outstanding, Basic and Diluted Average common shares outstanding Shares used in loss per share calculation Earnings Per Share, Basic and Diluted, Total Basic and diluted loss per share Loss per share - basic and diluted Net loss per share - basic and diluted Earnings Per Share Disclosure [Table] Class of Stock [Domain] Series Warrant [Member] Series A Warrants [Member] Series B Warrant [Member] Series B Warrants [Member] Series B Warrant Range [Axis] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Anti-dilutive shares of common stock excluded from computation of earning per share Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants, exercise price per share Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Two Thousand And Eleven Equity Incentive Plan [Member] 2011 Equity Incentive Plan Member Domain plan member Vesting [Axis] Vesting [Domain] Share-based Compensation Award, Tranche One [Member] Vested Options One [Member] Share-based Compensation Award, Tranche Two [Member] Vested Options Two [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Stock Options, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Stock Options, Forfeited/cancelled Commitments and Contingencies [Table] Commitments and Contingencies [Table] Scenario [Axis] Scenario, Unspecified [Domain] Third Party [Member] Third Party [Member] Third Party [Member] Junior Participating Preferred Stock [Member] Geographical [Axis] Geographical [Domain] Domestic [Member] Domestic [Member] U.S. Foreign [Member] Foreign [Member] Foreign Title of Individual [Axis] Gain Contingency, Patents Found Infringed upon, Number Number of patents Undesignated Preferred Stock [Member] Preferred Stock, Par or Stated Value Per Share Preferred Stock, par value Preferred Stock Shares Authorized Preferred Stock, shares authorized Preferred Stock Shares Issued Preferred Stock, issued Preferred Stock Shares Outstanding Preferred Stock, outstanding Common Stock, Par or Stated Value Per Share Common Stock, par value Common Stock Shares Authorized Common Stock, shares authorized Common Stock, Shares, Issued Common Stock, shares issued Common Stock, Shares, Outstanding Common Stock, shares outstanding Treasury Stock Shares Treasury stock, shares Income Statement [Abstract] Revenues [Abstract] Revenues and other income Investment Income, Interest Interest income Interest income Revenues, Total Total revenues and other income Costs and Expenses [Abstract] Expenses Expenses: Research and Development Expense, Total Research and development Research and development General and Administrative Expense, Total General and administrative General and Administrative Costs and Expenses, Total Total expenses Total expenses Weighted Average Number Of Shares Outstanding [Abstract] Shares used in loss per share calculation: Weighted Average Number of Shares Outstanding, Basic, Total Basic Weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted Diluted Weighted Average Number of Shares Outstanding, Diluted Statement Of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Treasury Stock [Member] Treasury Stock Shares, Issued Beginning Balance (in shares) Ending Balance (in shares) Adjustments To Additional Paid In Capital, Share-Based Compensation, Stock Options, Requisite Service Period Recognition Stock based option compensation Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Issuance of 69,197 shares of common stock for the cashless exercise of 91,664 stock options Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures, Total Issuance of 69,197 shares of common stock for the cashless exercise of 91,664 stock options (in shares) Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options to purchase common stock stock for cash ($1.56 to $9.60 per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of stock options to purchase common stock stock for cash ($1.56 to $9.60 per share) (in shares) Range [Domain] Maximum [Member] Minimum [Member] Auction Market Preferred Securities, Stock Series [Axis] Common StockOption Shares Issuance of shares of common stock for the cashless exercise of stock options Common Stock Option Shares Statement Of Cash Flows [Abstract] Net Cash Provided By Used In Operating Activities [Abstract] Cash Flows from Operating Activities Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation Share-based Compensation, Total Noncash stock-based compensation Increase (Decrease) in Prepaid Expense and Other Assets, Total (Increase) decrease in prepaid expenses and other current assets Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Increase (decrease) in accounts payable and accrued expenses Net Cash Provided by (Used in) Operating Activities, Total Net cash used in operating activities Net cash used in operating activities Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Net Cash Provided By Used In Investing Activities [Abstract] Cash Flows from Investing Activities Payments to Acquire Property, Plant, and Equipment, Total Capital expenditures Net Cash Provided by (Used in) Investing Activities, Total Net cash used in investing activities Net cash used in investing activities Net Cash Provided By Used In Financing Activities [Abstract] Cash Flows from Financing Activities Proceeds from Stock Options Exercised Exercise of stock options & warrants Proceeds From Contributed Capital Proceeds from a shareholder transaction Net Cash Provided by (Used in) Financing Activities, Total Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease), Total Net decrease in cash and cash equivalents Organization Consolidation and Presentation Of Financial Statements Disclosure [Text Block] Organization, Operations and Liquidity Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Auction Market Preferred Securities, Stock Series, Title [Domain] Series B [Member] Gain Contingency, Patents Found Not Infringed upon, Number Number of pending patent applications Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Relationship to Entity [Domain] Chief Executive Officer [Member] Joseph S. Podolski Executive Vice President [Member] Ron Wiehle Inventor [Member] Dr. Harry Fisch Accumulated Deficit during Development Stage [Member] Accumulated Deficit Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements [Abstract] REVISION OF PRIOR YEARS’ FINANCIAL STATEMENTS [Abstract] Revision Of Prior Years Financial Statements [Text Block] Revision Of Prior Years’ Financial Statements The entire disclosure for reporting revision of prior years financial statements. Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Schedule of Error Corrections and Prior Period Adjustments Schedule Of Error Corrections And Prior Period Adjustments Cash flows [Table Text Block] Schedule Of Error Corrections And Prior Period Adjustments Cash flows Tabular disclosure of prior period adjustments to Consolidated statement of cash flows. Schedule of Quantifying Prior Year Misstatement Corrected in Current Year Financial Statements [Table] Quantifying Misstatement in Current Year Financial Statements [Line Items] Scenario, Previously Reported [Member] As Previously Reported [Member] Stock option exercise price Exercise of stock option to purchase common stock for cash, share price Stock option exercise price. Issuance During Period First [Member] Issuance During Period 1st [Member] Restatement Adjustment [Member] Correction [Member] Issuance During Period Second [Member] Issuance During Period 2nd [Member] Issuance During Period 3rd [Member] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Androxal [Member] Earnings Per Share Disclosure [Line Items] Earnings Per Share Disclosure [Line Items] Document Information [Line Items] Cashless Exercise Of Stock Options Cashless exercise of stock option. EX-101.PRE 11 rprx-20150331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`&SU:ATP$``/(2```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F-%NVC`4AN\G[1TBWT[$ MV-LZ-A&X8-UEA[3N`3S[0"([`*G` MW2Y5K,XY_.`\Z1I:E4H?P.&=A8^MRO@V+GE0>J66P.5P>,.U=QE<'N1N!IN, M?\)"K6TN;K?X\9XD@DVLF.T7=ED54R'81JN,I'SCS*N4P5-"B3O[-:EN0OJ$ M&(P?3>CN_#_@:=]O/)K8&"CF*N8[U2(&WUK^X./JG_>K\O20(Y1^L6@T&*_7 M+9Y`F4($95(-D%M;]M>R58U[YCZ1WR].O+^(*X-TWZ\??"&'),+QF0C'%R(< M7XEPW!#A^$:$8T2$XSL1#C&D`D+%J(**4@45IPHJ4A54K"JH:%50\:J@(E9! MQ:R2BEDE%;-**F:55,PJJ9A54C&KI&)6^5YFS?A$#[Q_??L/MQ]SYI$RY9V% M=.6_@?NAYY)K%<'\R1&[CZL#O)Q]AD,KJV;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+ M\>QRI9$P4P>J/OH\^;*W-$UO>"_F M?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;',@H@0!**```0`````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``"\6,MN@S`0O%?J/R#?&[.;=Q620ZM*N;;I!UC@``H89+N/_'VM-(5$BK87 MM!%B)R7IE,58W1 MB3AJ)S;K^[O5JZZ4#R^YHFQ=%+(8EXC"^_912I<6NE9NU+3:A)U]8VOEP]+F MLE7I0>5:8AS/I+W,(=97.:-ME@B[S<+YNV,;3OX_=[/?EZE^;M*/6AM_XPCY MU=B#*[3V(:FRN?:)Z$).GG86HX!8R-M@8,R,!L8D'&YR@&0'9\SLX(QBA[M6 M9*D0N+D!BILY,YHY!0:0&0T@"8>;'"#9P2DS.SBEV.&N%5TJ;L4!4G$PW)ZL MEQ7&9*F60\)Q_EB%R[^[.'_7U/GGD(T"[-20W.!DR$;I'%7?*UWH M;+)P0O4-M^"1>@?<:("$@]RN!FE;,Z@#]>&S0?==EZZT'F:8$E-TWA0K4E5E3X5JC0]G"Y$H>!6&%)@N`M$U@>XJ0&2&V0W M>*3#0VXSCJ09'P\J-:Y05F=OWH:_+9?.ZC+\-U3RZH?+^@<``/__`P!02P,$ M%``&``@````A`),_BA?_`@``0`D```\```!X;"]W;W)K8F]O:RYX;6R45EUO MVC`4?9^T_Q#E?3C/0FZ5!Y M2FZ,C\^]]YQK;F[W66J],J6Y%$/;.W-MBXE(QEQLAO:O\/[;I6UI0T5,4RG8 MT'YCVKX=??URLY/JY5G*%PL`A![:B3'YM>/H*&$9U6KXKCMP,LJ%72%&B?0RAWK/%!;?.[+4]A]:KG]FQG5"?Y MH*R8K>DV-2&D=T"'>OE]WQ\4ORQ*\@BD+_@DV00BD?F`V?832_X#,>R;_]B[#@*SN21"N$!?_ M"L&RZHB#`,ELU5&V8<16K+0'=[,+V&`8$: M[*/S/;>]1ZB!D='+'=5PZ$1FQ:EE`3``%H77E:C, M,FZ*&:++HDTD>$9L8/3Q)G^P9%T_KR/1XWW`[>QA67@=E1[O1`,("\/KZ+3= M"Q+2Y[29$O:NUU%HLR4?;,@1J,.NH\7EK, MJ)C0=;,A:$W'XT"8D8_M`L%)0"#<.K5^@U%'Q9UF3YFA/,4&[#>H=`3<`O01$FJAJJ[E7:EU6HOSPXXB57`R':: M]N]WS!#`3ENE^](&?'Q\YLQXF,7-N(Q6I"U+RFB[=%RK=F]7G3XLC%X]R3ZER@*&62W>O5#/W/)GO:47DA#>T MAI4M%Q51\"AVGFP$)46[J2J]T/<3KR*L=I%A+B[AX-LMR^D=SP\5K162"%H2 M!?KEGC7RQ%;EE]!51#P>FJN<5PU0;%C)U$M+ZCI5/G_8U5R030EQ/P=3DI^X MVXV^;S/P0S@%W9)#J7[R MXU?*=GL%Z8XA(AW8O'BYHS('1X%F$L::*>IY6\73A/8&C>0=9 M(P0N1`\)3$1V0NA$@+I>(L1M2XP@@Z][?U*D-UF*8O.\]3DD-!'9.2).>HBA M$:P;:WQ?FP8OW>G(BCCM:5M#UPC!4M(.9Z,7QL'`& M#^E'#M9@TX?$LGZ-D+3U(8U":SDSEN-D<-$0I;]&H[O^?I%JL"5J,!F+%"$H M*@A]ZWYEYG+XQLV9?424!ENB(BM%"$%1U_'HU%9S9BRGLT&SX50`_>5RJUJT M)>NL_6G&I8L7ZPJ$#2>CL([D!$AG0V"F-*MCOY_%`)OJ^,HGULGK#@,"=..^ M\B>1A^F_#D68`7I&&0P\.!145 M.YK1LI1.S@]ZH`F@*/JW.&RM];#5CDO]`LPZ#=G1[T3L6"V=DFYAJS])H44+ MG);P0?&F_2AON((II_VYAZF6PA?.GP!XR[DZ/>@QH)^35_\```#__P,`4$L# M!!0`!@`(````(0`'IS,5F@(``',&```9````>&PO=V]R:W-H965TC>,D%G$:T\$&R(6DS=8[)$Z`PRAS_[_(`I;+W`VCO))G"4`1UMN[(-P ME!BQO;%*_@Z@Q(GJ2=(C20;JC_OIM20D"/+Y;:BER[E6!P0]`T>:CKH.3&9` M?$HLR.A3?2]34.=([AV+YX(D#%3G:9G&MW/R!):R(V85,#`0/289(M8GA*L$ MR.LU0N+G&C,HX=_-/TER04-)>3X\;W4)28>(]24B'_>0@4;P[JW&?VMS8&B! M-U:,1SVM=W05(%/OYRDK&9^>N`F82:CQ* M)Z]V>-WKP7X69^_H@JZ_WBX'/M=U=NXJ8)(X&!9'V9EPN!U\/[P"7OLS.!:& M/PR'Y+KB:]XT!C&U=X.=`''_-MPY*[AS_(22?@-FOJ,5_TIU)5J#&EY":!Q- MX'`=;HVPL*KSO;E5%J;=/]9PN7.8I3@"<*F4/2W<-/2?B^4?````__\#`%!+ M`P04``8`"````"$`R%TN=,H"``"L!P``&0```'AL+W=O'<\^]OFPNGWCC/5*IF&@S%,X"Y-&6B(*U589^_;R] M6"%/:=P6N!$MS=`S5>AR^_G3YB#D@ZHIU1XPM"I#M=9=ZON*U)1C-1,=;2%2 M"LFQAJ6L?-5)B@M[B#=^%`1+GV/6(L>0RH]PB+)DA-X(LN>TU8Y$T@9KT*]J MUJD7-DX^0L>Q?-AW%T3P#BAVK&'ZV9(BCY/TKFJ%Q+L&\GX*%YB\<-O%*WK. MB!1*E'H&=+X3^CKGM;_V@6F[*1AD8&SW)"TS=!6F>8+\[<;Z\YO1@QK\]U0M M#E\D*[ZQEH+94"93@)T0#P9Z5Y@M..R_.GUK"_!=>@4M\;[1/\3A*V55K:': M,21D\DJ+YQNJ"!@*-+,H-DQ$-"``?CW.3&>`(?C)/@^LT'6&YLM9G`3S$.#> MCBI]RPPE\LA>:<'_.%!XI'(DT9$$GD>2,#J;9'XD@>>))%K%8;S\OQ3?I65= MNL$:;S=2'#SH/!"N.FSZ.$R!^6U;P`^#O3)@>P0R5E#*QVT4+#?^(_A/CIAK MAX';<\*,$?D;B*B'^*"K%P=^#<69VLVA`]X7:0Y-1(8]O*TJF/>L@KF[)>FK2,+J:3^OFIJ.[]YS* MBN:T:91'Q-Y,O@A\[W?=4+X.4[@D,`TG^SD,:[OO]P$8EAVNZ#V6%6N5U]`2 M*(-9`F63;MRZA1:=O94[H6%,VK\U?!4I7+]@!N!2"/VR,`.]_\YN_P(``/__ M`P!02P,$%``&``@````A`#;=H$)X`P``!0L``!D```!X;"]W;W)K&ULG%9;;]HP&'V?M/\0Y;TD#KE`!%2%I-ND39JF79Y-8L!J M$D>V*>V_WV>;DL14+?0%D^/S'[OX_&EV8/Q![`B1#B@T8N[NI&Q3SQ/%CM18 MC%A+&MC9,%YC"8]\ZXF6$USJH+KR`M^/O1K3QC4**;]$@VTVM"`9*_8U::01 MX:3"$OR+'6W%BUI=7")78_ZP;V\*5K<@L:85E<]:U'7J(OVV;1C'ZPKR?D(A M+EZT]<.9?$T+S@3;R!'(><;H>CW04N[F M[C@>18D_1D!WUD3(>ZHD7:?8"\GJ?X:$CE)&)#B*P'H40<'5(N.C"*R=2#") M4!1?824\JL#:J5R;#V2NBP)K)W*I%<]46#EP$/IIYCS`2Q9&S-!PXT!UGR%B]P@B&E.R< M$L5#2GY.0=/PQ/$@S5.N,`EVKF.8[;=S54%6KG:JAC+1TZ?JL[*!S`;R'C"P M"'-VO445!&WKE]JW*KDT''/8M$<;R&P@[P$#C_!#?8]OET^1X?@.O(U/[='C MM#2-LDJR+9L3>'2<'J6 M;2"S`;AF*%ESN&^"<1('71V,:7.-,/]*->%;LB)5)9R"[=45(81C9!LE;_*:R9A/N'_KJ#ZR:!M[\_`O*&,?GR`#_LG2ZPB_\```#__P,` M4$L#!!0`!@`(````(0`:"LH[^@(``.L(```9````>&PO=V]R:W-H965T+KD3):F:5-TJ;=(T[?+L&`-6`2/; M:=I_OV,[4#!9E;PD^/CS=[YS,8?UW6M9H!LHH+?"@@[M=HBDG#;18# M^I(1P25/E0]T@14ZC#D.X@"8MNN$000Z[4C0=./=1ZM]%'K!=FT2](?1D^P\ M(YGSTQ?!DF^LHI!MJ).NP('S9PU]2K0)#@>#TX^F`C\$2FB*CX7ZR4]?*6>040ZL%7R]D`E@8P"C3^>:2;""Q``OZADNC4@(_C5_)]8HO*--YG[LT4X MB0".#E2J1Z8I/42.4O'RKP5%9RI+,CZ33$#]>7]\+4E@!9GX'K#"V[7@)P1- M`RYEC74+1BL@;@*S,MI0_Q(*7DC-E9#-R( M%A/U$?L&H2L!\EJ-$+BK<0(EO)S\1I(^Y$AR_.TN0!Q%0\1LWD)Z&B%W78T? M:]-@:(%N*D)7G,7$)IFCY7*Z:/V:E.][^XME'+?[/5W36W1IL*MKVO(:OSN+ MF1E=3HGWE_=Z>J#=K\^3!CMZXJ6CQV+LI=.]N.\8>I[GMWC68,?SH$(6T_%L M#0M;LL4\>D]=3\CB%B$:[`IYY[4EL9B.D,:@+^)HO)RU*>OIT,.I<_4_;ED- M=G1T6L[JL)B.CHZAYSF^Q;,&.YX'I;"8CN?&\'$&8&3^DTLJ,KJG12$1X4<]3R)HIM9J9]U.SSHSK=H-USNAW+#)6 M2530%(Z&_@*N@K##RBX4K\TK\<`5#!GSF,-'!85K$_H`3CE7S4*_A-O/E.T_ M````__\#`%!+`P04``8`"````"$`-<'&\I,#``!S"P``&````'AL+W=ONS M`R:Q%C#%SF;W[SO#``U.I;(O">#C,\=S[/%LWCT7N?,D:BU5N769%[B.*!.5 MRO*X=7]\?Y@L74<;7J8\5Z78NB]"N^]V;]]L+JI^U"_K MY"0*KCU5B1)&,E47W,!K??1U50N>-I.*W`^#8.$77)8N,:SK,1PJRV0B[E5R M+D1IB*06.3>@7Y]DI3NV(AE#5_#Z\5Q-$E540'&0N30O#:GK%,GZX[%4-3_D ML.YG-N-)Q]V\W-`7,JF55IGQ@,XGH;=K7ODK'YAVFU3""C#M3BVRK7O'UC&; MN?YNTR3HIQ07??7LZ).ZO*]E^DF6`K(-/AE^^"9RD1B1@G.N@XX:0!LS& M.GVY%SH!&R"6%\Z1-5$Y4,"O4TC<3Y!&_DSJ9&I.6W>Z\.91,&4`=PY"FP>) ME*Z3G+51Q2\"L9:*2,*6!/XO-![.O>5\/ELLH_$LTY8%_EL6%GAL%BS^K\2G M534)N^>&[S:UNCBP74&WKCAN?K8&WG]G!=*!V#L$;UTX3K!@#=8\[8*-_P3) M3UK$GA#PVR/8$!%W"/0/-/1"(#7CA2`8A:!=J&Q/'Z[CAE9<0H2-ZED(YO7C M`QF0@_$R$+QU9U>KG?:LI(L0M*]0:'SU81`72,;'13#LPZNX,RLN(6!K]3[\ M76^C+.X0M@\P9[P0!`^%+"PAA"`AAW]MF;A#V$(6KQ&"X*&0R!)"B$7K?["R M,A;3>./4P)CH-3(0/)2QM&008M[("`-FN](-V\G`*VST,47P4,7*4D$(A>*GX4GWE]E*5VC*J:^_^@ M#/0MS>,)FEL!UU3@`3A3RG0OF+>^7=[]`0``__\#`%!+`P04``8`"````"$` M/R$/."@#``#["0``&0```'AL+W=O/S6U\TBXH*Q=H<#UD4/:G!6TW:W0G]_W5RERA,1M@6O6DA5Z M)@)=KS]_6AX8?Q`5(=(!AE:L4"5EM_`\D5>DP<)E'6GA3LEX@R5<\ITG.DYP MT0')5XO.3LXT#2PI>BP:L%@`<0J ML1F4Y_7$(",5!/%&B, MH?.VI2K[B"H%GJJ*)JHTQC#,6+!V#N!T,PMR6<_T4>>:9@`9(LP56\4K MY^[YO@GTD0EGQ7BVG3[8`TAW3A1FB3^IU<9"I'Z6^B_-9:O\T,$+`_C4IVGW M#"#=/J$;9;[YF1P$:J8KRK-HK5J/;SW>.KPC/S#?T58X-2FA7KZ;P#'"]?#6 M%Y)U_1C;,@E#M_];P4L6@9'@NP`N&9/'"_5Z,+ZVK?\#``#__P,`4$L#!!0` M!@`(````(0#UNYVDAP(``#<&```9````>&PO=V]R:W-H965T+N137D&8R5NLUI$L640"MT(=LJI[]^/M[<4F(= M;PO>Z!9R^@J6WBT_?ECLM-G8&L`19&AM3FOGNCEC5M2@N(UT!RW^*;51W.'2 M5,QV!GC1!ZF&I7$\88K+E@:&N;F&0Y>E%/"@Q59!ZP*)@88[U&]KV=D#FQ+7 MT"EN-MON1FC5(<5:-M*]]J24*#%_JEIM^+I!WR_)F(L#=[^XH%=2&&UUZ2*D M8T'HI><9FS%D6BX*B0Y\V8F!,J?WR7PUH6RYZ.OS6\+.'GT36^O=9R.+K[(% M+#8>DS^`M=8;#WTJ_!8&LXOHQ_X`OAM20,FWC?NA=U]`5K7#T\[0D/:9A&Y0`#Z)DKXSL"#\I7_O9.'JG(XF43:-1PG"R1JL>Y2>DA*Q MM4ZK/P&4[*D"2;HGP?>>),FB<9I-;Z]@84%1;_"!.[Y<&+TCV#28TW;Y-ZSY!2['<,M'L_S,DVR!7O&FHH]9A4P^!PPR8!@ MJ&:0A#*.);U=Y$-F#_:9?=&]E%78.$Z3OIUF]"]I/!@K`">.)_\CP`>="Y@-_*'$`1,$9)?IPP"'_E9@*O@$36.)T%L_G`GJ'G:' M>^,^[4=_^(%SV_$*OG%3R=:2!DH,C:,I>C=A\L/"Z:Z?GK5V.+']9XT7-&`/ MQA&"2ZW=8>'OEN'*7_X%``#__P,`4$L#!!0`!@`(````(0#T]?B3!0,``#X) M```9````>&PO=V]R:W-H965T=V0$#)@'R`M@^>\ZA392-0F+_)!YHDE5)ILB87]^/UQ=,\]8WF2\4HU(V*LP[&;Q^=-\K?23 M*86P'C`T)F&EM>TL"$Q:BIH;7[6B@2>YTC6W<*F+P+1:\,P=JJL@#L-Q4'/9 M,&*8Z4LX5)[+5-RK=%6+QA*)%A6W$+\I96NV;'5Z"5W-]=.JO4I5W0+%4E;2 MOCI2YM7I[+%HE.;+"GR_1$.>;KG=Q1%]+5.MC,JM#W0!!7KL>1I,`V!:S#,) M#C#MGA9YPFZCV5TT8,%B[A+T5XJUV?OMF5*MOVJ9?9>-@&Q#G;`"2Z6>$/J8 MX2TX'!R=?G`5^*F]3.1\5=E?:OU-R**T4.X1.$)CL^SU7I@4,@HT?CQ"IE15 M$`!\>K7$UH",\!?WO9:9+1,V&/NC23B(`.XMA;$/$BF9EZZ,5?4_`D4;*B*) M-R3PO2&)1OXP'DVN+V`)*")G\)Y;OIAKM?:@:T#3M!Q[,)H!\]89Q=%Y?<\J M>$226V1)&+0[N#!0G^=%'(?SX!ERFFXP=X2!SPX3=8@`HNE"@C#V0WH[R5ME M!*,R)AU#N:,;^S+QVS*#C\@@&*JV%WP<[\(G9<*X^A_X&1X*88H'T(*G?>&A MA,%GEZTXWADA0<(<"T)/79Y`!/>=#;J,D1!A1JZPT^[9@#T4/!TJR"X[ZQ?0<)0 M-B?CSO9!"2-HRGV;IU4=NB_;+^(&M*GB.ZT3X6382^\979HCAZ_BSA$UCZ-, MV'%BH]YPN>QE=*?.U7(#>D,3!\/E_FB,'/KKEQ.6'=:<\KH;"U1.6F,TY6NA M"_%%5)7Q4K7"%17!6]S=[=;G;>P68/<`ME?+"_&#ZT(VQJM$#D=#?P*30-/^ MHPNK6K=#ELK"WG(_2_B?(F`2ASZ`&PO=V]R:W-H965T&ULE%==;ZLX$'U?:?\#XKT!\Q6(DEQ=J+I[I;W2:K4?SX0X"2K@"-.F_?<[ M]CC!-FV:O.2#.1X?GQD?[.6WM[9Q7FG/:]:M7#+S78=V%=O6W7[E_O/WTT/J M.GPHNVW9L(ZNW'?*W6_K7W]9GEC_S`^4#@YDZ/C*/0S#<>%YO#K0MN0S=J0= M1':L;\L!_O9[CQ][6F[EH+;Q`M]/O+:L.Q6MH-F*2G M33D`?WZHC_R6_?/+\:%B[1%2;.JF'MYE4M=IJ\6/?N/;;X0=V^JVOMW_4'06UH4ZB`AO&G@7TQU8\@L'>9/23K,"?O;.E MN_*E&?YBI]]IO3\,4.X85B06MMB^/U)>@:*09A;$(E/%&B``GTY;B]8`1*I%2M>I7OC`VO\0)%=T21*H)/"MDI#@[B2A M2@+?8Y(@C4FW9RH/6`.#^6HI')`C(+>4(0^6-Y0!!O_1>H0R5@N0(@5TT0DQ$\0$BN$`\H'?A"++=SU$,LCB2 M2WJYC!PAJ:RZ6%>A/3`(@#`Z@>OB"/#*C?25A];$",%VDQ-K#XR)(&!,3,+W;!9%H4Y%PXH`BX\I%20B)+6J%RH'QP,_& M\28QRZ&O5XJ@J^HF$(Y2HR8*@\TSSRQS*HQP&HX-;]*R3/D+6NBL!JVQ,14M MQ"B]LMB*%T2/!UGP&3'AI5IGWV9.1(RR"FH)DRL,V-#EG::I@UOO.L94\"YS M)VC-\#E.;MNGPFC=KC\Q)Q=F:JD4P;,ORH@6;)31VNBY.%R!DMA=8T\K>3X. MFM0L"Q<%3+X^DDR]/+1-DR!&N>;8/XK;)U&3W%U&3J9.'MK&J3#*.4D638T" MLYP1::0MS"1WEZF3J:N'ED?E"H-3/Y`PG114]W438%*[R]@)NK3>9Y$UR"R##57&'4:3.&\9[[3Q;U,;&4$?/32QEL7WB=:VN]I M09N&.Q5[$3>J``Y-EZ=XV\O)`D[=<,NRGA?B%BCO<9<`7,*.Y9[^+/M]W7&G MH3M(Z<_FX"`]7N/PS\".\IB_80-+SI]F6\6=1$2(]<&C%W*^D[*9! M(/**-%@,6$=::"D9;["$1[X.1,<)+G2GI@ZB,!P%#::M;QRF_!(/5I8T)_KTT^?5RWC.-5 M#7&_HB'.]][ZX<2^H3EG@I5R`':!`3V->1),`G!:S`H*$:BT>YR4<_\.39<( M^<%BIA/TAY*M.+KW1,6V7SDMGFA+(-LP3VH&5HP]*^ECH5Y!Y^"D]X.>@1_< M*TB)-[7\R;;?"%U7$J8[@8A48-/B[9Z('#(*-H,H44XYJP$`_KV&JJ4!&<&O M^KJEA:SF?CP:)&D8(Y![*R+D`U66OI=OA&3-7R/2$;V;1#L3N.Y,4'2U2;PS M@>O!)!HG*!G]'R4P8>DLW6.)%S/.MAXL/0`7'58+&4W!6:4GAB1_G![(B^IS MISKIKJ`6,*1F[9>B04'E7-YYI38@4L=."/9PT7I"*4N7*_$@AM= M`Z?$#MS8@3,2`X=0%">A+5CV""RPU`:[K%15)P=P8H^?&8G9_%1Y+X]>6`#J M3#S:*_KK4(GM@=W`,R,Y7X?GVRVLR3582NQ@(23L^/VS"$?S2;Z;,-@^2=?K<63$)9ZV^K>#;BL"J#0<@+AF3 M^P?U5?#^M;;X!P``__\#`%!+`P04``8`"````"$`C3:I\*T=``#86```%``` M`'AL+W-H87)E9%-T&ULM%SK;MM(EOZ_P+Y#P0AV'4!1?+]TIS-0 M9'OBF<166\IF&X/%@))*%KLI4LV+;37V1[_#[)\%=@$_P3Z$'Z6?9+_O5)$J MDJ*L!-W`7&*1K#IU+M^YDF_^]#`+U)V.$S\*O]O:;>]L*1V.HK$?WGZW]6EP M\>ID2R6I%XZ](`KU=UL+G6S]Z>T__].;)$D5G@V3[[:F:3K_YO7K9#35,R]I M1W,=XLHDBF=>BC_CV]?)/-;>.)EJGO9YX?;JE1E(7I=UL'!P=; M*@O]GS/=-;_L[1UOO7V3^&_?I&_/HE$VTV&J.N%8G8>IGR[496C6!]EO7J=O MW[SFK>;V??4Q"M-I@EO'>ER]^M&+VVI_MZ7V=G8/JQ>+G9SEU=\^^*%6EZF> M)?_1^,!@,=?5B[L[K[ZO_M;!0<9RF(O`NZU>+?;OZ=B/>-BQ.O/2VLK%?1=^ M,O("]8/V8G4!-B6-*]H[[<(K[_U^M_JT9?:-OO63-/8@@BMO5J/FYKQW<]U7 M@_?G-YW>^:?!9;>O+J^Z[8;5NA!E#*(O(9X']5>]J-[7S>*8XG8/U\0)2^&% M'^A8=<&JVRBN+=@9C32NX^H8B^)?U1T'L4>-5_W%;!@%U:LWO9M_K_YF]^U& MLUD4JGX:C7YJJ?[4BW6BKK-43`8K5A_K7E^=G5_US\\4_M6__G!YUAG@CW>= M#YVK[KGJOS\_'_35]J?^F7KQLOKP9:@&TRA+8(U)"^82Z"1143K5\;V?:)7, M]T,_\%-?UXB'?A!U$C7W%MXPJ"DXKL<9*,@/MWK[_`Q!\T94%S^E^2?J7[S9 M_%O5!51!3X"YH$MMAU&JU5%-\D^/3X_5347GIE$P!GC_JSJ':-*:XG^"B27^ M;2B:#Q%--"QKG*OKB_;.SB[.'"L(-=,M==C:V=GA?U5B--G+TFD4^[_H,=@. M_%=^DI`1(MPU6EZRBMHVQVOWV3MH[9^(%_)U8\^[N7FO_,.=% M]2GH1#;+`N'L6$_\D=^@E;):(2>:4%U.1G\=Q1$.;_+DAH#2`S#!)^K4A[MX MV00P930K%*-Z]/)M-579Z'8CTXUN72/D045DAI;JJNNL0/WMHYX-=5SS[#5K M:61'[MX42#'O0'\"\?SZ_@5*XOU'4/'GIP"<_3I`%E%Z,? M1GJ>*L0,QK6IL9=Z7^)YW&"KYGEN])T.LY*K\!%ZUN.+RS#5\*NI6GW9&$^\ MZ6KGUD-5M>1&)XBB1L;=C;%:$,V)U-7[_JQ#A!*!6*@WGOFAA$:I?U=S&X:P M)J=QI5,51$G-&7W`;VH.EHL:J5=JZ"7^2+8;^T&&&*9*4=^`=98`F0%S7-19 M``8_(DX!"[^I/OF.2U=_/%N]2RE@*>M5?W#=_>O[ZP]GYS=]N*+O/UT.?O@B M#9,3B'95B1$>5G]T`:AZS<']GL7][FK<+\!#/&EM'0??SU;C^SN$Q6'(N/&= M%WCA2"LO56ZPM5]=M/[$-@1F\.+ELT\+G50'R#F:4Z#(GV:,MT2ZU\90,A-'P]:"*O(D5R$=YE&]UCY:5\Z*.M<0O/Y$93_7&&I/ M5TBMD'=8$_;&)ZL]^L70M5FXY&J]L6':R^:655+9ZG&9>8DM%HIW/3&!N[H6 MVZ\9X4?OP9]EL\:(IE@(1+I;-QL+<8%FTK*^:![[HYJ7^P@/N&[;C2*3;J?_ M7EU\N/[<&)F0'^HBB.X3-8FC&9C`A)ZZWAG!^:[,Z\[T/$9.O!(=KZ)0$$`X M\954U(09S^2?#"7D M,'D(@!*<98[7R)PJ0R_#.\18ZQEJ/:E)A)%?90C+JHI;(\8O%MZI];T7LV15([`71R.MQU://*/;)D%##NC!FX)G];)B<:YY'-WYJ"RJ MX4)-"CJ;S\8'6F%H6FJO,!95H?PJ]5&\I/H;*11(&/E(&!"H^!?"9!0&U^P-Y6 MR(BE^_A1F[+(WSI#EAI':2TCN[H>G*M=]=NO_Z7*.UDH>):^&\!!E*"&!N.8 MZPRY<((B)&ICVPQ^?OOU?[J(IKQPT?KMU__EGZS[%?^69^4O@"(NWNO\4I;P M?O-KE,7XXZ6Z]U"9,TQDL!:J3G:;(8/9VVFIW=.3X[;ZC&@QQG_5T(_F".!G MWDA(8C',D(&P#`5=\S@)='(22B[4]VH<9[<)\9NUBU2A5H.@SN8F`*8X&F>T M?]0&%PD8K,9^$L4L&-5JL]=9S,)_$,W\^109#H!-'H:VPN]"B"@/L>*NXV"A M?@JC>X@T84$^CAZ\X.G_6B@-X3`)3#9@F0AI7"S><+DB*B0LP8HJ\.80'/(" M+">F(SO"P>C48PEFABMJ%@4:N8N$<'-4Z,;"-B94HY2G1DT#Y6B$KEBN1B]- MC6P+61N?9,2J@NN6E<27TJ'S0%C8*55Z,#K1HPC]#U`U7(`K+B:$FF8Y08)/1$)A#W2195CMO:2Q@DJ&#-%<%:]G55M>ANM##.*/T M]TS/"(>@#H?0QQ&Y1;KP"QH,HQ3B88$-;$ZR(2J];#@`$M05;/4,MJHZ\WF` M.P02MX$B5V<=P0OR'`1>1&CZ$"K-S4YU`;SE_1?V?BJJJ[EMU<^&"8J+$$A` M/M=(Y/+839`)00;J.J`-'DRVQ>_XC:#KQ`KR]`J"8&5-[0/SV&QK`VR59\NRK6(SY&C0)\$60T$N M>N$L2%JH.;)KJB6=-`C%(G<$LH7$VN2RAG*BM@GIC[-83!"G147(U_>)PB1DC\1)0:B9D1SMZI".=@E MJ$>`GYHMTOM(]22IWGL'N\_&;%J00&+4.(*E+;E+@*1"E;!T)7D$*-L\@>40 M;.FU($RHG]E,]EJL7+%\MFH(1+>6"]CUGW-_#F`)X=2$:]19$9KQ+=1\^&^# M9;D^BY>!/D1Q*BJ09+.9)[V1@B[VCHA8T7VMT@:^\%1/CUT(1/SITR-2BK$% M@WJYP4'GZJ$8+=4[O5?Z`CNIK=XO7-I[QZ55]R%< M%%!!/3*NQMA5]69!@6;CK]U>6&'URB>KP1=6@ZO7K4I4?R9J!!K0,_%C0CM, MV]2OEOH'A2PTRJCO0FTS!H'O"V"F\0*=D1_.!:QJ+/O:]>\\%`DWV^+<-=/J M^2XRNA4=QA$"H[)9-)ZAWC3LB%JC#`0OG`]!B.E//>B\4_)D$1DF`1MXL7>R MVSY2,S$X.%;RIO#H%!I@,F`H!?[Q^W3_"(-H3&[P9-0H8WR6VY;V6:OO9/O MPO!#D,6[A2>_!1TFK@,&C_PY_L1%^&1B^[(E:U,6F#O8-T0HL(Q?X%B`.0`< MQE,`+!,F"\'#`?G:.]B)ZC#*(J! M)"06?:44P9F$+G.B"^9@V*067`6\H[T@55Q[Z!%@2WR.2R:"RK$`)C@\0F67 MU5LOL`D$V*/@6?O4>,58L/IE8#!<+%H41O4N&C'AD64K7 M*Z&#`-TS1U@XO,9#23(1#09Y8J<(C%AT_D)!\:"*J4'Y3"69A4SN:VX?W2:? M0TY\L@=/&,O0##KGJ[+0JO%]CT)ZZD\D#%X^K#ZB;PS: MH0IUB=3AWQ_0KS_]^T842[*$\ERL5SYY+_]^M\;K?1Y M"D<")XHZERBIC_#&ECUP(.?\>:"R8,*E.7O%9HB-`,!<+ET$/Q&IDG$68=\Y7Q[V:$6:7$#YM\T%^/1 ML84;DPO>P>_;:+.MWCMF5O"`X2_2:4+0*,C(M#SNA?LR.R<8^D'@*['84"-K M9)2"(1MP+0&/5K)QJ/:=C[$J*`7LF>,M*]5;6!)"H9,$V6";(SF%0'U#!+69^&F`@&!#W@A? M@`RLO`@VD-X)$!GA^L_(+'%@G@*.PYJ''2QAXN##4)!FW5<4H."2]4%-J_'P MSK-F-1!!"@C$7FQFHF`.:)@Y!@B#>GJ$2279"`D/&43L-#YIR6[+9*DP@,', M@)T3%J#GL)N"\$.3XN=G-U!1CDDD3:4^>).)K`I^5T&Y(\W6$K[L0]Y.$&/G ME0PNT7>_O'K:.]??1CP;T7&%8ZV#LD#SA? MQV(:\VMA+&U$6$..1GSR8`=S2Z?YDWNMPUVD5^Z3-;171(-1A//CTBH'QZI!K7)(5;YX65U269\[_ZG/6H MT+SJE0Y6M*RO7GI1_:$R4/';K_]X?J3B]Q&+Q,(3X6ON'/\8L9`=2P97&="Q M[2/FAIS-?.ZZ>J8&OR]AQ::K6F>5`'!"!K,Y8AN-(U8_HW,5[:IU=_,@8XT" MWJQUDE5^]%`@C\)0!S!=$X"('Z[>=@VCK$T2B[)A`3,P57WDW(LY+Y(X(U7/ M\/I`>+U^59GBJ8[]P+,2X5%P$5\LSI3,#NW84>Z@3?V:V(<,P+M%V)])U0ZH MTM#3=J;0W'*;<09M9<>'UM&3L1`KF)9O*EO1`R%8R4W%+"A0BZC"U*")@TSH MD9;8.4U4_H!7`L!%=@5/+J-2]*`NM78ZQ!0BD41P682#K-J8S1@OX/=B(;)P M.29#EV''GXW?8%+PJM@)/D'<#_P\CF>JL/`0(;P8(BD3V]DHQDBF:(3)$A`! M@E=GDU0>, M*=`[K^9I]?Z>DY`[DH;R[V/6^*"U>W@LQSYH[9P+(?/!J_[1U M>'KHP(B49%R+PM*H*>@'.VUF[!_,?['3QF0ZQ6AW>+=ZAP.4KX]W,)QF%<,4 M.G)MX1@W\YO56^RU#T[S@!]F2=J*5L^)%,4Q&Y\-`1#P6!,IT'PAHPXV9=3) M\7%K=]\=S_O=.76R<]HZV?DZ87P-IZJ&UJMYBH^F!0WC3?Y@IJDUHR8I>4ATC5QKQLKR1GX]' MD$:@G(>&RS,A<44.DJAWD1>C$#:!TV3I*(IM88X)]*T,K_#BJJ'&?4QT.B]J M\"XH\,@U+F(_FKT>E%NCYA8M-'L<`HWY9AGA2QPQ<'W7OD3"F0AFLH"7'AIO M**V8>AN(1TDB)X;#0DS*X10]>-(PY/^A+XP7+`(C"YNVF'J\8:"4AG`OUHZ1 M11,[0#FY,D;>SW_+J;%E\?8&_:C3U-M8$/*.24&M1F\,)T4L"D9+Z5%@$*'& M!)?TN.9KC=C,05>>S-D*V4IJG13L!?S-4 MR*L3#X7\A5V!/[R61>5=SF\2%!NP##()]'CO]-9;5=M]B$?^&`K>-K`91W9> M[AQ`C'9X1V6V0T'-+Q7>;(EK69F3+'?$R0`(W\9@GU!FQU]]UH+0=5TH1.8H MN)@*T*=VOVW+@&(S3X]R%;`E=79;>K3Q([OY*)A;^*D2=CDSRB7[;;>'QV(/-&MZG&0%#2R(5I&;0L/3#&NW-HXB78 M'.TF=#D57ZSEZ`54O-Q*!GF(@>B>DP7'D%"_I`8YA#F]<3P=:[9Z$:'CIMIB M&$"0N1B^6@S]*.9!@&D@M#(L(^-B,BGX:M6@TTOPFM/GIK`M`9LS:6.GH`!Q MH,('^J,()YOFY4Z979*&3#`T#]B9@2RH'/G"G`0#\*=BQC MU7>4@\L;F4:D?-R:0DD$X(]9RI$7>8;JNID=*[)B86H:2;=C2L*>LT(:8(*#H-!"5?W:XL;L3L+_D8=N+4B3DO!R),""F\2&P#'2J: MH/7!"5VAC%9&")!R5 MPUI^\V"@,9"A-6J/D^_GLSE0>I=JP^-\:1;JQ4ES7Y)>!`'8 MX1J_N,!H$$=SA"&L(!IA1-DT2"EA\`R;+>_$5QEBJ=SE_(7?$0:M("JOQRF\ M/\NN!EI_J.+[M"-3]"EHLJC`.HR1LS$JPQS15..-D<"=/Z@>6R7(`EQTZ3IV M`GYT``R!LC--^RT&`'CSO[PO#F5ME^H+=KFDY9;,%\6+WE(,0$+3G=Y/Q-U& M2`5%@'[P!0T9GQB:,46P!/DFXQ&W50;-*84GXPCJ&$I9:,(,@XZK<3,Q,EG6 ML;0J11+?8,X>/7\$MX`@Q-:HX<-0.37KNFC7QJ7?`Z96K/TSZ`F2"%4#&;TT M9Z(Q6)`IH)PNRC`,.W`3L[\#@0(C^.P'O%RQ&0^>(^!2P2!ME.4XU6P;;,)6 M*"P4D09PY^/##J9)![_$'\FS'("L0(5-,V\!TA7&WS(.YEI5M_/]-&)ZR()L MC@1Q5DB4&^G3'(B/\/E'N.\$PUF"T#B0>#[C$>3%T+)`)W@>`0;3%L&.PF]8 MV!?`37V,JA#P';?#K='9);:R<0B)X:B)UC\!H)&#,;XU?HF'(N-P,._.\P/Q M-5@+%-MA#T$N+\%T,LN9=%O03!@IZQ]!(/^$YR":Y=L@5A47@^,Z;YY+LS"`Q"?R M-0LT:O'%F5OXQ2I%IAYP(=JH-0R!"Q6#9X3>_F$=Y\06KU;&#SR6PB$*D9%A^9( MGO&`B73)C5$4@HR0L6__!7Y^/E7(&'K1.`J2G_R6S,W*>(,LT)WZ>@(,RY\U ML8T9^;R!&#_[&B][M9P[_HTNH(=$3!9YB3>PH!6$H-R`25#U4`!N0"7?M\%P M$L3`5AZ[@)9VJ_0MY09=5Q%2%Y2?CO=;.T=H0!^WCM'_W$6EDR?'7X>GK?TC MC/!*6F.AM);3N/@F44H5/*!)4$-.:XDSY<@GPW%H"@+LF"S';B`X?T_"D:CH M.'!<1%H1$#E@!`HM(4;)T9!Q8]@5FF[<5NZK^M@-9AHR(S?7P9@!W`E'T2UW MZ08QIN^!?PN@P/B6)0`#@41`,XF16^(8Y6L&VP7'H4E+*,>1+<=EY/8:]1V. M0QNG"&5=TFX\/["`+[KG6`:5@Q\A),'I@(:<1+`'F0A_#/.UH@KPY281NP1=[J&6"Y5B4@0?\_Q5 M!+I#+%AX/#D<*2&05;5+A0RC\N#!,Y%:'4TW>N=+;0_H8.HCQ3W[OM`90B/[Y035LU/6;RI?Z/J: M6=;J&C=?,L_72'4?(_QCOF$$AIW+S-ERYL!@?T\"EQXP"DW&SOC'+#'?[ZG2 M4ZQTO6JE#M2M:25\MBJ9*AD3J"Y:[;$WGJ/<(&Z\K;O\%@1/7'ZJNOEF+]FI M[762QT#U&>HT?E!7F'-GPKUX9UG])W(:1(?RNI4[FU[<4:4RWWW3+[9Q3!Y^ MUDS)8X*S>4@>*\OH7K$UB/L$>&`Y(!].Q_N(31^0(?[\G@/ITCCXF@6_8`)] MU9'/W:GTQM-NJBS+PKYR).:H2=-W0X#"Q4?,]JM*<&8^T%$>_D((;Q-.-QE# M@^*V]@X[[$PZUG#8\@$PB4:\9]ZZ_D($RNV@Z8`=3(44,U)(<^=F)*U9O63: MF`E%TRU?1Z#:A316?X#N"Q=T9&U>\)*(8@-9N^/6[HPU4X$-!JL_T$)7?Z^Q MST:QG0(LYJG/&174WF:^(6ZQ6%(,[6Q#38IO?EF5J[TGTD?>QNQ;4H!\KO19 M:=:!_CEU[9& ML)W2*,YR'H#)`R-`F04H3U$PM,[0_:$)P1EJ,YO%22`S3U`%F3Z@'Y&=,^S0 M9'CY-`1'8TJC#<^M[8PY-*W=;VBDJ^T-N-[7VO>I@8F:\5G/=I[YJ=7[-0%+0EOJS:;`#4TQT MQU\P(?6['\C9\L+TFS/D]<0RLV]U0YRK^$@DTY2NVWK>0,S5]<[0&D-.-FKT M$^LW7/?YVZMB5M!FF]6]G1M0LZ,_-C>64LSJ0^"2]#2;3&`@?3.6@Q6QE[,,\_,SKYR,_YNXWO* M9R>*W3"8J-IU5U66'@3-0W)U:_N_OUK\9Q M\N8YGUX<)U%`1!!/U)1^]V;SJ^Y09J*N'6MT6$^%;TNEY=V:&_LA)W[GIN\L9DJ8IOWWYX#L+( MFGL`=:,9EIW+9A<[XGW7CL(X7";7(*X3+I>N[>RB''5&'9!T-P[6ONDGL6*' MZR"9J'IQ2TF_^;"8J#>JDIH\"Q<`XG?_7H?)M[])?[W[P[MWW7]]\^T_?G`6 M__SQ][O?_?B-VLG5$)G@@WJ9U]U:L?!U*KF367`W7H8!,40#FI"MV]<@_!*8 M^!T$`YB'C]V-XY^5SY8'=S2$9X=>&"D)>!GL8W<"RW?2)V:6Y\XC%Q];6K[K MO:6W=;S!`B-[SG?!37BSDVJXK)XYHLEM&B(,SJ8>WJ$V^6"2A3?K;;)^VF,3 MIZM_6-IY/5-.$'*)UNT@K==B9E(UF M7=!W,64W_8M9UC-[YJ!5R[A8W/4;*NR9;5)Y0*'Y?G!_,3K;5U9E79:&+U4# ML,*URZ(+5;>F?@],_+E$G%RX03N/QYA4+NFSJE?FQB?7=V+ET?FB_!#Z5H#$ MTD:-/E[18^OUL4\#=^[&T'E,G"@PX4+)/C^] MK:!'$T`_%VGII,\=>/HYLMXTG;7K8@7BT',7B.)YQOI163LVNWDP9P],+T$F MBJ)"J&G.!F<0^C`=S=I'.AN-VA:JF_#3LM#W??QI6:@)?V:M<9IE,J,MD(4\ M)7%QW-.]'HQ&HZ%V,QP.1T9/,PQ&\CR+:#=8.!L'AT*MT;2+H`\(1KWAZ$8' M(%UCR%1=%$$/``SZ_6%?&^D&_&6I\_P(VN:TK\KV*D$@R:L$@22OLJYWIX7, MG]44F(607%<)`DE>)0@D>770<@8>2/)0@D>94@N+17LV$5=JQ--GVPVS-KK7^<#^%F#P_- M=;%1(XQ3YV&T@&68?&U!,V",F-Z[&WO.,H$1:>0^O^#O)%S!O_,P26#1XFZ\ M<*WG,+`\^-C)2^2_:TK"L@ZLX$S4Y,6U7T$9-VN0&(NL9.)HP!D9W M8/3UFW3`UI)JWUFX:W_7ND+WWK@$&I';PX83#H-"218.YQVTPDS43WU`@GP/1&S'P0IL\OGP2)[&#U8IJFMD%]VZL94QQ_6.]YCZ8$2 MNW8>*+#'R@,E1&WDXR;W+B>\F+K`]+P'R1;?W./'P0!%:<$VF$`"HYJUH,;N9*[+6'3H+MN-YG[#Y M_ONRZ#'`)-S=>+,DVP9@+P>NJ^.N!/P(,]W9Q[1WD%Z`^56%],I"BK5:>6^/ M:W_N1";;X,%4L+LXHUY>35FWIKQ^[[G/@>^P:40U%?-]%":.G;`-*&P%H`I/ MKP(/[%X0QG.*?J-"/_!T$?TP3;77B<"+5/T07,+ZVXP'W&J3!36X@`9U'9XV M$DDS7-0`.$EE58J5E6*(VZ&FE13` M10T%)K2Z[31Y6E7.ET8(2;J`H60$TD`=(^U%)X%I(21@`CY1:4?83-*[% MN"`-!(*L#$FB09>5(BD&63FR=(4N*T42"+(R)/6$K!1),=N6 MGY"G<%S<*A$G8,'!Z=>"Y6OB16L[7FA2PRT?M+_2O-5M&]W_(RA?E*_N9Y[L M->&J=GS7@*3;T[6=$!2M5Y]?9$/3VYYOXKNA?#-GLA6B?#11&0(TC^0CGT;D MD-3!X\,U#'&`TVP]Z?R`26O9VYX\$\7%T9:T\ROV5>"_@?D%Z MR?B&=@EXY^_"W3_$J:MD1\4PVWW9<)`LD_13\9XYAPG&!&G8N)BX"+HCJEQ5 M#-?C;1["0FGM*P\!47A5G-8W"E\II_6@Z[+6V5Q>W3.`VB?>TAZ558]JRRH! M-\(KQ&>[^'8;KSJ'_]((O1S>ZG:U4004:+@VNSHSW1'HO#?<8>BO3%QPS>&YZZ_(96R:$A4'RF@7_DD6QC*C@N4IP M#F3WM\J5\MY&H05TG`*8KUT/7NW&]4%6$MDP1LHC67!5HQ,%F[**'$9L'S1%!<4 MR63QW/<%N3?V^9%M7RIQH`GG$(@.^$+>H M\%&/9]<09'=J+?*LRP<,MC,B,.#$8'OMP4G.(9X#S?;28/M/#,*=DT*27AS[ M59G!JY&%(+X^8#,J(NAAL_*LP$K"Z$W!_3.%.-[I?4%Q?PS#@B->@@Z7(H#^ M!*=FPX'<"O"2,L3',&Y":2*FJ`L\/;B9OHD8*)VBX>,/YZ>:B('2J1@^J6+_ M243,AV"U+CS$YU)LND5$?'2#5V?!1P[/L`X@120].NLDLHKXXZN4+DC,([Y0 M6\C@4T1Z0F;^]F_6_WR$]V=S$G&'#JD[.+(2`?Z7=4)H9&^UE/T4.-I.2,B3 MF\`I"7DEYG$`+!$<3R'L:2M$;&4401E_LZ(`:PM7=;=BM,*BNB_$`T+MPEM;:2YZ*+R=J^?G/[/P1"*;LJ>_=SV'"1$S4\O-' M/-@%:C&\BPWIYF,,AX7`;V4=N1/U/P_3P>C^P=2OAMWI\,KH.?VK47]Z?]4W M9M/[>W/4U;NS_P)E>`C_+9SB?L(A]^PP?M@CJ!FWL0='X4>9L1GX3^6]B4HN M4OCL-`>`#<<&UL[%E/;]LV%+\/V'<@=&]M M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^-"0/E(<8 ME@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;` MU#*NU^MU>[66\/7.=K?;=/`&9/'-)7S_2JM9=_$& M%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!` MAA6-D9HG9()]B.(NCD:"8LT`;Q)__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\*1R5 MD1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM' M+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO= M?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JV MY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77 MY44IABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O-29 M#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H< M8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AF MBJ+#+5=9F]B(K5"MQ:FNP;<#N+DXKLZBO89=Y[ M$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.O MA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/, M>E$*E%2CLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q M@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\F_W4`BA;JI)6@8, M[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QI MT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD* M0Y/L(&,<8[Z4%3]F\=%]W.#W!!0M83NKK0KK59[>3:) M0ZPF<62;TO[]CFT*N505Y0''PYG#.3-C9WG[W-3HB0K)>+O"ON-A1-N<%ZS= MK_"?WP\W"492D;8@-6_I"K]0B6_7GS\MCUP\RHI2A8"AE2M<*=4M7%?F%6V( M='A'6_BEY*(A"K9B[\I.4%*8I*9V`\^+W(:P%EN&A;B&@YT:RXL6#[J!YR;HL!Z(;E6BFLK;!J6$4762\&/"`X!U%!V1!\I?P',NE-S M6-_N%%17Y]SI)),*:`G3];3VT]G2?8*1R$^8^RDF&"(V;R!&D&P*":,ARW8* M\=/Y&>."S;-7F(2^U_<]:C#4`J.+QR0Y\YHZW%N,G6!=F,TXD(T#VUY@H`T& MK*]-]V$&Y^Y]C3H)<'V-:3C2:#&IZ5*0^)&G/T/,QF(N/K)Q8-L+#&1#??JR MWY>KP4.YP:53MJ(6$ANULSB)PZG8/F0>17"SC_UD?4B4>+[&#"UO^Y`X3+RX M#QE8A-/0MWA=9W32T*J?CB;WWF).G=$NQB(W%M'KRS@`E[C^'X.PHNV=;(]X M1_;T!Q%[UDI4TQ)&RG-BR!#V1K8;Q3MSE'=MWH M.__\*E[_!P``__\#`%!+`P04``8`"````"$`EO[K6YT#``!0#```&0```'AL M+W=O]6VI-.J]V[9Y,8L)K$D6U*^]_?V!,2V]EVX:4E]M?CS_S(,*P^OU9E\$*% M9+Q>A\DX#@-:Y[Q@]7$=_OSQ-'H(`ZE(79"2UW0=OE$9?M[\\6EUX>)9GBA5 M`5BHY3H\*=4LHTCF)UH1.>8-K6'GP$5%%#R*8R0;04EA#E5E-(GC>5015H=H M82ENL<$/!Y;31YZ?*UHK-")H213PRQ-KY-5:E=]BKB+B^=R, MC-$PJ/+EUV/-!=F7X/=K,B/YU;9Y&)BO6"ZXY`J):9-AD)^EXM5_*$I: M4VADTAJ9`GV[/[G52(1`QK]'HLAF)?@E@**!*V5#=`DF2S!\=0PQ.E??\Q1< MU$:^:"O&%C@A(3TOFR1;K*(7"&G>:K:H@3>BU[B*W56A,P%X'2,X[C-.(86_ M#OX521]RD=+4O6\[E$Q=Q&&$V-F,'[-I,92`%8IYTIDU$=VB)#.Q M7$PGWO;.V4[G67?:@9K=`Z7%'M2T,XM0*%D8J(=TTH?";.^<[476A]N!@H*_ M/5):[$'-/"B4(-0(J/IKD5F_XN*:UV+UY4-,HL2[& M!4P=%'D?(0??P&!/M9M?DO5N MMC0HLFFL%?=VW0IOKM($&Z=]^Z!,6XU].9Y*S;L\F?5Y=$GN:K?)#?VVU=@D M>.IW)'?U6#W(^.],[V*;$-38)+B"WU"C]X-R5U^%&6Z`,JA4U-@H?BN-_5<8 M!SL0!P$3H3XH'ACYHX]5S#)F8\GF-PI=-IX#.(#Y^KZH">=[K?`YG\```#_ M_P,`4$L#!!0`!@`(````(0`0_1ICR00``"D1```9````>&PO=V]R:W-H965T M$+JN&;(VZJK(./S8-;?.Q&0&>QA>HQSZVY!4RKQ:&`"(CL1H.. M2W/M!*GCFM9J007ZJT"W=O"_T9[Q+6Z*P_>B1J`VY(ED8(_Q.S%-#P0"9TOS MCF@&?F^,`SIFU[+[`]\25)S.':1[`A&1P(+#5XC:'!0%FI$[(4PY+F$!\->H M"E(:H$CV2<=;<>C.2].=FL8>M5U4$"K3R*]MAZN_V9<.IV#.+G>&D3M[_F@R MM3T'YGKFZ'%'&+FC,QU-'7ON39\[CKDCC&+&ER8$5AHFC&+"YZ'YW`%&X?#: M"D$].A.,_VJ%L"&I'XQBPN0G89$&A)K2*(AZ1"19`$!AK(\3S\QIK&+%6\X,N[K?:LAH8;L M-"32D%A#$@U)AX@4%33N852LJXW(\=*=B_Q]@R%WT`<>1.M!]V(]C7#(P7*$ MG:2TLC4D9(@GM4)?:86[WDCH&&E(K"&)AJ0,84>[%#^22L' M;M6OBT6M9;4XY$D=WU?BV@HKKR_C4$#T`4![RDY`8[8]QNY4$3`2%G>>6$!W MGD1`G,>S/54/84%Y9$'(!6APY7N^)QQV78+S3FRVC8"&]>/X2B!;836H(`%) MCEH)<2MO2C5ZLT>>HG4D>.[4L8">4BETV=MV29&/0 MH$>Q=QV[CE>H.:$M*LO6R/&5O-D@@ZM%#[,'9>@'<`Q`)E1\&D!GU?%X&D"W MU'%XF*YI1A6>#7FP/K#?N`%<('6>C1?`C4O'U^-@S1Z^Z@3C`.XBNL-F$L!I M#KC5.\!#]9*=T&]9L*=KD?G?$N!,?R`3]CQRK?P```/__`P!02P,$%``&``@````A`,(E!-\3`P`` MK0D``!D```!X;"]W;W)K&ULE%;;;IM`$'VOU']` M^QYNOF(91TFCM)%:J:IZ>5[#`JL`BW;7E\\2DXJ*.2>#ZQ&%U(E)>YS'Y\_O^:DD=/Z[V0 MCZI@3#O`4*N8%%HW*\]32<$JJES1L!K^R82LJ(9;F7NJD8RF;5!5>J'OS[V* M\IH8AI6\A$-D&4_8G4AV%:NU(9&LI!KTJX(WZLA6)9?0550^[IJK1%0-4&QY MR?5+2TJ<*ED]Y+60=%M"W<_!E"9'[O9F1%_Q1`HE,NT"G6>$CFN.O,@#ILTZ MY5`!VNY(EL7D)EC=!E/B;=:M07\YVZO>;T<58O]5\O0[KQFX#7W"#FR%>$3H M0XJ/(-@;1=^W'?@IG91E=%?J7V+_C?&\T-#N&52$A:W2ESNF$G`4:-QPADR) M*$$`7)V*X]$`1^AS3$)(S%-=Q&0R=V<+?Q(`W-DRI>\Y4A(GV2DMJG\&%+2B M#%@WX!6#<73$ZR`-H#+#T*E\2R2H0Y(;9(D)'%0(5^#L MTR98SM?>$[B1'#"W!@/7$Z9#>*"FDP0R^I)>M^>8&<&8&>U"*;?F03]-^'J: MB9WF6/GY=!@$#O6+6"XZ?J/`8-H.6G5-[83G$R$X)G`]N;5<#A(9S#@1G(;+ M#43PH*(P&"0R&+B>Q(33#F,5.?](;@0/X:3!V[EF'L7(O[-R7=12# M!AHBO^,W&@QF;#1.YM[+<[ZC"'ZOHP8S3A1])!&"!Q6-.FHPMJNGXV6Y&L`X MZ%>)MBX@\GRU;=1`Q:BW!Y`E(SH=/EL&SH^>V9=U-S!3QWIAH]-`,.T]@,:V M!Q\:12WZO0X?0*_DPK'1J^\=>\V0L>H:-3DP(,O>\*TN#Z;3A?::$63)&'?Y M.*=ZXV-Q>LU-E\W6-*NI8C)G7UA9*B<1.]R(`>R4[FFWK6_"=K5U?\"R;&C. M?E"9\UHY)&;SV./<6Z_OI8GYSFOFZ(Z M;UQ_,G6=_)Q5N^)\V+A__R6^W+A.TZ;G77JJSOG&_9XW[M>[GW^Z?:GJQ^:8 MYZT#$<[-QCVV[27TO"8[YF7:3*I+?H:1?567:0M?ZX/77.H\W75.YUM_8@TMWMKH`,4':GSO<;]]X/1;!PO;O;3J!_BORE,?YWFF/U\DM=['XK MSCFH#?.$,_!058]H^FV'$#A[S%MT,_!'[>SR??IT:O^L7G[-B\.QA>E>0$:8 M6+C['N=-!HI"F(FDD54G(`!_G;+`T@!%TM?N\Z78M<>-.UM.%JOIS`=SYR%O M6E%@2-?)GIJV*O^51CZ2ZH,$*@A\JB#H_([#7#G`IW983N;!8G73/?8=SZ7R MA,\/\_5D[IV4<=JF=[=U]>)`?4)VS27%:O=#"*PUE#1Z5=\2%83`(/<89>/" MP@*]&JB$YSO?#VZ]9YB]3-EL1VRH1:0M4%\,&]M`8@/"`#S(J$\+IN-_2`NC M8%J:T%8#0YY6EI&VT"ZQ#20V(`R`Y##C.J!>? M(0E#A(F0+$#KZ[-`XRX+_>RM0F9]]40,B1F2,$28".$'R]7DATLW6$S`_(.+ M%^-0Z@H!90RU%Y;:O9'..&9(PA!A(B2;%%4+F7EMR]42\W0Q*&"!,AZ:QI.N_+C<:4LD(,N1D2 M,R1AB#`1PL^'XX"M]P)V^P_6=A>&4M<0E7MER3U8]7IS*.&0(!!-"9N544+O M:^[+U@;[HB:PU9"A.H=B#B4<$@2B-+$?74]3=B]"4T%4X!M;X-Y*YQ?[#$HX M)`A$F6-#NIZY:E^FP`HR!690[#,HX9`@$*4)PGR`)EI;%2PA?(*Q/Z]M@975 MLB^@V%<0;'*#8^!3QT1;#8Y"0["=&(Y#DZ;Y8<>Z?AI4?S.G04(TOV!*:49X MU`=A_(%FK*%5GW*BH<%*:*@[UU'FV)VN9ZYZFWWK3O() MMQ($HC2Q:UU/4_4XDZ:$K`*R.ZJOK(;5'G,HX9`@$&6._N'J$AV"2,&ARV%9(I3.ZG,NW\Z':F(+.H M-&2DQ:&$0T)#)(?9L'70'#[4D.%]R=Z(%4282RMS5])60S()AX2&NFJD-+$M M?J*H\)7*ZAP*PAUPF.*9U0`B;64LC`$R'`.[J`8KO3V(`3(<9V]TC@`[JY'I M^XNFL[9*B;7F2%N9R3"KA%L)`M$)P39JT,15OH*KHP^?3@/9CT$CK==60[2` M[0XR6&G'F$,)AP2!:%+83HVD?J"];+Z$N82Z"S\96=[NF,J\/>92?3HV3 M54]X*S>;PD51#\LK0SCBAG@TA:S82``CG5!L9`8CW6NV/1+`"$SC2+1@#B-= M2=@^BQ#>N$<\EB&\NX[@JQ#>&4?PFQ!>OD;P=0@O/2.X/X4LNHYI,_+7X19V M!^X3P4@T.A+#2#PZ`AM_B-L/CP;7M??C^@*Q$?LM3,BH/8@^IOG]'.*/2@MS M,385D3\/\93'J<)!-L3#'A^!PVN(9SX^`F=8R&-L9.LOPRV<1K@/G-2`P=A( M#"-XSN$^<$@#!F,C<%8#!MV(U\\Q7$A?TD/^>UH?BG/CG/(]+(WI9`6+J997 MVO)+6UVZR]J'JH6KZ.[?(_STD,/MW11WGGU5M?H+D/+Z'S/N_@,``/__`P!0 M2P,$%``&``@````A`-UD5UL.!```E0X``!@```!X;"]W;W)KUNIE:ZN[LLVICDZEK6[1*6997AXW] M[S_/D\"VN$BJ+"E813?V.^7VY^T?G]9GUKSP(Z7"`H:*;^RC$/7*<7AZI&7" MIZRF%43VK"D3`8_-P>%U0Y.L'506CN>Z2Z=,\LI&AE7S"`?;[_.4/K'T5-)* M($E#BT2`?G[,:WYA*]-'Z,JD>3G5DY25-5#L\B(7[RVI;97IZMNA8DVR*V#= M;V2>I!?N]F%$7^9IPSC;BRG0.2ATO.;0"1U@VJZS'%8@TVXU=+^QOY!53$+; MV:[;!/V7TS-7?EO\R,Y_-GGV/:\H9!OJ)"NP8^Q%0K]E\A4,=D:CG]L*_-58 M&=TGIT+\S+:<+WYT1@%L[RL5S+BEM*SUQP4B&2[;MC9@J:!*7F=R!8D*R"^+`QE]$N]M5)8HB3Y(EE:+E@$A_*\ M;L/%VGF%C*8=)$((;(@>0G1$?$'(0H"Z7B*LVY0X@PI>S_U%D1RD*_*,^:(K M$$/1&+%8]A!-(Z1.U?BQ-@G>V',E%>%`VR8T0@BVDLQPK+S0)@:6QR>68&@] M9>+EO%\/3HR0L*WA)%AX1AEC/>Z'LWZ\)@NZ^G%9$JS+"OV>%F4A9-'*(JX> MC+7@4&5-T/)7!$FP(2C0YXP0XG>"/$\/QQA&O:$W"-8T^;HFN??N-[8<9&@+ M]B;ZM3P[-9V"W5Q M'V\W"39%#5V"HA"#Y9P$P=SHOUB+^T$XI%RK*`%?4K/VL;`6K1L!<8U\1!U( ML0+UC3Z[8>9W9D>_5=V`N,-VQKP0!&&UC$K&-X*Z)L.][VA"Q]4UF19%$'1# MT_6@KDF:J=+;=S1)M%DEPQ8C@B"U2LH;??9?LFPR]FSBFE^+#G0C(\B`0>(. MV=15&8[]F!G),]!H;QE[)^I`%P%&@\=:>&@Q79UAWP^J&_LX<4TC)ZI5C[9? M;(1O9>^WK)R,O9RX@[-T.Q!!%VORYT;KQ1U+!_!]Y>2EY_"W')U5<`R M<,G0J*@1;P=X>BYIPD3_X$C@+]6[R51/)6TMXK^@!<"NKD0'\D MS2&ON%70/0QUIS[LHP:O%?@@6-V>7G=,P'6@_7F$ZQ^%HZ`[!?">,7%YD.?E M_D*Y_0D``/__`P!02P,$%``&``@````A`%`_.]&Q`@``'@<``!@```!X;"]W M;W)K2=R6V5X MG`3Q-!Q'`$=K;NR3<)08L:VQ2O[SH&A/Y4E&>Q(X[TFB.)B,XNGL!A;B.^H, M/E)+EPNM=@@V#6B:EKHM&,V!V3D;0SZ^C][K1U;!HR-9.98,PVZ'<@/+\[*< MI0OR`I&R/>3!0^#80Z(>0:"9OB/HXKBCRQD?A!W8";O,72ED/Z3;]B;WD5.>V=%W10&\\T/.0N$LW#3Y8VNFI M^/5L'7@@^IZ=-^DAYR;=>+_P\5S70&E83"%]=1^P/D;J]IN M2*R5A<'475;P'^+PK84!@`NE[.'&C=#^S[;\#P``__\#`%!+`P04``8`"``` M`"$`XF/@;7`%```0%0``&````'AL+W=OTAB3UB6 MGI=EX_F^P=_,V!Z\^O)>G8Q7WK1E?5Z;;&Z;!C\7]:X\'];FWW]EL]`TVBX_ M[_)3?>9K\SMOS2^;GW]:O=7-NNRPMJRV.O,K;>7WA9[#L MZZ;*._C9'*SVTO!\)TG5R7)L>V%5>7DVT<.RF>*CWN_+@B=U\5+QRPO[=5;54QQ5^7-\\ME5M35!5P\E:>R^RZ=FD95++\=SG63/YU`]SOS M\N+J6_YX<%^515.W];Z;@SL+)_JH.;(B"SQM5KL2%(BP&PW?K\VO;)FQT+0V M*QF@?TK^UBK_&^VQ?ONE*7>_E6<.T88\B0P\U?6S@'[;B2$@6P_L3&;@C\;8 M\7W^7AV$&Z?5`DA"UWWQ/>%A!1<#-W?.&IJ$\P`?AK5*4H#8A( M_BZ?;^6N.ZY-=S'W`]ME`#>>>-MEI7!I&L5+V]75OPABO2MTXO1.X-D[@?*: MR'5[+CQ[+O/F3N@S?_$_9N#U7N#9>W'@WXE3`*$R!O"\3L&=A[[O+<)@>A`6 MO1=X7KU$<^;9$V18F!29XR3O\LVJJ=\,6#@0]O:2BV7(EN!7)->%$AE.+F15 M<+X*DJ0"NH6*?-TLHI7U"D54])`M0B!)-TC`=$@\`'%T2#(`<75(.@#Q=$@V M`/%O$`L"<8L&E)<:C?$H"+`>A<"^N96!VB)$+DXY$-.!A`ZD="!3!K2Y0CE/ MGZL`0V;5="S(7!$2R70&CL](1F/5[I`L)*K199YGWP,LA:>($B:@A9\`6(9@X9I.- M.U:M9*:):GM@IJJ5,+-AFR8W^A&Y@D3DDO-LBQ`E>3B`R6.^;9.Y)I207@>& MDG>UT>0Q.-#5[(TO-XG6=2Q(8K8]!N<]"X.(G`=Q#QAER;_3+S`KJSQST`%3^Y#KW\M+5BY9!43_MC&38:&A1>,@[8I0"[ED8%\=U["A8W*04WS+$H`1H71C90>,>T*>6Q"31Z"X+ M/9?P4PTQF%IU!C,G<&UEQ>GJ10.AJ)^86FP[M"C0]H\IK8E,6]R/]*GUW##T M'^N:LE*--9Q:A:.+$QV$(NZ3U&*_H8H*:!LDOE-A3T8)S%863"\1[1]L4^/D MM'<^2,X^,.IZ11LQ72\V':I>I4JDGBU##.J=0;Y(K<<]8'#.R9@Q'3-F(^_5 M%8O^8KIB[$94Q2%96UN&&/QL<1<^(\LSU@`.L2::U661YY/6,M40@XM7G<', M"9D?WGWHZD7GH:B?N'BQ7]&B\%#GUYY&7+_(KQ>X$;I7OO/!XJ6L5&,-+UZ% M@^+PX@@O%2K>''C,3Z?6*.H7<2DD*NTVBA=66[:$#V.8*1F/V1*^CQ_'$[:$ MS^3'\90MX6OY<3R#"S$Y;MU>`/=1E_S`?\^;0WENC1/?P]3LN;A[:?!&"W]T M]45^T3_5'=Q$R7^/\V+K=96[^`P``__\#`%!+`P04 M``8`"````"$`[$3'OQ(%``"V$@``&0```'AL+W=O$0&XHR>H0PD5JI:K:ML\CFO[ MKV_QEX5M-6U^V>=G>B%K^SMI[*^;7W]9W6C]UIP(:2U0N#1K^]2VU\!QFN)$ MJKP9T2NYP%\.M*[R%G[61Z>YUB3?=T[5V9F,QS.GRLN+S16"^AD->CB4!8EH M\5Z12\M%:G+.6YA_[]^*6AU!8G7\ERVWSM1VZJ*(#M> M:)V_GB'N3]?/"ZG=_4#R55G4M*&'=@1R#I\HCGGI+!U0VJSV)43`TF[5Y+"V M7]P@0= M=Q7XH[;VY)"_G]L_Z2TEY?'40KFG$!$++-A_CTA30$9!9C29,J6"GF$"\*]5 ME6QI0$;RS^YY*_?M:6U/9J/I?.RY8&Z]DJ:-2R9I6\5[T]+J'V[D"BDN,A$B M\!Q$YNYXZ-0D.X&Z3;F%I$(D1TB,2()(BDBF4JTJ&8_$Q4SUJ,2!)*FE,_3 M%_.V-Y+)B!#9(1(CDB"2(I*I1`L4;H?GR\>,]4`%40@IE@;/ZSD;UX(;A]P[3T(,5A+<9W>F#2,2)!P^E M\KY>^5UO)"L?(Z&DMU&%IKI0VAM)H4P5TE("%[":DCNA0T,D8V?&>NR"*+$C M$@DRZR^H'2(Q\DJ038I(IGII4;G04#X?5F>MQR41+"6E8#,]SUMI-=R]D42: MHV\X[H25-^\:E]G46`FQ5!F$$XD>"J>Z\&1A"&=2I1/64\::%&5S/%X)+F]I MX+J22RP4R--OL+F9,N[H>;UC-#A*K9U$;.E];&;&$1G+/P\BB43#A%*)N(@_ M7>A3R>3?.Q4]%ZQS47+!6]2?/"A0/T>TD8B?3 MQV9NK+`8BR328Q!))>(B2Z.3R#01/4.LZ?G/&1*=TS"AT.5(6T1SH]W;2J.A M_)%`OG:UXFW'U7V^(N9+M*[$Z(-P\I1P*JVX\,)#VTX5UA/).J@'B?Q&KS^Z MDY2#&5ZUS9-9H.YDYB/REVG^*E:1^DBVY'QNK(*^LQ=EV`V;58_Y6WPX#^`R MA5UI\&@1P&6%>;((X.[!'+X&O'1%-G1"]I7@CGTX">#E`>N$7@#=-N8O?O#" MOS:8`_@!M*C8(9P&T.3=X;,`>B+@3B\$7PVN^9'\GM?'\M)89W*`9(V[LZ#F MWQWXCU84ZI6V\+V@J]D)O@\1>!N!UV3;.E#:RA]L@/Z+T^9?````__\#`%!+ M`P04``8`"````"$`4V\Y2PL)``""*0``&````'AL+W=O78<)3'&M@)+ MFED-__-7>',W'%3U]O2T/92G8C7\453#WQY^_>7^HSQ_K5Z+HAZ0PJE: M#5_K^LT;C:K=:W'<5K?E6W&BEN?R?-S6].?Y952]G8OM4]/I>!BYX_%\=-SN M3\-6P3M_1J-\?M[O"K_[ M\OA&$H_[P[[^T8@.!\>=E[RLW?P!\L?][EQ6Y7-]2W*C M=J!XS[H"8?O@7#ROAE\<+W<7P]'#?6/0?_?%1Z7]/JA>RX_H MO'_*]Z>"W*;[).[`8UE^%:')DT#4>02]P^8._'$>/!7/V_=#_6?Y$1?[E]>: M;O>,KDA1PL'NOZO+XOS;(D5*MB"M%Z+-'Y$+'B>Q(G]S1O;V; MS:;SNP5]_86>4]F3/F5/;=@7^I%J<[WT*?LY2W6]%SK.94?ZO'*H"]F3/J\: M*DW19JCTR4.E7R\,<2D[T.>50W0H[]HT$`G8WN+/^>ET"42_\#`_YZC#:2-^ M^=R`1VWV-I/!W];;A_MS^3&@)PQ]>?6V%<\KQQ-R/`U:M[J)\?_F!4T(H?)% MR*R&Y#*E?$63^=N#,YG>C[[1!-S)F'5/C!FQX0@QVX2L;X/`!J$-(AO$-DAL MD-H@LT&N@1$9U[E'AOT;[@D9X1Y?]YJ!LM.UK.(([N+;(+!!:(/(!K$-$AND M-LALD&O`L(J>5E!XF_<];SBO1:S6D9Y665S/3BG4;X[9/5I$V&R`^D`!( M""0"$@-)@*1`,B"Y3@R;Z%(-FR[;(Z)70Y<\U_R96_[((/I*+6AA!FVZH"ZA M@`1`0B`1D!A(`B0%D@')=6)81DETA64BNK&,+W0MR:2;?AL@/I``2`@D`A(# M28"D0#(@N4X,,VB5-@N:%ET9V51%\3F^D`"("&0 M"$@,)`&2`LF`Y#HQC*--AF'>,J!*LW&&D)0\B'U&`*$04 M(8H1)8A21!FBW$"F,V+GJ#O3EB*WHIZM7_>[K^N25A[RH\>Q"94(D68NR1GC85O'-!A&1+]&$YKQ:X*:.F8.!BF+Y$%&$*$:4($H198ARB=H+ M,CT4^TK=PQZOJ%MGEMR&ZF:U:++L_-LX@'R)IC3S-;.L&B504K MIZ5$M&/I$FYN3?4S4E(!HVEC$)U@6C^PE2Y]59?OG8D,E+E$C)1.S#J+5J?'5CEF)9.B3,8R/)S%TLJ5G#OU M)*O8@U_AJ]RRZ[ZVR$A69VJ??S@R2J69STAI!8S:-+L9WTXLG9`CE$[$2.G$ MC#J=L97V"4O>;%04K\<^H@!1B"A"%"-* M$*6(,D2Y@4RSKBMHZ)C63B-&6AHA\A$%B$)$$:(848(H190AR@UD.O.O%#3B M<->:=XRT@@:1+]%/"AH5Q3D8(HH0Q8@21"FB#%$N44]!XXIZX?,/J2;L!>O#PC%F[LD30BQIG;-FVX2BU+_,9*:V`D=R7@4OOF*DME+:"^>=THT/^?A,GM MW6I?QVG?0#@6YY=B4QP.U6!7OHM7;9J"IT!K5[P(U)QBV"UW'IW0D[3- MEQX=5O=P9^R)D]F^%OH..IGL:R$QVBGVM+BD1MLB;*%G+[4TNQEK9/1.TY?& M'HNOQ=?W**U=$NKC]`7-_;)TODQ)OZG?K(;UU*/_G^)0US./_I78P^<>_:>L MAR\\^J<1IK>%UFE/K,*HYKM3:ND; M04A]Q.*!?2)J$0L&MM!2[(EU`UMH1:;KZ6NA$V1/G-9BGS6YL^YUA\Y6O4UO M"QVQ>N(`%=7H2)!:^D804A]Q[H=]Z)#5$V=]V$*GJ)XX\L,6.DREZVE:1ETZ MT1MP;]N7XO?M^65_J@:'XIFF[;@YHS^W[]"U?]3E6W-6_UC6].Y;\^LKO>M8 MT-L9XUM:^I[+LN8_Z*M'W=N3#W\#``#__P,`4$L#!!0`!@`(````(0"][MXA M?@(``"L&```9````>&PO=V]R:W-H965TND=(38.A<01OO^YPQ)QJIN4M,+SOX4QFKN8=/6S/76\G+L$FW;)*F M,Z:YZFADR.TY'*:JE)#W1FRU['PDL;+E'NIWC>K=GDV+<^@TMYMM?R&,[H%B MK5KE7P,I)5KDCW5G+%^WX/LEN^1BSQT^CNBU$M8X4_D$Z%@L]-CS#;MAP+1< ME`H<8.S$RJJ@JRR_FU.V7(1\?BBY@7<]Q>+(QZP9[!M/B- MN8L8>+YA!@0#T4$9U,Y71C`J8RI8REU<.)29G):9CF4P],N_AKXWBIL`=VAB M=C/PQPHB)C1JY`MVG>\+P=!17;:SGPL^^_Q1/!8*JX<]"@>SG@" MM+2U_"#;UA%AMGCP)C#3P^IP)ZPFF,:?ZY?Y*MP5;/@!9[7GM7SBME:=(ZVL M@#(-$=EXVN.'-WTX=VOCX92&UP8N90ECG2:09V6,WW]@&X9K?OD+``#__P,` M4$L#!!0`!@`(````(0"AH->MJ00``+(0```9````>&PO=V]R:W-H965T^8+F1EK;-.;97GV.0]SGG/F:U??/^O*^$!M5^)F;=J3J6F@IL#'LCFO MS3]^Q-\6IM'U>7/,*]R@M?F%.O/[YN>?5C?-R12"]A4-?#J5!0IQ M\5ZCIF)05F7_145-HRZ"[-S@ M-C]4D/>G[>:%T*8OFGQ=%BWN\*F?@)S%!JKGO+26%BAM5L<2,B"V&RTZKZ";TE;'G\I&P1N0YU(!0X8OQ%J=B00!%M:=$PK M\%MK'-$I?Z_ZW_$M1>7YTD.Y/`HR$QF'E$J<`4#@)]&79+6 M`$?R3_J\E'(1]SZ0)Q^'+]`,X,GC%I/AVT_B?!X'3Q[G3=R9YR]HYD\" M8>K0#\*3!]K39R.UF.6T@F'>YYM5BV\&3`LPM;OF9)+9P=(T1.G8IX=B_E,M MH8A$9$M4UB8,!LK400-^;.R%L[(^H&D*SMD]X,B,O6"0#B&RH0I$*A"K0*(" MJ0ID(\`"$P8GH''^!R>("G%"Y+`3P-V:F9*V8(B04`4B%8A5(%&!5`6R$2"E M[A`RK$'@V2G2J),I)LAM*U^\'TE!=#8DT)-:01$-2#-!I1U8HMC"133D9#G"]BG:OAH2,L21UCO/E=LC&DC"QU@32@;.N,\\62@= M2$(H&PM)EL`^\GJA"5G.G2.CW#4DY,A\:(9(0V(M*M$XJ89DXR@I*_#Y]:P( M60])]T7[O!1F*N$18SD^'3/FZL]$&NJR2NJJ:0Z6RB=E8U5 M):-@`W_=*$*6C6*((Z]ZOF(4)SE#_<,A3/1GQ!&/N:(LB;&FD&@*J:3@>@MY M$-E80G+`AL/KV(+_M"A0$=D:`G-L\$B[64OU1[2A=.1,A3X52PF/#"4>>:)"P;24Y43XS\@:_T M>/U@_X%KC=B`X%ZF3D,.T568?9'=O-BYO4;M&>U1575&@=_)K6H)8@/*;GSA M/(#]!VJCX,D\@.U$Q^&&N*6U5/@[>N[[`?=P M5Z0EN,#_!A"<1.&*9!HGC'OQ0CXP_+=A\S<```#__P,`4$L#!!0`!@`(```` M(0!JG"D3W`<``#PA```9````>&PO=V]R:W-H965T=MX5^_S\LNK_]:=W-^_W MJCH][]-C<[77&Z@,13?LSK'URTWSOMEN'+ MN2C3IR/D_=URTAUJ\P]$_I3ORJ(JGNL!R`W%A=*<%\/%$)0>[OO.A0??IGOD_R<@=MPG]@=>"J*5Q8:[AF" MP4,RVN-WX/>RM\^>T[=C_4?Q$63YRZ&&VSV!C%ABR_T/-ZMVX"C(#,83IK0K MCG`!\&_OE+/2`$?2[_SXD>_KPZIO3P>3V-N56E!]HAA8&8H;/5;%<.4KK::,X`\Y$J[[V@BL&4L5S?5[/Q25RR>" MF];IPWU9?/1@=8&OK"XI6ZNL)5/#*2"^O9D4_S4G8#(PE4A^^`Z3;R=CUATQ>L0&(]A,8[*N";8F\$S@FR`P06B"R`2Q"9(6&()Q MC7M@V/_A'I-A[F'>:P3*SK%A%4;@$-<$6Q-X)O!-$)@@-$%D@M@$20MH5L$J M1:QR8"'I7FNQKMBH51\6*E57]D2W8BUBQF)5966S(<0E9$N(1XA/2$!(2$A$ M2$Q(TB::39"J9M-U>UCTJC\&SY4_<\OP1P9I)CK&Y-PT04U!$;(EQ"/$)R0@ M)"0D(B0F)&D3S3(HHALL8]'<,DQT+8G33+\-(2XA6T(\0GQ"`D)"0B)"8D*2 M-M',@!U6,T.LYP.VL=>'?/>Z+D1#TE%7-JS;8C5G(KI'DH@FB,\Q0EQ!;&T3 M<(QBW#9!:+]'B$](0$A(2$1(3$@BB.CE--N@O]!LZ[`'1J$_+%KW1Q![H6J( M$%<0!]H#-5D=8UW?-D&-/X3X#6D+.?JL#YH@%`H)B1K2%C*6U[@)0J%$$)&L MYB+<>LW%GRH^)J*;*TC;7$)<2>#0,M?6/=DV09B*)XBC]@Z?Q`2$A&141&)B M0A))>(UHMD&OJ=EVO?A8M.Z/)'!;FMRGQKS;R!C58[B2P*$993E3PS$19(]X M2S>SQT9Q>$36_XIL(&4M+CMVC-H-B6KT%=58JLJ+G4P7>C))6U:[`:QWO^$. M\'#]%DADMW?BJ5%^&PRRFU7"131NT!:1P\V!YS+C5GH8H&1\1$HF0,16K?<' MZC&>5RH1(J42(Y(7,UL8!9!@`)?1365-<_O1XGI9LZ<@HZX1:85MU,H&@UJ5 MC6C6,E6HVU/NQMU\XAC%X>$@I>,C4CJ!1/9,Z'38*M-0,A&5B5$&+V>V,&HE MP4%<1_>5==@W^"H:1B@='Y'2"1`U.B.C[$.,4#H1(J43(VIT[+F>5X(1'17+NO(;G)5-O/KV MM240;Y/TF\:ZUQND9;/;7DZLN=$KK*VF)6XOX4:^&Q6%!>!2M*7(H\BG**`H MI"BB**8HT9#N'VMX;_!/]L?M6]-NF7F;NV$_];$E1W7^+D5;BCR*?(H"BD** M(HIBBA(-ZOHK`&/8I\B@**0HHB MBF**$HDZNG^+=;1M#S_9JD0#K"VI`K5[5"X*JZQZ)G`E,AX!C)UHJZ*464(> M!B+R551[\AN[8Z"B<&!(4:106\O8ZF,5A5J)1")'O2Q9M]NV].?*4O3,FM/M M-EJ6)4&N)1$<6MVML3J04?+QX&XVM8SZ\U!'2?N( MKDH'*"T>$>[&*1AP%*QD>D9`)$0H:HA'A>J42(E$J,2*@8 M/R\F>)8V7?"[[2U%SL,-2T7+W6JZQ`L_\9[CE)4OV28['JO>KGAC+_-XN398 MO&E<6Y,EVV1A'3#.P!H'9W@I&&?@[>0C-\#@:WAKR7]0,/D8WF9V?,/:7L+O MP?2;'YWE(S24],3:6<*OH1T<@;T/\NDZXT*BG7E"FEWQ&TBRB[N08F>&D&!7O`?I=7$?DNOB(:36Q2-( MC/-A<]/AW?4E?ZN/`W@T]%#6^M^9\' M^%\*&;Q;&0V@:7XNBAH_@*7#YO\]//P+``#__P,`4$L#!!0`!@`(````(0!P M`/@]TP4``&<7```9````>&PO=V]R:W-H965T//E>W6UOI&Z*>EM:[NSN6V16T&/Y>V\M?_X/7YXM*VFS6_' M_$IO9&O_((W]9??S3YMW6K\V%T):"Q1NS=:^M.T]<)RFN)`J;V;T3F[PS8G6 M5=["Q_KL-/>:Y,=N4'5U%O.Y[U1Y>;.Y0E!/T:"G4UF0D!9O%;FU7*0FU[R% M^3>7\MY(M:J8(E?E]>O;_:&@U1TD7LIKV?[H1&VK*H+L?*-U_G(%O[^[R[R0 MVMT')%^514T;>FIG(.?PB6*?GYPG!Y1VFV,)'K"P6S4Y;>UG-\C<1]O9;;H` M_5F2]T;YWVHN]#VIR^/7\D8@VI`GEH$72E^9:79D"`8[:'3<9>#7VCJ24_YV M;7^C[RDISY<6TKT"CYACP?%'2)H"(@HRL\6**17T"A.`OU95LM*`B.3?N^=[ M>6PO6WNQMJT7TK1QR:1LJWAK6EK]Q;]TA00?O!"#X2D&>_YLM9Y[+KSKHX&> M&`C/_JV3!B[%0'B*@:M)XV`ZG9OP%./<]G M)@KKLAL'ST]-]$F,@^>DB3J\#KJR"O,VWVUJ^F[!6H6,-_>&VM)!#0A-$)HA-D)@@ M-4&F`,UM6).JV^,;BC4-OU&<7D0B1&)$$D1213"6: M[[`-3O>=&7>^RQGO!5GV17U`)$0D0B1&)$$D1213B>85;-*J5VSK\A[9L2>. MHLF[%Q/2/18$`JJDUERWO9$,5(A(A$B,2()(BDBF$BT(<."H0?AX^3)CW5%! ME-0B$B(2(1(CDB"2(I*I1/.*M:O*J?2Q5\Q8]TH0/7V>L3)[HSY]B$2(Q(@D MB*2(9"K1'(4C=[JCS%AW5!`E?8B$B$2(Q(@DB*2(9"K1O'*AKU7=XEW%;`U+ ML[V4Q>N>PK*"03B3Z4#H55KWT^LG8@!87W/]("(+FEX^9Y="[#]4\N9;SARD%9#LD.)M(&XCKB\M^YB M]#"?>4:L8ZDS2"<2?2B="BM%^E$OXDSJC-01ZY2FATWT56K8U%:K.XD.+D(A M1A%&,48)1BE&F8;TLH#0J?ZQ`\7WNJ/UL[_9F9)QO@H$1:FLH;4>_(/;6\G= M/L0HPBC&*,$HQ2C3D!X.UEE-3[?HP]1T`"\>^P9>`='! MWT`7%+!69>P;-XC@>,;?P$$/8\:^@6O-YRYHIH?LNG-$:;\(X,(!OV'O!?`+ M'?/G9?#,KTW-%RP#^%F+!^Q7`?PP!.[T`^":\YZ?R2]Y?2YOC74E)TC7O%L9 M-;\HY1]:>N^:SQ?:PD5G]^\%+K0)W%3,9["IG2AMY0?V@OZ*?/;?]_HKL6-FEZGZ,IFE16U*SS@YA$?]'@L M'`A2PM#L- M.6[<'<(I6KC>=LT3]+T@MU;[WVG/]/9;4QR^%C6!;,,\L1G84_K,J%\.#`)C MS[).^0S\V3@'@"(F#!_>8M+FD%%P,_%Y&#DM(0#X MZU0%*PW(2/;*G[?BT)TW[BR8+);3&0*ZLR=MEQ;,I>ODU[:CU3^"A%A0O1-? M.H&G=/(!X[DTAJ"(G/,5QUF7;=4-O#M0MJ&XO M&5L%"(-CE5N1B3[;[R4;$L2<[)B7C0L+#O+80H6\;-%RN?9>8%9SR0GO<$Q& MI!@L[\QM/`:2,9!J@`>*>EDP3?^#+.:%R5(!A0H8=/HC#8JA3.(QD(R!5`,, M#3-;P_S=LES?W^A MJH@9>>/ZD(4AY.5J%+(DF;I&I*@G]5"-\1C)#964/; M1G]<\8QLABP0]&0D=;1L(TG20I:.H*,.4^C/3:6)99;VB&ZVZ,T,81#2X\(8 MV10F$!"FED4D$4V%M.*'`+[O)Q8GU1$C/@3B'P^0L\T()30JEZ#/!H\H4JQA M-<@A%4FK"HTL%(%\6HTPV3=3`OSX:*2 M75`/6$#LI#U,\6RTTT=(LO2%T4.:H6\55<\:BJJ'-,/E>T7%^J*F]"<3(KNH MKD]`_,8@:(6A ML]C\>(7C>WBRPM!E;'ZZPM!K`/?Z`>`J>=G")Y/^>X4<#`N?K*=O5CY1VZH4-T/\,L?T7``#__P,`4$L# M!!0`!@`(````(0#KJ3"ZI0(``/D&```9````>&PO=V]R:W-H965TW[RHACP+8Z5NC?UK*S M1S;%+Z%3S#SMNRNN50<4.]E(]^I)*5$\>ZA:;=BN`=\OZ8SQ([=_.*%7DAMM M=>DBH(M#HZ>>5_$J!J;-NI#@`&,G1I0YW:;9[8K&F[7/YX\4!SOX3FRM#U^- M++[+5D#8,"8XF4E/"]=5K]#:#4-Q6X?&MWS+'-VN@#@7$#VG8,+T^:`?''O4`3B-TB.*=P M'4'&0G[/FW0Y6H(]NI]K*$"4GB1A]-:C'DQQEFRBJ!\/DD\-Y8(E71L>?ZQ MF^58];P4@L=2H0)2[]W@1AW<^N#F.EJ"_?,:>'"L$2KO["P^MK,:RYZ70O!8 M*E0&-RZLFO`^*V$J\44TC25<[W&-3.`-[:O]AMOZ--[79]G6;[ZX_P$V3\(C,F%WA0>G.[]%=MK!SO%?:_B+$?"2)A'D66KMC@\XAOY/ M:_,/``#__P,`4$L#!!0`!@`(````(0!WQ,RQ,P$``$`"```1``@!9&]C4')O M<',O8V]R92YX;6P@H@0!**```0`````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````"YMVPSE"FX'*GAP(3A3?8G+7!9LTY$:[_7NS MKJL3?1+R$LZY7\X]*1<[TR2?X%&WMB)%EI,$K&R5MG5%GM;+=$X2#,(JT;06 M*K(')`M^>5%*QV3KX<&W#GS0@$DD6632560;@F.4HMR"$9A%AXWBIO5&A'CU M-75"OHL:Z"3/9]1`$$H$00_`U(U$,B"5')'NPS<]0$D*#1BP`6F1%?3;&\`; M_'.@5\Z<1H>]BSL-<<_92A[%T;U#/1J[KLNZ:1\CYB_HR^K^L5\UU?;0E03" M#_TT`L,J5KG1H&[V?/?FFP1Q6]+?6JEDGXY)#R*`2N)[[)CNI#Q/;^_62\(G M>7&5YO%`+S/_?//^1<```#__P,`4$L# M!!0`!@`(````(0`R'MNAG`(``!0(```0``@!9&]C4')O<',O87!P+GAM;""B M!`$HH``!```````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````````)Q5WT_;,!!^ MG[3_(?S_?"OMZO"V8#27(J1>W8Z9DM847V*:H&:7*H5-7A4"T_F.6VVEC^P28&O%S6LP\+WVT4\8+2!"QT%."PV^=[CP[X!629M3 MKG3@;\S5!IB1RM'\#=,V=)UGJJ&B,W(W5'$J#-*JS)I#+1>E-BKX+=6+7@(8 M[7MHT%S68MNV+?.+8'A96Z#4M:P\-$Q0T>68-+_-99OY_@U1/!M/9LED3%!*XNG].$SQ?##OF8S9(2I^Q5:R<6S']+[;'Z<<<$^?" MRNU39L=@*"_^*;41+=BZ:!H!*]OJ_\-OA%G&JYE/BWHV62%?E"QIL%9(;^5V MB'7&[X>!.^7B13^6J1Q3`[N-TKWTZT[+<-;N](<+_PZ7B2HJ)]&28M]D.YO/ MBFK_/35+/CB[.!V<#W"UM>Y\[[#.@W<```#__P,`4$L#!!0`!@`(````(0!# M5A'%E@```*H````0````>&PO8V%L8T-H86EN+GAM;#R.00H",1`$[X)_"'-W M9]>#B"194/`%^H"0'4T@F2R9(/I[X\5+0]%0W7I^YZ1>5"46-C`-(RAB7Y;( M3P/WVW5W!"7-\>)283+P(8'9;C?:N^0OP456W7!E&UL4$L!`BT`%``&``@````A`+55,"/U```` M3`(```L`````````````````#`0``%]R96QS+RYR96QS4$L!`BT`%``&``@` M```A`,U1(LN\`0``N1$``!H`````````````````,@<``'AL+U]R96QS+W=O M@,``&P+```8`````````````````%H-``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#;=H$)X`P``!0L` M`!D`````````````````W!8``'AL+W=O&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/3U^),%`P``/@D``!D````` M````````````HB<``'AL+W=OFD$```%$```&`````````````````#>*@``>&PO=V]R M:W-H965T&UL4$L!`BT`%``&``@````A`.NEVH/]`@``\@D` M`!@`````````````````?2\``'AL+W=O&UL4$L!`BT`%``&``@` M```A`/MBI6V4!@``IQL``!,`````````````````KUL``'AL+W1H96UE+W1H M96UE,2YX;6Q02P$"+0`4``8`"````"$`I3:,L<\"``#/!P``&0`````````` M``````!T8@``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`!#]&F/)!```*1$``!D` M````````````````3FD``'AL+W=O&PO M=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%`_ M.]&Q`@``'@<``!@`````````````````)7P``'AL+W=O&PO=V]R:W-H965T M[>(7X"```K!@``&0`````````````````\DP``>&PO=V]R M:W-H965TMJ00``+(0 M```9`````````````````/&5``!X;"]W;W)K&UL M4$L!`BT`%``&``@````A`&J<*1/&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`.NI,+JE`@``^08``!D`````````````````UJT``'AL+W=O&UL4$L%!@`````E`"4`[`D``+*W```````` ` end XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT

Loss Per Share (Additional Information) (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Maximum [Member]
Earnings Per Share Disclosure [Line Items]
Anti-dilutive shares of common stock excluded from computation of earning per share	3,274,157	4,086,885
Series A Warrants [Member]
Earnings Per Share Disclosure [Line Items]
Anti-dilutive shares of common stock excluded from computation of earning per share	39,595	877,137
Warrants, exercise price per share	0.01	0.01
Series B Warrants [Member]
Earnings Per Share Disclosure [Line Items]
Anti-dilutive shares of common stock excluded from computation of earning per share	429,704	809,805
Warrants, exercise price per share	2.49	2.49

XML 15 R9.htm IDEA: XBRL DOCUMENT

Revision of Prior Years' Financial Statements

3 Months Ended

Mar. 31, 2015

Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements [Abstract]

Revision Of Prior Years’ Financial Statements

NOTE 2 — Revision of Prior Years’ Financial Statements

At December 31, 2013, accumulated deficit and shareholders’ equity were reported as ($237,623) and $75,425, respectively, and were revised to ($240,529) and $72,519, respectively.

The effects of the error correction on the consolidated statements of operations for the three month period ended March 31, 2014 are as follows (in thousands):

	Three months ended March 31, 2014
	As previously reported		Correction		As revised
Research and development	$	7,325	$	244	$	7,569
Total expenses		8,551		244		8,795
Net loss		(8,549)		(244)		(8,793)
Loss per share – basic and diluted		(0.37)		(0.01)		(0.38)

The effects of the error correction on the consolidated statements of cash flows for the three month period ended March 31, 2014 are as follows (in thousands):

	Three months ended March 31, 2014
	As previously reported		Correction		As revised
Net cash used in operating activities	$	(7,614)	$	(285)	$	(7,899)
Net cash used in investing activities		(285)		285		(0)

EXCEL 16 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\S,C4X,S@P85]E-V)B7S1E-C-?.6(Y,E\X8S,P M8SEC,F5B.&8B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3E-/3$E$051%1%]35$%414U%3E137T]&7U-4 M3SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O MF%T:6]N7T]P97)A=&EO;G-?86YD7TQI/"]X.DYA;64^#0H@("`@ M/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E M;%=O'!E;G-E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DQO#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D]R9V%N:7IA=&EO;E]/<&5R871I;VYS7V%N9%], M:3$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O'!E;G-E#I7;W)K#I7;W)K#I%>&-E;%=OF%T:6]N M7T]P97)A=&EO;G-?86YD7TQI,SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E=FES:6]N7V]F7U!R:6]R7UEE87)S7T9I;F%N8S(\ M+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%C M8W)U961?17AP96YS97-?1&5T86EL#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DQO#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K0F%S961?0V]M<&5N#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O M;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7SPO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M6QE#I!8W1I=F53 M:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N M9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S M:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'10 M87)T7S,R-3@S.#!A7V4W8F)?-&4V,U\Y8CDR7SAC,S!C.6,R96(X9@T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S,C4X,S@P85]E-V)B7S1E-C-? M.6(Y,E\X8S,P8SEC,F5B.&8O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^9F%L'0^36%R(#,Q+`T*"0DR M,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^,C`Q-3QS<&%N/CPO'0^43$\2!296=I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^4E!26#QS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\S,C4X,S@P85]E-V)B7S1E-C-?.6(Y,E\X8S,P8SEC,F5B M.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S(U.#,X,&%?93=B M8E\T938S7SEB.3)?.&,S,&,Y8S)E8CAF+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'!E;G-E&5D(&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D+"`R-"PS.#@L-3(S M('-H87)E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\S,C4X,S@P85]E-V)B7S1E-C-?.6(Y,E\X M8S,P8SEC,F5B.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S(U M.#,X,&%?93=B8E\T938S7SEB.3)?.&,S,&,Y8S)E8CAF+U=O'0O:'1M;#L@8VAAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XU+#`P,"PP,#`\'10 M87)T7S,R-3@S.#!A7V4W8F)?-&4V,U\Y8CDR7SAC,S!C.6,R96(X9@T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S,C4X,S@P85]E-V)B7S1E-C-? M.6(Y,E\X8S,P8SEC,F5B.&8O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S&5R8VES92!O9B`Y,2PV-C0@'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\S,C4X,S@P85]E-V)B7S1E-C-?.6(Y,E\X M8S,P8SEC,F5B.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S(U M.#,X,&%?93=B8E\T938S7SEB.3)?.&,S,&,Y8S)E8CAF+U=O'0O:'1M;#L@8VAA7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N+"!/<&5R M871I;VYS(&%N9"!,:7%U:61I='D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@ M("`@/'1H(&-L87-S/3-$=&@@8V]L6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J M=7-T.B!N;VYE.R!F;VYT+7-TF%T:6]N+"!/<&5R871I;VYS M(&%N9"!,:7%U:61I='D\+V(^/"]D:78^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UEF5D(&]N($%U9W5S="`R,"P@ M,3DX-RX@5V4@87)E(&$@8FEO<&AA2!F;V-U M7-T96T@9&ES;W)D97)S+B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!- M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE3XF(S$V,#L\+V1I=CX@/&1I M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE&AI8FET(&QO=R!T97-T M;W-T97)O;F4@;&5V96QS(&1U92!T;R!U;F1E2!A2!B96QI979E2!H M>7!O9V]N861I7!O9V]N861I2!T:&4@1D1!(&%N9"!T:&4@ M1D1!(&%S2!T:&%T('1H97D@<&QA;B!T;R!H;VQD(&%N(&%D=FES;W)Y M(&-O;6UI='1E92!M965T:6YG(&1UF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T2!C;VYD=6-T:6YG(&$@4&AA2!I;B!T:&4@=')E871M96YT M(&]F(&5N9&]M971R:6]S:7,N/"]D:78^(#QD:78@#L@1D]. M5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)U=)1%1(.B`S,"4G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@F4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CQF;VYT('-T>6QE/3-$)V9O M;G0M6QE/3-$)U9%4E1)0T%,+4%, M24=..B!T;W`G/B`\=&0@F4M861J=7-T M.B!N;VYE.R!F;VYT+7-T2!(>7!O M9V]N861I6QE/3-$)T)/ M4D1%4BU"3U143TTM0T],3U(Z(",P,#`P,#`[(%1%6%0M04Q)1TXZ(&QE9G0[ M($)/4D1%4BU43U`M0T],3U(Z(",P,#`P,#`[(%=)1%1(.B`Q-R4[($)/4D1% M4BU224=(5"U#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@=&]P.R!"3U)$15(M3$5&5"U#3TQ/4CH@(S`P,#`P,"<^ M(#QD:78^3D1!(&%C8V5P=&5D(&%N9"!U;F1E6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78@6QE/3-$)T-,14%2 M.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[ M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z M(&)O=&@G/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@F4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@ M#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-, M14%2.F)O=&@[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T#L@1D].5#H@,3!P="!4:6UE&EM M871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6%B;&4@86YD(&%C8W)U960@97AP96YS97,@;V8@87!P2`D/&9O;G0@'!L;W)E('!O=&5N=&EA;"!C;W)P;W)A=&4@<&%R=&YE2!W:6QL(&)E('-U8V-E2!C;VUP;&5T960@;W(@=&AA="!O=7(@8W5R3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\S,C4X,S@P85]E-V)B7S1E-C-?.6(Y,E\X8S,P8SEC,F5B M.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S(U.#,X,&%?93=B M8E\T938S7SEB.3)?.&,S,&,Y8S)E8CAF+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T#L@1D]. M5#H@,3!P="!4:6UE3Y7:&EL92!P65A"8C,32!I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4 M:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UEF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG#L@1D].5#H@ M,3!P="!4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE#IA=71O.R!724142#H@-S4E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA M<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B!4:')E928C M,38P.VUO;G1H6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D%S)B,Q-C`[<')E=FEO=7-L M>28C,38P.SQB"!S;VQI9#L@1D].5"U714E'2%0Z(#

6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D%S)B,Q M-C`[6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/E)E6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[ M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/C@L-SDU/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/DYE="!L;W-S/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B@P+C,W*3PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A M8FQE/B`\+V1I=CX@/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U!3$E'3CIC96YT97([(%1%6%0M24Y$14Y4.B`P M:6X[(%=)1%1(.B`Q,#`E)R!A;&EG;CTS1&-E;G1E6QE M/3-$)TU!4D=)3CH@,'!X.F%U=&\[(%=)1%1(.B`W-24[($)/4D1%4BU#3TQ, M05!313H@8V]L;&%P6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[ M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B0\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B@W+#@Y.2D\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R M/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@ M/"]D:78^/'1A8FQE(&)O&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'!E M;G-EF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U! M3$E'3CIC96YT97([(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)R!A M;&EG;CTS1&-E;G1E6QE/3-$)TU!4D=)3CH@,'!X.F%U M=&\[(%=)1%1(.B`X,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXV-30\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R M)3X@/&1I=CXV,SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXT-3@\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXW-CPO9&EV/B`\ M+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D M/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=B!S M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M2!S=&]C:R!M971H;V0@=&\@<&]T96YT:6%L;'D@9&EL=71I=F4@;W5T M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CIC96YT97([(%1%6%0M24Y$14Y4 M.B`P:6X[(%=)1%1(.B`Q,#`E)R!A;&EG;CTS1&-E;G1E6QE/3-$)TU!4D=)3CH@,'!X.F%U=&\[(%=)1%1(.B`W-24[($)/4D1%4BU# M3TQ,05!313H@8V]L;&%P6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXR-"PR-S8\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPGF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE&5R8VES92!P M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5R8VES92!P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE65A'!I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S,C4X,S@P85]E-V)B M7S1E-C-?.6(Y,E\X8S,P8SEC,F5B.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO,S(U.#,X,&%?93=B8E\T938S7SEB.3)?.&,S,&,Y8S)E8CAF M+U=O'0O M:'1M;#L@8VAA6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J M=7-T.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T2!N:6YE(&ES&%M:6YA=&EO;B!O9B!O;F4@ M;V8@=&AE2!T:&4@52Y3+B!0871E;G0@86YD(%1R861E M;6%R:R!/9F9I8V4@*"8C.#(R,#M05$\F(S@R,C$[*2!B87-E9"!O;B!P&%M:6YA=&EO;B!C97)T M:69I8V%T92!W87,@:7-S=65D+B!792!S=6)S97%U96YT;'D@9FEL960@82!S M96-O;F0@2!R96IE8W1E9"!B>2!T:&4@4%1/(&EN('1H92!R M92UE>&%M:6YA=&EO;BX@5&AE('!A=&5N="!H;VQD97(@87!P96%L960@=&AE M(')E:F5C=&EO;G,@=&\@=&AE(%!43R!";V%R9"!O9B!0871E;G0@07!P96%L M2!O9B!T:&4@2!D969E;F0@86YY(&%N9"!A;&P@8VQA:6US('1H870@;6%Y M(&)E(&)R;W5G:'0@8GD@=&AE(&AO;&1EF4@;W(@;W5T+6QI8V5N'!I6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE2!&:7-C:"!T:')E871E;FEN M9R!T;R!F:6QE(&$@;&%W&5C=71I=F4@5FEC92!02!&:7-C:"!A&%S('-E96MI;F<@82!D96-L87)A=&]R>2!J M=61G;65N="!T:&%T(&AE('-H;W5L9"!N;W0@8F4@861D960@87,@:6YV96YT M;W(@=&\@86YY(&]F('1H97-E('!A=&5N=',N($]N($]C=&]B97(@,BP@,C`Q M,RP@1'(N($9I2!J=61G;65N="!I;B!F879O2!O;B!S97!A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\S,C4X,S@P85]E-V)B7S1E-C-?.6(Y,E\X8S,P8SEC,F5B.&8- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S(U.#,X,&%?93=B8E\T M938S7SEB.3)?.&,S,&,Y8S)E8CAF+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%RF%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!0'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE'!E8W1E9"!A#L@1D].5#H@,3!P="!4 M:6UE3XF(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`Q,#`E.R!" M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G M/B`\=&0@#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CQF;VYT('-T>6QE M/3-$)V9O;G0M6QE M/3-$)U=)1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T)SX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U=)1%1(.B`U."4[($9/3E0M4TE:13H@,3!P="<^(#QD M:78@6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)T-,14%2 M.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1)0T%, M+4%,24=..B!T;W`G/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78@6QE/3-$ M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78@6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78@6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78@#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T2`H=F%G:6YA;"!D96QI=F5R>2D@*%E%(#(P,34I/"]D:78^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@F4M861J=7-T M.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0^(#QD:78@3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S,C4X,S@P85]E-V)B7S1E M-C-?.6(Y,E\X8S,P8SEC,F5B.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO,S(U.#,X,&%?93=B8E\T938S7SEB.3)?.&,S,&,Y8S)E8CAF+U=O M'0O:'1M M;#L@8VAA'0^/&1I=B!S='EL93TS1"=-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE MF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE#L@1D].5#H@ M,3!P="!4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE#IA=71O.R!724142#H@-S4E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA M<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B!4:')E928C M,38P.VUO;G1H6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D%S)B,Q-C`[<')E=FEO=7-L M>28C,38P.SQB"!S;VQI9#L@1D].5"U714E'2%0Z(#

6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D%S)B,Q M-C`[6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/E)E6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[ M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/C@L-SDU/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/DYE="!L;W-S/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B@P+C,W*3PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A M8FQE/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O&5D.R<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE#IA=71O.R!724142#H@-S4E.R!"3U)$15(M0T], M3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/B!4:')E928C,38P.VUO;G1H6QE/3-$)T-,14%2 M.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\ M='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D%S)B,Q M-C`[<')E=FEO=7-L>3QB"!S;VQI9#L@1D].5"U714E' M2%0Z(#6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/D%S)B,Q-C`[6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/DYE="!C87-H('5S M960@:6X@;W!E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/B@W+#8Q-"D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B@R.#4I/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXD/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.T-,14%2.B!B;W1H)SXH-RPX.3DI/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/DYE="!C M87-H('5S960@:6X@:6YV97-T:6YG(&%C=&EV:71I97,\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B@R M.#4I/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C(X-3PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)W=I9'1H.C$P,"4[ M('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D M9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)TU!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CIC M96YT97([(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)R!A;&EG;CTS M1&-E;G1E6QE/3-$)TU!4D=)3CH@,'!X.F%U=&\[(%=) M1%1(.B`X,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI M9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@1D].5"U714E'2%0Z M(#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXV-30\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I M=CXV,SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXT-3@\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXW-CPO9&EV/B`\+W1D/B`\ M=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`P:6X[(%=)1%1(.B`Q,#`E)R!A;&EG;CTS1&-E;G1E6QE/3-$)TU!4D=)3CH@,'!X.F%U=&\[(%=)1%1(.B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXR-"PR-S8\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T M86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`H4')O9'5C="!$979E;&]P;65N M="!0:7!E;&EN92D@*$1E=&%I;',I/&)R/CPO2!(>7!O9V]N861I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^ M4$151D$@9&%T92!O9B!.;W9E;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0@17AP96-T960@36EL97-T;VYE*',I M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y#;VUP;&5T92!F:7)S M="!C;W5R'0^1G5L;'D@96YR;VQL(%!H87-E(#(@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S M'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\S,C4X,S@P85]E-V)B7S1E-C-?.6(Y,E\X8S,P8SEC,F5B M.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S(U.#,X,&%?93=B M8E\T938S7SEB.3)?.&,S,&,Y8S)E8CAF+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S M,C4X,S@P85]E-V)B7S1E-C-?.6(Y,E\X8S,P8SEC,F5B.&8-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S(U.#,X,&%?93=B8E\T938S7SEB.3)? M.&,S,&,Y8S)E8CAF+U=O'0O:'1M;#L@8VAA6EN9R!-:7-S=&%T96UE;G0@:6X@0W5R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA&-L=61E M9"!F&-L=61E9"!F'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!P'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!);F-E M;G1I=F4@4&QA;B!-96UB97(\+W1D/@T*("`@("`@("`\=&0@8VQA6UE;G0@07=A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'1087)T7S,R-3@S.#!A7V4W8F)?-&4V,U\Y8CDR7SAC,S!C.6,R96(X M9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S,C4X,S@P85]E-V)B M7S1E-C-?.6(Y,E\X8S,P8SEC,F5B.&8O5V]R:W-H965T XML 17 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9

Organization, Operations and Liquidity
3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Operations and Liquidity

NOTE 1 — Organization, Operations and Liquidity

Repros Therapeutics Inc. (the “Company,” “RPRX,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

Our enclomiphene product candidate, formerly known as Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. We expect to rename this product candidate in the near future. We are developing enclomiphene for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. Enclomiphene is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism. The Company believes that secondary hypogonadism due to being overweight or obese is the single greatest cause of hypogonadism in general. On February 2, 2015, we announced that we electronically submitted our New Drug Application (“NDA”) to the Food and Drug Administration (“FDA”) for enclomiphene. Subsequently, we announced that the NDA was accepted by the FDA and the FDA assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of November 30, 2015. In addition, the FDA has informed the Company that they plan to hold an advisory committee meeting during the review.

Proellex®, our product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. On December 29, 2014, we announced that we have initiated two Phase 2B studies for low dose Proellex® in the treatment of uterine fibroids and are currently conducting a Phase 2 study in the treatment of endometriosis.

Our product development pipeline, with dates as expected as of the date of this report, is summarized in the table below:

Product Candidate (Indication)

Enclomiphene

Status

Next Expected Milestone(s)

Secondary Hypogonadism

NDA accepted and under review

PDUFA date of November 30, 2015

Proellex®

Uterine Fibroids

Phase 2

Complete first course of treatment in a Phase 2B study (oral delivery) (YE 2015)

Complete first course of treatment in a Phase 2B study (vaginal delivery) (YE 2015)

Endometriosis

Phase 2

Fully enroll Phase 2 study (oral delivery) (YE 2015)

As of March 31, 2015, we had accumulated losses of $281.6 million, approximately $37.9 million in cash and cash equivalents, and accounts payable and accrued expenses of approximately $2.0 million, in the aggregate. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates into the second half of 2016. We continue to explore potential corporate partnering opportunities for assistance in the clinical development funding and commercialization of our products, as appropriate; however, there can be no assurance that an acceptable corporate partnering opportunity will be successfully completed or that our current liquidity will be sufficient to fund all of our product development needs.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References+ Details

XML 18 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 37,875	$ 46,620
Prepaid expenses and other current assets	569	289
Total current assets	38,444us-gaap_AssetsCurrent	46,909us-gaap_AssetsCurrent
Fixed assets, net	22us-gaap_PropertyPlantAndEquipmentNet	32us-gaap_PropertyPlantAndEquipmentNet
Total assets	38,466us-gaap_Assets	46,941us-gaap_Assets
Current Liabilities
Accounts payable	1,159us-gaap_AccountsPayableCurrent	2,090us-gaap_AccountsPayableCurrent
Accrued expenses	793us-gaap_AccruedLiabilitiesCurrent	834us-gaap_AccruedLiabilitiesCurrent
Total current liabilities	1,952us-gaap_LiabilitiesCurrent	2,924us-gaap_LiabilitiesCurrent
Commitments & Contingencies (note 6)
Stockholders' Equity
Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding	0us-gaap_PreferredStockValue	0us-gaap_PreferredStockValue
Common Stock, $.001 par value, 75,000,000 shares authorized, 24,388,523 shares issued; 24,276,173 shares outstanding	24us-gaap_CommonStockValue	24us-gaap_CommonStockValue
Additional paid-in capital	319,459us-gaap_AdditionalPaidInCapital	318,437us-gaap_AdditionalPaidInCapital
Cost of treasury stock, 112,350 shares	(1,380)us-gaap_TreasuryStockValue	(1,380)us-gaap_TreasuryStockValue
Accumulated deficit	(281,589)	(273,064)
Total stockholders' equity	36,514us-gaap_StockholdersEquity	44,017us-gaap_StockholdersEquity
Total liabilities and stockholders' equity	$ 38,466	$ 46,941

XML 19 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	3 Months Ended
	Mar. 31, 2014
Issuance of shares of common stock for the cashless exercise of stock options	69,197rprx_CommonStockoptionShares
Cashless Exercise Of Stock Options	91,664rprx_CashlessExerciseOfStockOptions
Maximum [Member]
Exercise of stock option to purchase common stock for cash, share price	9.60
Minimum [Member]
Exercise of stock option to purchase common stock for cash, share price	1.56

XML 20 R22.htm IDEA: XBRL DOCUMENT

Revision of Prior Years' Financial Statements (Additional information) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Shareholders’ Equity	$ 36,514us-gaap_StockholdersEquity	$ 44,017us-gaap_StockholdersEquity	$ 64,750us-gaap_StockholdersEquity	$ 72,519us-gaap_StockholdersEquity
Retained Earnings (Accumulated Deficit)	(281,589)	(273,064)		(240,529)
Scenario, Previously Reported [Member]
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Shareholders’ Equity				75,425
Retained Earnings (Accumulated Deficit)				$ (237,623)

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References+ Details

XML 21 R24.htm IDEA: XBRL DOCUMENT

Loss Per Share (Calculation of Loss Per Share) (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Net loss	$ (8,525)us-gaap_NetIncomeLoss	$ (8,793)us-gaap_NetIncomeLoss
Average common shares outstanding	24,276	23,033
Basic and diluted loss per share	$ (0.35)us-gaap_EarningsPerShareBasicAndDiluted	$ (0.38)us-gaap_EarningsPerShareBasicAndDiluted

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

XML 22 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 23 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash Flows from Operating Activities
Net loss	$ (8,525)us-gaap_NetIncomeLoss	$ (8,793)us-gaap_NetIncomeLoss
Depreciation	10us-gaap_DepreciationAndAmortization	11us-gaap_DepreciationAndAmortization
Noncash stock-based compensation	1,022us-gaap_ShareBasedCompensation	920us-gaap_ShareBasedCompensation
(Increase) decrease in prepaid expenses and other current assets	(382)	(393)
Increase (decrease) in accounts payable and accrued expenses	(972)	356
Net cash used in operating activities	(8,847)	(7,899)
Cash Flows from Investing Activities
Capital expenditures	0	0
Net cash used in investing activities	0	0
Cash Flows from Financing Activities
Exercise of stock options & warrants	0	104
Proceeds from a shareholder transaction	102us-gaap_ProceedsFromContributedCapital	0us-gaap_ProceedsFromContributedCapital
Net cash provided by financing activities	102	104
Net decrease in cash and cash equivalents	(8,745)	(7,795)
Cash and cash equivalents at beginning of period	46,620	75,807
Cash and cash equivalents at end of period	$ 37,875	$ 68,012

XML 24 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	75,000,000us-gaap_CommonStockSharesAuthorized	75,000,000us-gaap_CommonStockSharesAuthorized
Common Stock, shares issued	24,388,523us-gaap_CommonStockSharesIssued	24,388,523us-gaap_CommonStockSharesIssued
Common Stock, shares outstanding	24,276,173us-gaap_CommonStockSharesOutstanding	24,276,173us-gaap_CommonStockSharesOutstanding
Treasury stock, shares	112,350us-gaap_TreasuryStockShares	112,350us-gaap_TreasuryStockShares
Undesignated Preferred Stock [Member]
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, issued	0	0
Preferred Stock, outstanding	0	0

XML 25 R17.htm IDEA: XBRL DOCUMENT

Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2015

Earnings Per Share [Abstract]

Calculation of Loss Per Share

The following table presents information necessary to calculate loss per share for the three month periods ended March 31, 2015 and 2014 (in thousands, except per share amounts):

	Three Months Ended March 31,
	2015		2014

Net loss	$	(8,525)	$	(8,793)
Average common shares outstanding		24,276		23,033
Basic and diluted loss per share	$	(0.35)	$	(0.38)

ZIP 26 0001144204-15-028236-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-15-028236-xbrl.zip M4$L#!!0````(``)CIT:]0$[4&#T``!@^`P`1`!P`"TR,#$U,#,S,2YX M;6Q55`D``Z.12U6CD4M5=7@+``$$)0X```0Y`0``[%UY<]LXEO]_J_8[8#S3 MW4F59.NPXBO)E&,[:<\XMLM6)CV[M96"2$A"AR+8`&A;O;7??=\#"!X2+1_Q M(5E,=2>2B.,=OW>`Q`/?_OUJ%)`+)A47X;N5YFICA;#0$SX/!^]6OG0_UC=7 MR-_?_^=_O/U+O4X^L9!)JIE/>F.R3S7M2NI]5ZX_::XV5S<)?&BLUS_3<;W5 M:';(?S=:V\WU[?7&_Y#_/?W\?^3@O$OJY/+R&LX M>Z/=;JXDC0,>?B\TQH%6A1Q`RT9[#2_W8&+7'*_Z/.V0;_QFS5Y,FTX-?=DV M;9M;6UMKYFK:5/&RAC!H<^VWST?GWI"-:)V'2M/0*]#"9]`^V9XKL=YJ;LSJ M85NX#CZ+)/-0M=?VV5JCTI,B8&M]ZNDZNXH"&E(MY/@C?'<#>2(.M1P7Q::8 MMSH0%VO)1=1,N]YHUC/=>+&4@+OK^B57L>-ZL://>'D?N%#2G%UYP_+V>*6D M`P\OF-+E7>RU$FY"RCU5WL=WA2DF'6-4'E$9I MGSY5/:/9Y$()ZU?!#/S\=I0#=:SE#-C`U16P7D+>HB%L*P/Q,]8GQC"V]3AB M[U84'T4!XM?\-I2L_VX%K;ONK'CU2ODK9`T&LDYB3X2:76ERSCP-OL-YC?X#_GKBD;[6]M^MB2E/5BHN1XGOZ6_1^TB5/4FYR]U,BPV3LF8+MY`3;643!=NXCV,ZC"797 MG80+)U`;@W2)9-R5AY),Q\%N(273R0'M@273;"68:2^>9-KU9NOQ,)-*9E'\ M?DXRZX\JF86+B`7)_+B?P5QBGX]8:%8P=\@F"D'OVT'H!6+$HR$LD3ZS48_) M6&%>=2J%'WOZ1)XS><$]MGO%U3>8180^E>-?QY$8P)+%YVID>V'.D_11:2>5 M=MB#"#,0DO])D4P<[(FU-AE%V0!$I]/YD@L^$`+K`^YQ;=DBOA/QNY4DX]PN M$\W*>Q3`]K0TWZZ5CINCZ#93F\'O*%[39X;&KJV MI,H"'ML"2M19P7\ZG?SVF5[Q43S*`_:,AH,%1VF.!?=3@=&G@$#)\*WTBE8 M"6?J*Y42QL]K]EP#B)"AO8`J==(_U\+[OMB:GL%2DA-.R6(9E/^ATGZF_0]+ MH_Y.Y<^?3J>/?`,UTVGES^?/GS^Q\BM_/E_^_/'4?\WRM'LIND,1*QKZNZ%_ M$+`+%A[\$0/MAZ&'3%RPTX"&A84G?#^FHP5W_44N#`KN)(MJU3<#5?NP1E:: M>Z5NY1,3`TFC(?=HL-@8FL&2`511#!5B9B#FHY",#\(E!TQ!"A5>9L6M(9?^ M*9`V+H7,.?AK"K.]$+@4V;'!:D(`%5I*DMPOH<\4&!3N;3R5K,^D9+Y)_I8\ MX;U),"\L^2WN`JE@L5"P>-PM,-FVJ6][8C02X?4XL&L!:!6)$+ZJ%X*%-@U_/B41Q@D-QG?61O/Y8\'.RS"Q:(R"3LF@Y8!9'4:=Q)8B\9 M/>M5EC&_6<8399KK59:Q>%G&DV&CRC+F.LMX.A]191DO+\MX//24%[I6V<:< M91L+4=);A%"5K"Q&LK*`T*IRG?G+=1801E6J]%)2I84`7W$G0I5AS7&&-6?; M$ZZ!4)5A+6"&M1C0JC*L.<^P%@-&58;U(C.L.0/?1,EAE5G-5V;U'&6G56JT M&*G17I;Q1"5G[6^N@O-4L@LN8A6,SU@D)(AF^>I7T\LWR.19$/%X M^\"O>7C]F8=+[9OPOY_O7#)Z\ MJ6P;6MQ_[&_`\+=S)'!B%I]?`-PFM8!=C^,1ONQ.R$FLW9JTO,`G1RR9<)^% M8L3#V5/>).K).:<'=5=SG-]"AE$$;HB2=C@5OK!%VX('":+J#V0R"\[R2!\!F^/.RZMU,9 M;O"-==S_UEQY_W.@=T`21.EQ`$[J\^[9I\/C;=*(-/Q_M4,^GAQWMTD3OW?! MHRARS"[)F1C1L&9_J!$\.;!/5GX>Z!TR,=S>T<'NV79/Z*$=J?YQ]_/AT;^W M)X;:,=?.#__KP$ZUD#;YF8ZBG;\V.\T=DJB"'%Q%X&"9PO9K M60?S%43PD.+H'OS6K1\>[Q^@$!JK'1[ND&<5D97&F\9R<`ML86/'5YX7\LO$ M[+_4?E$X[R\)SQE?F8&LX6CXS4&))5!"`U9<:2+Z1`\9D!@$XI*'`_**A_"+ M/9A1O=Y>"K$_/LAVCPX_'6_CN99,[I"B`)#]KX?[W5^Q0^.GE$3;.E.F1@\] M[3ZOMFFL13K$9N.G'?+AY&S_X*R^=W)TM'MZ#I1XH%\:*9#*R;\.SCX>G7S= M)A=<\1Z^"=)C0:`BZIDWT3;L]XCZOOM^'3W2$?/KP>&G7U%;K>@J=]UWUW,B M($X&5DS=?Q\=.-T4Q4JTD6L(WR9_[9L_4]#?( M]W!O]\C-!PK38I0T_)H0NM$`MBZYKX?O5CK-GPH1Y09$K&E_T3A\"`831'TX MZ79//@-U#?.'-*,KHD3`_034W):ZGDJ_J_CO_5"!%!I MN.*_0OB3A^R`]?4/B\+S&+N_*-9O"-AG3#%,X0D-?>)G6UX@V5-:W0,`3\OS MB/M^P&;P_-`&/F6MF%],U M/9PN'YJ]Q_-1#\AS61AMS[TN*ZA64,7/ZYW-N5?FRP^GC[LF/=%#)IY<'2`]T=^^.JQ7=E)I69W&`FF^UGNXT^#V:2 MSQG6S'[F[&N^ST-M@C<#NSWPA6F,L,V&ZIZ0/I-FHW,RHV%S&_=B[Q#3IA[0 ML8CU=I]?,7_GQ@W3Z?@R_>2GU.0_RNRCD\7;M1\LS7%516Z8`RI#H$N=,FFJ MLNY?P].J:GAN5<.SGJ_A.1)*$9`],<(WNJXJ>%XNMQ^HXAX)4.D15N2BT@G' MF&%&\\UQ+V8@6W.Z2O9Y8":=04^L7"YA69#,#6@V MU]`H"L:NCT[.)4K(&3$]A&9:D$AHK,6E08#\`A7\@A6H%1&6(ZI5,0[:3@5+P]W2@(N/LCYA?T`"/P0&Q`;T4&M73F6`2Z`X.5.)DP;AF&X5" M$QYZ0>P#YZ;.B262H$@-BM.;YJT5F>#>B@9(V`">NA,A+`0D6R*5TB[62,8 MLXV58J5"L92O1MB5QT"PV!2P^0%EGY57N'E>(5[EX[<4!*Z M8-6_SUE!M/1`J8J#JPBQ:!PN?>G@LO-?E4XN"(,5PBN$SU_(GK/=BV4!^SAY MSO)<3][G8;?>/+`W!S66S\-6B0-ZM5GKM#JOYUYG%227"9(;6^VEAN2SC_7`B8AQUJ\\!>545YVT,)UFNMYZLYJN!:P?5N M<&W7&NVEWB8_)_'U<9>;=@^@.8BJ=#/9,B=8\\!>E?/GQ4B MBXC<7&I$/G^13+7]<\&Y/2W?-2_Z#PH=9[W6V'Q3 MV]SL%.V8A`>DQC\8*=W.S<4GEPBHQI\9<5_9`]22I23F# M,M"!?W;)5\ MDJC&:J,YC<)$*!^>0"CKK:W:1F-]OJ326EW?*E+$E8IM\0M2])'U9(P%")L& M3DV032^`Q8OH]QE6$]T1CNO/`L?-C8U:L[TQ7Y)_=CQN-K9JFXTYL](?QN-T MXK0P];S7%N).5NQF1;TG?7S;.PN5B2IG]E#./3R3TXSP`4#CG](Q'G2M[E_7 MVZ[J>LO+PWKXP93T=M*2WL8..4=[J1OAD[Q^C.)[*00>.,6<"V%,9-&/QNR\ MY=/[66WM=!E>:0Y9,XWS\,`O(ZXU8^ZE>WB5AF,KU,U6RPR9U!2\+1M%@1@SII(; ME6XRDT4;ZHS_/?@CYGI,#D/<\X25M:0>+29N.P/NC#)>8O^+&GB8>[.XQ7Q1L1'H04F1V#\"5$IT?,B]O- M@120JS*7G7]9/5\E$=7&B<,H17'G%P?9S52L2SXYVR8:W#*CD`PXM13B1A4;$.[#:+H19#0EZ?+]""(BU[$BW7$$64A) M4R"/]@2N"]4X]*48F0,_\H11I83'S2L,$#GL$H)]S32:&HR'L+34>)Z2(6XX MCL0`L@P?.42XU9C MY[1[DGYK[KPF/;/Z@DDB2/@@@93:8CTQ`A0D*(>.;"9HSGD)*!\IQ_<$J>`Y M/,80R>"<+X<<)!DD_6!F%+L/V)0C]%UZ2+6][9N,GHQLTD<[OTD.8:8+#K9M M^!?(O[F7D1B;S;/-6[CA@Z7"'*\S21J:'>#)0SU>@GHM,HSD5=Q3*/Q0!V-( MJI%B2A1#.W!:,?J>&#&1/S(&-`;X3-!H/W?<$$V3[0+55L9N:*3&).';K_#&L,>@92;?UH;I9J,(D:=2NQ(;@'DQDI73@FF=DT7Z^\. ML6`#[!P@#1[&6'$17+9W`6(&!EFDBP/-1S"RX007*]/$X#E->`FDYC-TL>8% M9"GN[H:&,BDX'1\+G=R=LTPZ,7QDOIE]CTL/UFUH'^59$2#7LMG'E>((-2\1/YDUG(/PK'.2,J>M)00Y5ZS2YHM M>Y\/?#/8/-K7!$T.4*G^K3BM<`R"K*.D(3FX`LU+L)(SED?[7LY^X.LN.(R` MM+;,O.T:Y@JP!"O.F]ET$E;RI#D+MQ$C(4\R%)V)D@E]QP@$N!0PA2X%'_P$ M''ZS[@-3E_Q;ZF"80B;C"WQ&;4ZKZN-"%UWXM9,E<0UOX&86.-T(#_X*+R") M-'[S`M;:(D8#%@"^?"C/V[YSKA->`'P/:%@4><)9$^>3NGP,9<[M,$'`IA1>.(8Z^./*#/GF!(I M&$I'=`RDDQZT1M^7C)_8&!HQ1M*4;/#+0$T";CPMC!F3_!W"O/*Y12G>OI;F MQHEP>BTJM!\C&"3>QC"^(XTGU&52!$]T'$R%(YPZL.Z<2XS\.(5B[#NT]V!= M#SBQ\0J90L'U\"0WR@,3@S!^P&H1[^DG/I@JT"Q>PND!F2AR`QSS$2(*&H"; M!M)+8SK`;I`=.EE#:NVD'MYX`BWD)S>#"Q0BZJD?X[P9$;#8P8E$K.L)`T5! MQ9#3!$4-V%LTAE+\!^5XB8\H0D$"`;8AD1[P-EYR3)O+D)=A`;A)L0`67\N#"A%'O0 M2X5!B0XHWJE$X!MO"G[+K3"OF)<<7VC24LB"7_T#`G@T))B_"E\$ZCNOD5/) MT&$ER>S>D+,^A"37UZ:TTEP[`ZO\RMDP8+55TS1I[WQ^:F\`13 M%,E%MPI=T*K"Y&YH0GMB0;5"KGTLP(-OU)H;[5KCS7H-/FZTX>NFW?8`WSI; MM?:;1LVNOY.P-[7XSANM"0B3L4!AC`C8('%P:+JX"@/#AW65Y%9,&)#C`6B8 MM'(:-=X"PK)?HB"4@.7=W;A`UO8YP`=\<9*%N-3C'&8#VL/L.E#>A>Q`9=+% MK":@D',)D.KOL3\P`=EP@0%M:-RO\VT^YOM491(')&61.5OCK!*`ZHFGA4F\ M'&L9[3:1,^?[@EM,0I-P-^RC`/.PE$1/2)EE0VYJ->21"_96Z>D"7]NL"$<, M89&2FQ?Q`N/5,\2DZ566C`:,^HF53#"5#518>H"!1K%;&%JYI0F,80Z'0O%- M3EV$90Z5-K^S4=1Q"H(*S).:E2^&3;L<0[@A'`.7 M\MC[`::4&T9/1\VGIZVVW=8`ZHQE84E%-;`0LN*SFSX^3L'<&"R8XQH-0)`^ MT=YRCR$F44!13DDZ;]-W:W3<`7^<'&W9Y$3#['./<@ MSXP#=M(_M7<*#[/#.+LXV?V?873F]1G&3 M$-@QUIE'F'@S$E-8NZZD4X\W]9#C8CH24M=PC62-'HA);\TG)@F37"[[2:V% MTU%SQZG./`SUL4B_A<>;*'2:W$2N1516[Y0PUF[\=),K>')+-D_6$N^9Z6G/ M/7#)?GIU"#_9C.+UG9_)/0];^3O],T@NKT1P8/SIFNUXUS-K/V*QQ/`F^-_B MV#WWV"TY(*?L93/9.3I3C1T7N>.%327E5,,;ZR,`VND01PXLU`F'J3= M1.[J5+\R+HJL5V.<_;L_9+"8BQQ M#P*=`6QK?_WI'D`"))@!#3*RV:JMV+)@^MT]/3W=2?%)"00&5G[Z^#PSNU`[ MN0B7[@XDK/T2Y+^"`"S6G3=TH;$&O1`^NQZL^\Y-FQ@A)FV^C"IHH_.5+D?% MBJG5_FJ0R32(Y8-Q#_-'=*YJNC-&?+.L1KT"\]K?J7EENG0VPGD8>!@4'-8% M)TZ48!Z^9H2O4W!P<_;C8K2,U:^0K)\!7M]8*.^[QBPQS@^ZA,LFMH7-*LTO;7",[*IY[;AS(A'3<V-#7;D,O M6'$-L:EC61'M"MO)@JU'&!5J?4@H?LR7?4"X/FIWRP/"7G-`*'ZGY[6?<(72 MQ8X%60D?JW9TO>AL<#4],C'"L1G4N'>#&@>`6'WT&#L/E1"`5]/;N0[HU:#;^)9C.JKM0-[K MEME6-"+:B.C.1%0;O&D1K8D3E3LP/J@.Z#73 MKD3=Z)N>=%4']!I1%1353G=0>V:^?G=:[9Z4#3)XRT%3V6.CFO%V]P38UTW" MRTU&;<2]$?>=B_M0>\OB7A,?7NV6^,[Q=.LM1VI4]D'YS#Z2Y!Q(;WQ*[ZQ&HUIP2-VP\O;RUM.IYS49X MA8-F27JV;-3P<7TB%F?.;?*:R2&.N"6`_NK-^@Q;E3874/;O`DJ_VUQ`*53: MU>DUQ6NO_N:!UH_?/.BN)QK0@L8ZC:$I=6.]R-"8QOZ\?EWE38O)*[R6T%B% MUV,52IL;G_S@M)<7&L\Q+YA^.:OM;QU_)MK/7N"8"/AC837 MSV77K+)FD\.^(AY+JK[4J5`=*DGJ@%X-[O^\#%H;#-"[P6%7X_1MJP//&I%\ M2R+9'[;?M$C6Q!W*J[?;Y`Y'.,QZ$@QDQ*EZ>!;HXNQ6U\.)/_;DI22@#M43 M=4"ON>$C>F&VM$2^Y@+N0F78434WG=/GCV'7 M_V!ZITB!]L_XY-=OK.6L[R(XX9NNZ7="'\TQ&3V;[L_E3,/X2,/@*5P^?,9= M/N0N'SC5/3)QJ/DW*^K%ER5*PP<'GW+']/WOAW7TMD0\FHG&13J<(A4-D5)E MX#L\^!3.K*@`L\2(EI+0"I,G@9;:*HP73CJ-YILNIYKND>2J*J"3D%2!0YL;-5QTO0^0DYQT/@ M.35=S+'IC<9C?\:N/M"=7D]K;0_T#25S MW33.@[DQ\#CK:C-R7>*YISZE08]503KW\T'N]H8)@`76E@)N%H4'^>!J@ZW! M+4G'(4=>!YU.)P':-D!D4$=K\>1OV!J*`P'6;DZHM[BQ=-L#VJ&$,OW'`@E1 MPF@JAV-:BF'9:VX'7Q;--`[CRL,7$%><4FVN"/5Z&[@GNFP6`?*<1R`T'55D MV?&870^\T1>X*RNJ0!K'X*MJ-R6Z&]+*]L<(YN,'=++E((D"V^.W2T&R2DKSBA#$([=34EB>IWB M<&21@V=IB\$Q,@P3MXJZ=0/QWZ5]JL]-#_9VPF3AV->V.NRD'=+F)4M#ED4H MCGEMJX-.NU\&LCM*=->GBS)2Q+.O[4'23ZZO50::#!)U./:U!#2WQ---FQA1 M0CJ^/0XVS,*TZG`BXB/8KG=3^QC^\C(`SB(G)T0^TOKM5J^S)<",]E/',@AU M,:KV%N(4Y47.O:Z:!&]]L3+@9-&+%U%W6FJ_(#BQ"``\[3:TXB56UG89O*6W M!S6+CMQT2GIG(@HJ2^:%<6WRZ@+\3FO0&PQBB&X) M^2X)@4W=B!L^$B<'5E,0C#K"U5G(MT:>7HM/GD&_K[;[>TR=S^7)HPJ0IS4< MM/91>+KB6M33^'1H:_V.VMU'.>ENK45M`?(,N\/]E)*ME:@C8(*U8;_5V2UY MSI\)'9LNN:'FF"S_N'R'6JG=[0JZX-9Q2^60A8?'KHBQA83T!*FA'7>&-:?& M]L9$-*C<`]&08#Q$8]4*1",*C)YT: MUW/\HON%O?[2OF$]AK]0P5WLS[LGYRYL-HQU%!9Y)':0I8/M*:QA/A(LLDB4 M]\'O5_IL@^<6B'_;J4JF"O"63=H+ASX0T_,!G6B=G9.V+Q`[=Z42=@/6:<)^ MT4U[==J\N`$=`UY<.+YM7-H/6*U(C!]SQPY\J1#-SIP9<3USO%%YOQ!G0O7Y MU!SKUCJ%XN'SW$_J;.O@4TQAB\&]`ZR!UL2=1; M;$3\.^B(#F*WCG0['VEM!SA?.=X+B'A'AHAO!GTWN)<7]"X'=9FX)PL]0$*O M*8/28&?2448J-Q3Y81O$!4SQJ>3KBH* M4*M!GGW%'?G>%.\\I).?57)\(.;MTT76.;!OBVE5[!4(&2O`]-)U_1WR!K>*.#@02%M*PRUV_+([Y@GD(SD(QL#>&LNJV"B05BR/9:Q.L(P[ M34+:*><1!&"0`G;&4?I`*`LG&^PB+BP);O[)*9.'_IIESEEY*R"S:-K?-9!\ MQY$$4,"1:YWV8-#5VCD`;C:0PL!E44_`]\H#3M!T)V^E"_A-=GZO]O,@%#-, MA6QO$DP!%[@=F(G*V.#;XD04\%^JJK6[696XP7JE0,HBF("S*0'2I?T(.VMT M=4%IS27>IB6NE[$US:ZU&'+*>9)53UG+;@E>=DW%D'=)JQ1XMYB?]--<%*$6 M]W96LB0Y6*;@\CG4X!1[JH++YU11%B<)IXZSG[[0F[N\#%ASZ,>IX^RWM30) M"\#ZA=B$ZA9\=V3,3-MT/:ICYKLL9=46[U:!IB7+N3@0R`$XF[QJBU/GJ6JM M[C8`GSHNN_<5_KFX_JHM3I7GH#],7?)/+5D2I#RB<:H[(2;I%0(IKZC/35?U ME2!A?MU!\5+*-9BJ0"B/`0*UH84J)\LB%!;\<:(S(1X)%(.*\B@+JFJ0RN-3 M_A:H$)]$D2ITF:2=@I?G&;6NFCHAEGM)J/TS%GAOS),$K\!34\=F=VK7NTIQ M7*;6KA:#C)N$);%1.1ZUK78Z*1FTCP3@I9BL4KE2 M*<#+H+PFD$@M0OF1\?]^D%-R[YP,<[JY`(UA$9:8W1(`W#4]$O8)#*K,;LG8 MF=CLC<5C?%Z?JV&J\]N.$*DQ_20H!Z]Y5T/O.+WE1A^\=F6-P*\Q0(I!%6\; MU%"\ZKB.U[3NK3,C)WW$ZZRGME*=(1L"RG"8G".KAMYQ>DMVF)P$9"/Q&RKU M97A,3LZTH7A"YJOUF+S6ER_/#/9PL/D,,`^>8'5OM\3UJ(EMWX-:1KRU=$6\ MZX?8G:7B6\?UOIN9--D6N)=`5H+;6N\1^KHH)-?1%.AQNI?4DN$4"G1?W4L: M56W&Q3<^.R)?D#3<[`]V9:4$*I=[0W78YQ(G#YE=T4.*E@D<&_!%10(UF+3% MPX+HEGSQ=E@JKP&OVMIPD%,$I)W@)$/>Q0/KFM)`KM_EMAW>#\&0H?B\'L?U MIT+%#I374WD'!`K-Z@L:D$3?YJS#P0WU/X5PV1$UI&B-0`\IJ;0HW`A5!M/% M0\>M^Z96:NTY">SJ\)`B:N*)8-E*VU"[:,%JFTR]I*\5II]SK!)5K9E7]2'1JO!7?RMU@K\08IFUKLB7;.)&&U?+*FJ4Z39%F MTEI;:PW[/4TJ\#),EDBO9YDUV;)U._^&I;#8L`DV,6HZ+-NPJ2.#2%J])WYZ MDK=PFK)G9$[A)4$/4ML8S1SJA6/D2\#(N_&?O*^>L_;V8.;4UJ7;"6]J3%`. MS/+G22D(.6XR73PL>/A3!+H<^O6YB?QT6"4$'NRA4'O)&0G^O;3#\>1G84NK MC6/*BQ.WS_%L[50"I!QP.Y!NDE*-=BE)CVCXJS-GRK!.\Z.N-WM M<;`3@:M2[/)XQYM6->SSF%<&O2OBG>KN](8ZCZ:!DQ1^@*9>VM=S@OTM[,D( MH'LLRS#>Y<7^8#A,9U,$H9&.1QYK>/OEP:#3EX1'V/0;R_K&$*U0`N^`I[P% M=B'WL)<&?,H"_!+\$$]LBX,A'8$\1G"8Y>1 MC0.WA>@K7E>9O[040/.(RG&S$+]F"@(?V@R9OS!MW1YO:3O2O4IY(BP.BW0L M\NC/O]LD"0M\#.P\_H.V_E&WT!\$=0#IV*D$-W@9YOY:?ZX"\%2`2QY/^.?" MG:IQ&0&;*5T`1WGS[%.]BP:\3GG=0:LO`'P*`$E09XG/D.-'>X.6JFT/]36= MZ':8KP#KY3J6:42Y#-CJN?`*]NOU0ZA0NK5,EKEGICNV'->GY`YP^FR!6RDN M6T/UX-.OEG=BF(^*ZRTL\OO!M]'ME\NKCTIK[L'_SR?*Q?75W4=%Q=_OS!E8 ME2ORI-PZ,]T^##XX5'"*U(-R\.O$.U%2KSO]>CZZ_7CO>-/@34<7HV^77__Z MF'K5"?O;]\O_.P^6.BD-QHGR`%0X>(J?46#H M@:);YL3^_0"_:#XL&`Z(P@?`X37A(8NNX:]HG MRDL2X);,J>,J=U/@_)SXGCEV%?`1Q\H[;TI"21EH6NL$\X.ZO3AGL3^^5YYT%[[!Y!D">L=61OX$,%6T MUJ&B#@?]8^5/HF#_>5VY-YWY5`>BC!G*+%1EZ`'AQKX;/(X$,%9'=HKSH-C` M!X/Z$U?Q'`6HJWO*%&B+9[!,8RAB:O@8]1#%7;A@JQ7#=!V*YV['M92AS6J1 MU(8ZZ\!&^*]]JA`;_./,G$^)3920+$! MMTN=9]T*L>]W3@X5$TRAXH('MPC\[,`3*`>Q-X]-[#5+&/OQRS;(H&[!:_5` M"F#E.36)I].%XH(66LK,L1QQ(&`P[@.?CQ06*<'>;F%@!BB.IV`RW!GPVG;]!SRO M1Q)%2^,Y#)"+T2\$8<%^@RVF;R);#Y6GJ3F>`H]\;-R[&>]C-+%*:$25>V*9 M@"Z8D2E`E$&ID!+W!,&,,06XZ=Q#=(CH(2"A=$X0.]8;'>%`F-.,# M@3541O.Y!=]@M'H7L]!79Z.$A48>`,`7CF,P?0D>CG5L3CU_D7H>!3DNV)?_Q@6'68A,*N!Q`P7R#/AZ3.<(>,A#>SJ!8_NR&HJ(K&'V/J/-V8^+))03!W2#Z2KPX`H8QV:]M5L!H8_!O2IZ6+ISN%Q\ M"@":-K-)`421J$1H+)2Y!<8%2(AE'&AG=.,170O6HLP85P@(,\'D'8@.92H+ M[Z'DT21/QTD[OC_FO6"(P_"XH0ZQ+/(.6WU'*_'?[FXD*_A4BN$%F][`.^+0K\(C6/Q^YSOHYOO@-K8L2Q][I+J0!^#77+G.B:@ M<=(I^WV.+C?X?04TC2#^Y_GMW>7IZ.O1Z.OE%Z"NY\QC7S-2B+5;O_!R73M7 M)Y:PN`DD?\6GT\C3K3YZ=PD?!;':^\*ICI=!*Q[3YX#\P3.R>:;^DF,^-B,; M_*C@SSSQW[QT*/J?K^_NKK^A!ES#Z_X1S%8[49AVA_)FD0=OJ2IWUS=K7XZP MZ*XTZO;RRQ]W:U],VQ!E@V@O7_'U_"+]AL)$29GR(FP^R3&&J4U^4B`P"^Z[ M*5&(7$#]Y2)??(.=.&SL;?+.39L8(29]\&AY M&YVO=#DJ5DRM]E>#3*9!RY3#'[$D`2.^65:C7H%Y[>_4O#)=PL1#E)C`K5&0 M^`IV[34C?)V"`Y9VR$:/S5M9O']W)>B)A.\^^:SO4K"=CO;43S,*-:9JG5R4WCP8!%,CIN43=KU:7"D4T]CQ\- MI`QJ?;2]L:&OW89>^'A:3FSJ6%;J1"O73LHZ%$GRJ;@5^,#R^1R*UK+(CV?W M7N&QS(@=77W#^>)*6XV5H,_GU'DV9[`^*(349=O]X^'&5=%UCW5WRM(I[`>R*LD^#,Z?P[N8RCRX MC!E]B-HJ3_`.Y9XHL4(FSV%UX::-Y43K)8T;"R.P%B4LU@F*DT"6K`?\.@A7 MC\&S>J>#%+.P+FSN>%@?P4HSAP/4[&P/BHFP)(;')D\ M7M:UC2V3%1LEP'SP@U'/C*'.;(;7ID`1_EY69\600`Z[`=_F%&L93I2I\P0O MHZS8!@L/=!M)9#NXO$_9ZD$]AQVFXIA(<%"(TQH>V/=G/[ M8_.5`!=K'B%A*A+N4B&6]WP)KN8EM@--85NN% M@5SG,%$,:AKH7Q],5J0Z9\(W9]?Z%$*I@\=&8;%TX+O#,`>!P+4P>/AO>]?6 MG+BQA/\*A^1A4\5-0D+@LTL5BW'6E8UQL/?DY&D+H\%614B.)&S\[],S(XD1 M=XN+1FSOPU89Q$QWS]>MUNCK'A;S_,"O%"!M-'DPY8PF*B8?<@SAR7D$BSQ9 ME.\=)%MHP0%8X<3<]F6"(LT@EH\8209I221'5Z?U]^&U`I?!%N MX((,/JS"*PU[(WMJ"HQ?5F5))?"?W*EM]T["BTP.J1@KPM0 MBNT<^MJZT:CYA-_RT4*.-RLZ\G@Z\$8'$EW:%Y>_0_F'HZ<2>S'LLPJ]*'HD M?L.8M;!4-FTE0]`4_J._XSI^G38A'FF%RF%]8"!/P/1-)J)5UM'4,DM:0KK0TB MG1V5'1WHD/A)$MUIU"8L(,?$=9X'"'>^L(9U%#]C$[.0O'.[\X+ON/CDR:.% M1##-4YQ;+M\5-%Y(2W]FV^XK.#.[U4`2`'[C__*CT^$/I2U_]3:"Y2)>2&F+ M#4#5%YCVL8C\:N%5G4C-G]MK=C&^`WCEQ[EV('XZO-L%:M#I/!%-N!FNO_K:R]^E94P*\O'?5:SY3&[ M%N8YY$7AIS'[MP./#Q8L<"?AA7^&@AHU4(MMHGTJUIM;BP#V?D$HM0&4X^N? M8'C&',J"\CPKL(B69'E*9Z&Z#EX)+@1.`G[0?*^Y(#.'4#PW&HO)_OQO%I8% MUC6-S_,_(5#/_Z`1&S'W;@H$!B@$RQD$J#GQ?:6(ZPVHB/%+?:\U.T*LFF\1 M)6W\X%79J-%S88YPE]JJ",M,8=F-'Y`0;`BV$\;`<)\I1ZC+8Q[&:[WVM-1H M1$AZ2VG[96&#-2^F4@#GM,:86*9IDPW&.$$TRAX*[XDT^QGGYQ0V\6@+J=5& MN>U<7E[?_,HK'R\*>K2=)IVAMK=?6+244:JKRS6!LB$(_0?]1T[_4;4TVT?H M/>@]Z#WT[J,W6M(C*#O_D23IW^_Q:,^D_]ZE!V9$I0=9@65G$YQEL#T<`$ZL M_?'"Z@%-\OZXV2SINB(]&-`5T!6.[@H9)N#H".@(\CA"LV2T,MO)R8$K2))+ M9[J!?D,"5NN,CUQ2:Y^CB)F-^N^/CA\@9=9:R[UH9%MZ!#X"_[#`AP0982^W M]@C[8\1[HU5'X$N?#V>ZM_P5!K7_%AZ&OC7B/!/+GJ;C7_XH M3U8R:'^>(333#84/M4K=R"R"(NX1]YGAOJ8@[N76'G%_E'C?1-RGZ@.:^,U1 M>I5N4"=A9JE;86&+`XE:'+`&H&/6HP!;'$@(Y0ZV.)"UR@Z"R,Q&0RR"U]FG"CE1UIE(:)<5K#*/44)#R)KGVZ"V2>(O:7'%" MIVQH05]!7Y'`5XQ2LX4U!/+G\IER2I=R>:[4!D^0'@KH"#EQA+R`_D,-H__^U%+YSS+>[ZC>Q1.+[T9/Q)S: MI#_N48+C_$6>SXY$AK%O&4VQPUA\R4%3'/NKR7KLKW3TQT5@GJ&.>)!8YDN` M+%MDV9XNRY+.`$CE0);MV6`.6;88H,XV0$G`-<.#Q!"6DL`2^;8(-N3;2GIK ME>0=/1XDEB]JAPS:YYX(==9'N>!!8K)KC_XCK__@06*R:X_>(Z_WX$%BN4CZ M,R7FXD%BV0?;)H2N@*V2=@*,CH"/(XPAXD%@N#Q&37'G&/!XEEF3'GN]O#(?HT1#T?6.>(%`-UA_[3%:V0OZ=R[=/^ M09>U_0.V>LA#JP<\4`U;/6"K!ZRD3F,`K"+$5@]G@SEL]8`!ZFP#E`1ESGB@ M&H(1&SP@V/)B0&SPD*_L2S+2"AZH)LF[":RWE8;BA`>JH;>@M\CH+7B@FO3: MHZ](XBMXH%H^FUSQ'L\URQC@>JR:Y]CAPA M+Z#'`]5V39SS3;$],"UVZ82U`#Y\_],[6"MR1QMN/W'44-";/U[W[ MRM_<4?Y6I5';4?YHA08D&%H.,7M#SP'L^YW1:#J9VI0J>TG&UL@*3H2MUF9L ME=6ZT5#K"71ME_VPVB8D5FE(W"RQ5M/5UMX2\[;G$#,NYTW/>[PCXDXX.]02 MP6!;W+^^X/T;93^\HC!"I,0\IKY71W6SCJJFI5>QZ_H!#?[AU_Z)EZ^^6;6F MKBL)W1;%/8@Z!UDD[7V+M$V1&Q)<.R-W0EA)^&D71=\21)JZE@PA"6'WU^0@ MZ[$E+R@O+LA&':+8"-D1N\=]IM7XU+]X+?Z)UV?7U*%,"Z;G&FY1XA@Z'V0E M=\TTRK1.-K6ZL/XTU;WUW!?+).;GMV\^,:^=?D3XZ,1[Q"=>[6U)B-%0EI"\ MHR9'ML$A5E_9FM$T]>-J?QV])L@*`RMO$NOB MTH6D%^2X?WM>E]BMK_A4(0UO*[7R'Q^KBV.)#;>'3KBM)S1)#KYK[RO)'0YN>UWX%GZP# MRZ;9&WSVY+P+PZZ?F0N8=FZCV/Y#636S,*PX=\\)K`"\^]'R`V_H!#?#21J# M-XOM0>]VT+\KW'_I#3JWO6_WU]V[PO5-M\*%637/LAQ=$-<;VM>.26:_D;<4 M@K2*;?JZOMDR:H8N3KTPM#AW=^IYB15*#3RU!B&MK*@QZM8-O:SZE643KPM? M/;I>"L55I=B&IU]BTUL%9#AL.%'_Q/CB]/?>D.[2W;U-'EP[Q<20O0QN!__G M4U?G\:0)AUZ&^6=PIJ>C3]PI3BDQ?K-N6+D?7ZYHH^ MLZB07!CU!`0VS)[8AZ)!V":^'^WT],?"]L].MX\%@;7M`K>41D,+-YLVS\]$ M_?B?77&]QZI:J]6K].LJO;`87A_`K>!3$?1EY8'%-AN\NC0Z?/ZQ M2H>R+NC_3(I_`5!+`P04````"``"8Z=&CLM09_,%```L0@``%0`<`')P`L``00E#@``!#D!``#E M7.M/(S<0_UZI_\,V]WGS`$XZ$/04$J@BP1'QJ"I5U]CJ5GNH\2="2A[HG`<5VS#J/\ M<4`4.*@85V>UL=:3DT;#T,\&DM6%'#4.FLW#1DQ86U">S!1=HWXZC&E;C3^N MK^Z\,03$I5QIPKT7+B,FB:]U?'SJ(C_2GA$1Z[*U;GMK&G\3G(R`&[-+)IY^F`$K`I_U]PCS0A:9=87:KMD!,PTH MTH\M,:OL')11*N/"3'AKBS%31(1<]]IRK:A2#(D:1.4B5.Z(D`F6C=91`YA6 M\1/CWR.WV5I6C0_+QU_;2D7IL)#,R`!8M-[738+8*U6HUPFE1)ARM7RF6U%V M!<2V7->;2"\6B1^W$%ROP4N*A@J#()+F4@R>F'\H19#LM^6"(E/?4.'28F+$ M$E9SA/1!8G/%WOH$=#36^+DJ!$QBM+EO?ES\'=(I829AVKI#I)QCT_^=L!`R MD"G(;PUB&[&V"5Q!-"6&ST&6331"G'O"YB%C$F&\L`.*`7V M73WO8Q/1J+Z)R(EI:%\@&\,L-FO`2T4#"BCFH)" M']YIX3V.!4-G*>-//<^(GWS6:M)A1:_\0I9$;$'H%X5E,RF2S+&X">'N1X38 M./MD3@8,"@QX*0QV09;3;]*,L!LHLTTME5H9//L&5YH=%@\%I4IY3O&V`*-2 M53")TF*H.B((!(^4SMU&;9%:`%-Q8+;5M[GF^3Y=Z-7'W4&/=\B$:J-D>L5+ MX]@KD%*ML#B%[B40% MX1848.B8P\$N3(&)Z$ABZ;5T/^XI-JD,7=?W%>^XJRD,>X3R`6M2E_4+#B9#3EM7(%_>8+Z!Y'9>%*J*Q7 MI!MT58U:4^`A9.GY0F)!>"+O8XU-0VD3LPJ`>UR#Q2082Z2P6 M(+,929N@I"MO,4@=H;0Y2WJYL)1QU+)):@$HA=)E6_/\WEWEYC!C(,PL8YE\ M%H"5%FS;Y2W3$HO3:7&QDZ'B;3^@G"IM^O04\M'+Y=PC_')MV9.7T\T0HH9GQPA'VTH(2E.69QJ[3AX)PJQ(!#>6$>SLF?Z(0"]!_ MP^1/--GB\1'U]P!\=8E.BN[MW$1JJHL92(^JEX.TY&_-Y/%:`';Y`$_X>DV> MG1;OV%>U[PBN)1V$&C``"XVP$`%0`<`')P`L``00E#@``!#D!``#M75M3XTB6?M^(_0\L\TR!#=A0 MT;43%!0][%*%%ZCNG=C84`@IC7-'ECPIF<*]L?]]3\H79"MODC*M8VI>NFC( M3)WO?'D[E\S\Y<^OXVCOA;"4)O&G_KR0FS,](N/S/?CAZ.3@JS\[ MZ!YU3O?^ZZC[L7/R\>3HO_?^=_#U__:^/#SN'>S]^/'C0P@M9'D+'X)DO'=P MP+\3T?AO3WY*]D"P./VT/\JRR M+RR)R#T9[N6R?LQF$_)I/Z7C2<0QYK\;,3+\M,\F[#5GY.AX_JD_727!=$SB M["(.O\09S68W\3!AXQS@_AYO]_O]S1K2/Y+8?R8QI^N0__U0W<0A2-A0QCOV M[,?TC[S!NPGO??!#"I^[I7^?TA"^.&!).`VR*_)"HF3"A1G0"8%&R17)?!JE MAE"L?&DKB"]"^"_\TH\*VK8-5OT1"S@ODS@D<4I"^"%-(AKRB>6S'_'1^3`B M)#/%8M*0!7DO@H!-2?CE=<(_EE;3MZRR!;ENDS0=$/8P\AFY]*-@&LU9'1;_ M4$W::DU:QF"A=YLW9T'VARP)\ID<^M^8TYM_P0**.@U;&9?C,P%8$]`26H!5.W6MS+C#*##Q-F(9#3P(VO3ST:KKI`\P&Z*Y)J]&[[-Z4U0 MR%JT@T#XF;S3CY(HA"WE%UB*LIDY`.,&MRI_S3Y5K_5M]*U+/QU=1\D/:UVK MT*`%^>_)"TWSU6K`:,+^2GR67M,8AB/UH[?/6IC+K'QI>XB=@&L/1\<)D$X! MB<^")9C%C\6/K4PR&F>'(1T?+LH<^E&TKT4O,0Z7MAVW"D]SI>2M-14)?H81 M"$HX",G0GT:910$%;5L4-QG[-'8C[:+IQL+F[1R,R?B),)N2KK?;5,P12,2" MZ1,Y6*G`HK#"UIN*'"?9A=6QM&QP)1CT6!KGD_,M-+?V(?*:$5BWPN6GN$0- M?"&YKP:^&"7!VF^27*%RP8"N29__#V]RB!3=:G_8Q-23/RAG[ZE&MBFAX\^_YDSB") MLG3YFTTJ%[_V5NOI9>2GRPWKQ2L5=4%M':]_./(4.MBJF1XQ!P=[S!'7FE_YI*K]7VF M4[+>@(E)V_)2]@C-:I8O7L3K'Y^XI$*T+;6U?+W)+];XZ78T?@&RA%R>Z\A_ MEJA\K0S(?+IK.A<`$"N]M]UN/B!@3L-.-[R"@:SI[VME`4-OUTA0`!&3T=\N M&=Z#?]&:<#1WU5"A%#$E)RU0&0^3X=\F(V?DDC"P%H9 M$-JE.]*)[@4`)%K?DC6]F"V3\3B)%1 M[TWY9`$6X[J>T_$C#+>8:EOBCS="]!X",`M\=^R!L!<:$$WL153<.W'I(S.* MNE3C32@#,=1GO1(0DOWS/":$RNZ1-+:)AVU)2(2WNG+<8;;+*A M@&(B(W2WFF+P0<'1(C@V0L(20U*`$HR1I.4ICJ+LE34.VTQ MOF"3`ADV>Z$A]7Z`)XD*$V?*A;S3%I/*ZGFG)2#4(1Q[ROW&?=FO$Q)D)/Q* M(Y)F22P*"VCK>*=X+-`:JI=CDC#10Q9,4QXP?1=QM%[#W%:L<;2>2YNR=ARM M5W+95$.$)XYFFFQP2Y[]:!YBESA_!*6\GDO[P[)WIU=:X&6(G(3'JF5]2(W\ MS2)>SZG1H77*R'18UG1):B=!+7=JQN$GJ:UOQT>$&JPOTZ<4%G'8ES_X?/P: M'9B4U?%Z+DT_YS.2&3XG)XX:$/@F(L^NOAL^,C]._4#IK#2O[/6X&!P:_8RBY]QF:`X3<_FJJZA%%] MKXFWE+_B4:@?I(NCNLH^*W0 MBG?)^B2[S++4/XMKL>_2KU7-D"^3H/Z0Y#Z$?O'.&S?VOI&ZT>\2%-8/B^>^#G_0+E!6BOH]3%8MU46!8'\R#R" MWT$Z0P"7:M($4%`YMS;COG81V!7R"EI8CCV;>;IV\HV(!.? M+I_6``AWV8BP-?C*K`-M;:^/P!M0E4Y37,C<@::T;0!I\6*>N@25$2#SM`U8 M`F9"-AN`>9[?:0RS0NX;_$;4`TI>S3MK\=*>RHN:%@DZ#UJ.3#MJO+,6,[5K M;BURF=WM?7HE9&XN6K+"K/D^7E[) M.VLQ'[P6(5I.10C=7--D+:)0.7BP7)S/$-C(&M4;10F*>-Q<[M2(JSJQ'DG( MXPR!\5R7,04D>R<#7$V3E:9'[PR!G5R+)@D6]7F!%KP=\L?V5#X.>2WO#($I M;&$ATT&4$-F:CZ/6WE*E&00&LP4:-0@E++;FW!A`6P1FBSE8G:M14-H[1V`_ M:Y0N=4<)P4@H:B^]Z.V"1:TK>*.H=][B&?'3*9L9#:5R8>\'*OC25_;.$7@\:O%GB$W"9VN^#M$SQQ5V MAMXY`A]'+;XD6"3\M.;?T.UV&_B(O7-N&E6017TUI' M[657)*W.S95=0;>*_%3SRE['XLU!JB_*DE+-*GJ=(Y>^!F&6:E4EKO?C*KA^ MECS6SE'K-R!6H66=4"F@G4IM[73:O;A0JL6RLLMR[U1V*TB,-[W54.7;N[-Y M,1#O24H`&L\]*YP_6RRM\JA"U28`6]OWTS5;6"IC=7T1]$*@`>S/DC@F427* M)+5`\K8OK[/"DA(>LI38>6)@C?"KNB)@;=&D;$9E%83(LF'MQM$[G19-2SL< M:L`I\U^W9$[>)FD*,T;^HM.E'P7F!R0[[;DYZYZ0['1< MVBU5CTCF"I2YO\IR_S3&9=>E9=/DE&1.@X$QV96:.%B-R:[3(&<]8[(KO-NN M+/=N&9/=#F)CTDSE:$]+?B/930SK+^$KK&)56"L'B%`$):LL#P(`R$Y+_D[H M\R@CX<4+8;`M^C;E\.^&^9ZG\+KE9S^E`3=Z:33-WC97`L[J-0BZ01&QK$)N M$Z3(C-!EM'6YVS6G6U,3T**(;%;AU0B2TNYLP7"Q=PFU[$K^#:U, MJ,P2TZI>_\3>,U[R[REC8IIJP'L[$3%C]0D<8D:8\!@L%BS-R\A/4\.+7&5U M0"TXXF9&]&DL4S$X9*^P%H74WO)9+NQUCMN-LAEJ74R5#`^RAUT(TU?_E8ZG\F4`$8*3G:6N+F9" M(#FVJU@6R]YB+;MC]]Q3MW+0D6#*YJ%H,+I)^'FV*)Z":ME-V7/0-,]CJ*VBV MY%#-M\E/?GY#]IAGCLW?>T;VOM_2*;TA)5?KYTZKES;SP5J<:0R(.;/"C;\!G3\K3N4;=,L\3W:5=%[\$_S6^SXVS$: MN[58#,"W[H5VQ*BXVY3!(_-2+P74>C_7"\)0P>&=+BM83411?&3.Z`94X#)^ MZW.R/9_SXX_D<91,4S\.^46<$7DA\?Q0Z$T
D MVE624!0>F3.\-@VX%J6Z?.B6I-:\Y)*9(1_Z,#O`#'(7Z[WH%5H!;2!(:!0, M&(G%5A49,J^[7GY8I"WPNVH%M(`@L=$BOQO(L'GT:SLL[G(,Z:^YT_$F'A!& MD_!7IDX\=_`U4"N"ZU8=^WU6#B_:,W MUE0;BEB%X@Y=Y[G@BF^K8@S&=;W3;HV=1'5AE>G@NGK0%UP:3_)\<',-"GP5 M9JCP>-P='V$]=;E)-T\.,V-EG4XIGMTZT7KJ=!M=[T3K:>GF>;'O2D6!X0NKSOP^UT9(`,F=-[*>#W.)V0@`XI M";5^.VD=0(@CJ56A?UFP7@D)F9_;.FDXYD0W[.FFRQIN=IZ-HJ]Q4F,#IE3N_&!NQZ.M!.-UL54 MR?!@FZ]=F'8#8>L:*O?5+C`[;"Z`/<[=@ M45C]9EU6!R#B2%;1D"!A3@T+VWN@UIE#NL99HU"[U-D[F0X?Y6'_0+VBK9<" M$1&DHV@&@6#]$J&P]\RG1,'7"2/T69/.NE8(!$.0#5)=O0(0V-[>?*093^V\ MB4/Z0L.I=@,@+`_0=M^SJD"&[:G-DJB_TVQT3^87*ZVRCNN+<8V.H!NT]'>)B))-J`!3!'4D62=6#M?<0 MJ63S>A._P"<3^6`3E`+1$%RM;($'*39L[X7^"@#>=G^S`9BCL"6\3J9Q>!,/ M&?]U^'V2Q/.+-13#JUI#L/ZTF(3<*'NM"6!LKY$J,'Q+,FL=0-P6J*3%D*OK M/J#"C.+Q4I`[Y&]2<=AI$M&0/VW\V8_\."`/(T*R=.#S]W%&).,&_$X^.--O MS5M0^\&9OLO=9>4'9_K2R[=$I%LO* M+LN]6^FY?20QD@8JQY^>:R<3JM_ZJ0'S><@0#K+`[*VEWG['R=*H@0Y:XNRYZ+F=Z,D25(V))]N4\XB>LN@P:U`3:"8&,U)HUA88?E3 MU`*8"$*4M=D3P\&6]5L26+OJ26H`/`SIILW8*D*QE]3KB"FSQ4Y5#8!BR&%M MQED)C[UD84L9=6CL:>RX^$".3^::*QYRZMVD91D+-2YH@4P&Y% M8\^=VJ+UHK'GI2P\L=R[%8T][^"(3310.=IH[#V_('\*YM!3FC$_R!0+PV91 MP(74#)0O$F(,R`*N/&DVS5/R;F+8&9$;6*1@FZ;B1E8%\"&XZ5:L=3%#:B3( MPJY+8`:CQNL>(?`\5V%B77)DE_M?)FF>L/KEE=\F:S1_R:H`/J1N9?D\IL:" M++!Z3U("VAB!O%?0IZ)DPG$N1%<.'44]0(K`A:SF03:NM+"0Q5!_)3%8W1$( M?!&.0R MV._[`% MQO-V0!4(HJOU"&S6&0KPL45D)1`64U:5(&W%ED`="'9)6^@-:@6H`[W;"R4* M(XAYX'.41"!3.G\9=!W>UUXPD=COM/;$N4:!1)#&7&T\DT0)Q\V[/ M7V)*XOS@M^'I*U$]4$_K=U&KB--0+(>$[+WS#4&UAWR$Y:'7X[B2RT#_$G-$ M#@O9J^C6",,1_'3''-K8:"&C37]=UF990(;`-Z,8+C)OF1`'L@CIVZMZ`Y^& M-_&E/Z&9'VE94M8#I`B\,Y49,\"$+&JZEH*HY4Q0&E`A\+%49DJ*!%EL]2(( MIN-IQ`VG*U!L0+.K*;_%IQ"M@E7@6?]&=[6&0!<(7"G5QU\-D,@"M`*36&4- M;!8&3#C3H)4VGA@%LLBKX=&/M4,2W2Z"E)^*;)3DQQ8ZO0C_9SI/2TH?$\F2 M*W[D..]IBV>,[PETM91FY(&P%WXM9?Z2\3T)DNZ&A?>T=5-]@Z:][O'N M3456,&,+:4M0S>==\="HWB]4K8%:=FY:J0T36SA+,^"75\("FJJW&E7; M`I7@O"FCYB2@`(DM(J[NP':(5S3F=4\0I#S;'/-RE-A"X#7SR4X0^"RK$28` ML&/AYYV_8_CX=.=.M79/7'HLJL:BU_Q&+!O6XM#<:Q:)/Y,^& MZR&]SUCTB5.+P%8L^D1ZE8("UON,19^<[50LN@9S#F+1LK=A8(_)WQDH[C*O M*4OEK_B85//Z700)B(J!L@*=#P06$G#ZGP4ZX'T"&(CS0DI8[(6 M5*[`R#&K0<>JDM?#V(3ZR:&XN MG38V7RCE=4]Q9`5NZ%6A_*+@R$*VM=2/:U]5AP?MH]NMA6Z_^J]T/!UK*5DK M!Y`0N,)*?5U,A4!R;%'*KZ`\(Q**Y0`*@@7;E(2RY-BB@!?3@,ORU6=_(]G; MS<0D@,U%1A?^[0?88Q"=&Z9B2Z`.EPE[CI;Y6B"QQ?XJ@,@?_=3Z!NHUZ!T[ M[0'F>XQ:I#;N'R5-8`L5(NHFN/9"*/J+=G/5WF'`7-S/VG5]K1Q`0I#IVV3X M2CSY99#V[CR6N$D*!S;FGY%>9*PJ#MT6@9O*+#2FQZ&^RMB"T@N)`,L\@`&C M@2@`J2SO]9!>X")3NQJ(1.\U/"&RSNZGHXBDJ^2+13A]D9(A[?/*6EX?@Z57 MI>L;P)$P<8[K,F^.Y#I*?NSD7=[=WNZ=P.^Y-* MY=WMH365>Z4)20I@I^[R[O:<;D=KW>6=:[&L[++<.W67-TB,P[QKH'*TY]6_ MD8ROJ`.6O%!8J#_/OL.$=Q,OGLR(GR_`WGG)31N#>\^J-P:ZP6E#*!::NBB1 MG8>OF>W;0W`ZIRX#4CXW`2([_'Y%)HP$-#\MPF^/'2@UZ70S/*]KM!4TT@2R_HPSE(@B2:9RE`W_&[20^ M804!6)GA+?6?:)0KJ5(O,6D0=(/`A^ZZEYAK`EO6B;EFK&S"00D($G^M;^8J MH<>6\U*XEN!;$@<`);=''A-^IT`ZV'9UA MRPDJS[DK"(N;,PRZFWDC,%(1=)SM4&VZR*EUA2VA2#+HYN]V6?(R*1H#I2`P M=ZUXF;0HL24)P2YL>FS/IDODOZ:Q#TNGG05`T1@H MY;TL`%J4]A*9+"T`+`D("=-KT$?5^V.T=0$RWNE>2Y5DNC<#;2]QRC[/ETF< M,?K$G_M8[$\-22Y7!+`(KH)RQ[`,L3H;"_,,;F7F]HZ/\+HJ:])>%;TD'Z:] MIR!!>-AM\G_XCO/%C_BN='Z^>--"572"*LV`(A#LY:HMW-7Q28ANS0DI1G`! MO9>Q&734_$Z[R@QOU`?H.[A_[*_%9NIAN M_.@MJ_;M^MN;>)BP<1YNO2*93Z-6TFS_8PIV+1URC7ZE:;J4\R:^G#)^[QG' M(8!Q:Y"4V[1IKW?47L9`,"+A-")WPP**%;%%.)<)@.%WSNIP:9.!'7W2.W6Z MJU.F%=OI`I+,!:?ZPI/.;"$/_2$@L0^:,;V\K5@>*'`9$:B6\.R4ST,:=TN>3;5@3+7&Y?QW:*=W?0X M:_^HO4>N:AYG[9V[-!RJ'F?-%:C9XA?D?E?VWV7DI\N[[4UMP,TZH!:7Y_"; M''S-"=-0*X:#S((K"JFU`LJ%`9/3^]BJVVQBK4LO3?9`8L0\%F>5EUA?0[."[-5>B_J@]>)DY09X.T:AO^]:7@M0(KCEMQ:!6E3( MSJZ"O`3TPO,>"L^3+\[>JMF3UX/9"H%'LII%;@`(VX'2RR3-4GY`8"ZD:G>Y M610`X]BU=Z2#/8%70(`&`[R;CT(P\(6UXZ00,^P&G$,W(5 M[&AJ`EP$UW)4X\L(DOIH(4K7>FOMG=BH[UMO+:=+ID!#W_I[RZVRXEOO M(\JQ$A!6U;?>1Y@=U=1OVS]R:L9:\*WWY5DU,CSOS+<.F)"ZCYJ3]"TR,#$U,#,S,5]L86(N>&UL550)``.CD4M5HY%+575X"P`!!"4. M```$.0$``-5]6V_D.)+N^P'V/W"K!XUJ(.TJ5_6MNF=VD;[U>-=E>VU7]QDT M%@-98CJU+4LYDM+EG(/SWY<722F)=UU(UL-@JIW!4`3Y13!(!H-__O>7IP0\ MP[R(L_0OKXX.W[X",`VS*$X?__+JT_WYP8^OP+__V[_\GS__Z\$!^`6F,`]* M&(&''3@-RN`^#\(_BKH].#H\.OP1H'^\_?;@8[`[>/?VZ#OP^]MW/QU]^].W M;_\;_+^;C_\?G-W=@P/P^?/GPPAQ*`F'PS![`@<'^#M)G/[Q$!00(,'2XB^O MUF6Y^>G-&TS_\I`GAUG^^.;=V[?OW]2$KRCE3R]%W*'^_+ZF/7KS?S]>WH5K M^!0"G!?WE5Q$^;!`M._K;.X8HO M19+G;W#[-RE\Q(.%O_`!?^'H>_R%KZH_7P8/,'D%,.6GVPNA0A\ZO*I&;Y"4 MMN2\@7F<16?I,('[K>U+?E<&>3E"]G9[F]+?9V60#)*[W=*FQ%=P6#_OVUGM M7^0TX;#^;;6<6N*2E=:X4YG>3/!_7R(9.M+!EQ*F$8QJ^7!KB5\ES(D_)BX2 ML\W"#L,$.^5/ MQ+DO'PH\+94U(R(^8?]W@[:U]K7^'5%S6&3;/(1&NM->[
S+N\TJ4S+ACVH.E@ZI*)Z)/`@V!#D0*3LJC_TH=,]>>_H_F_A%B@DR0HBNO579F%?RQ?XH*# M&XTVUL"C(W\?080$9"M`B)#W060.H:,]!#5^#/O?'HB689AMT[*X"788R\@9 MHK_D6Q30Q\%#G,1E#(N3;9YC1RF>_49QLPZ\83KW(5FU`68QDN:/D8#FJ%CWE^&34O0/<2NE="V9]MG09[&Z6-Q M`_.[=9!#C=E(W,2Z=4JD[P.O)@6(%A!BKV86U3CT8:8W".YPI#,+2-HX1Y+, MA_&@-+^C?H;Y0Z9VU2:*7&9%2PG_C$#I;#419,\,]I[]>G62/>$YCJQH;V&" M=Q)/LJ(LB*3X*")"M!0:3G$+:L9>.?MI4-(WABDAXJ'%'+>EUIE>1G/VUV:$?3&UT7@SK4W?-62/Z("0 M=SKF"W(/@T"B/L4E]54IDC(MT8P/T["SCM*800WY6#=^4SV9 MO=Q]>[*UT.'0V53P:"8<-+A]8(\86<]@K#.MF3+R$\@RSZR/9$^VQ^;5^`NQ M4N7\,P:X]NST.G\,TOB?9&9$,A99$D?T\#J-;A""D/CD/Z]7YW$:(.F#I#E] MTEG(3<3?NE5/U2]]Z+?Y+D"',S&%-F\331D%B158XSRJCDGLP-XLR0;I6RMX"E\ MADFV(6DL-_$&HH]YL!%ICE0F(V$@3%U8(WM`-<`:U4P<6J.&AD)KO%YQ3VFI M,?H2@8Y2U;\S67-LBNW/#)@N[*]_BG$<%'&()O33.-GB]&-S8S3DZ-`R3767 M39KLN=P"$'XDD*PX>CR-CNV+DR`)MTD3*?MVNC<2\&(+'X%VCX+?,3&OCZ'N MX`C7@S6<]F`9AWVNX%>)K*O[]#1["N)4C1M>&U?@XY3V1U>1D:.>1,"7X:5WZF=(97UZ+CA)'ZAF6&*.X@DCH)\=Q*4 M\#'+J]UE08`PA(EU,!AI*)P*KO/]3-"P`%T>SH.,X8/:1]O0$;4!1F'<,8R- MIX!41R=ZD'0>M8P9W&&PG#BV:;[RU]TF>\S2((J+)_D,*&UB%W!RZ9E%>8.C M-KDO,Z7&2'00HST,(]#QJ81YG,+S^"'/XJ@XD@-#1&T7$T*9^W"H"$%-"8Y\ M@8*\VSLHT.GS\0!85>S?:0&`H78"`%9F`0":\7^G&/^Y]\D'20^TQ;<-7P%H M>/"5(F;4RCW*GF"9QUD1%ZJE.X?4]MJ=)RV[>&]1^3+DDH[N+=\5O6Q]TZ^U M;7V)D'A1PB>-[6)^*U<;?P(=1)DHG8,(W`"0%HY/!VWHXF`C4X8OP5:F&ESC M5Z(X5VZKVO:HB9RL(AL)14-/"1Q.U2I!9Q4PJHH)$9C,V96VE]%=9/(6R3Q8 MCK>(*_A2XKR@L(31QSB!19FEO*-JC39.[$4DOVC,,3VH&X"FA7M[TE5$H,#K MXAL/3&[6T;!MDE+3X%FHAEW,50OO$CX&":W')]C8YU)9K7S'RLC4*\`4==E$ MUSOODFYME[>3]NE]&%?! M$_KG?1ZD11!*3^),&MM'F(Y&#-3:\%H`W!#_9ZNI!S[*?,P8^!D.F#T<7MQ< M"W])L'NY#"GNR#0-"-%LO`[.^!H87L(T3S*D2Q9P^]EM(0#(%<_O%8*;H$:8>3.NZ':$!>[8+4#$&+AV=Y^60U-O=A;0<6:%I7`_V@U M78"@!'5K0)HO`'E+Q&DMC;%JAO@?<-]T)F4VS&,Q]E3"`_<`'^,47WO",2D5 M9E9-]T_ZV-43HK\K-+1:"L7$NS`54,Q=BX-W#UJU(VZR(E:\T&+6W-UK"'*M M>(=4I!F^_KTO.5*W]*K@B,G`"1].T!XU!X!47H_L$;H#F?#B8P,G?ZXX@KRV^45$44*O^5I_0_HL2 M?4F9W9W=W[D'+1\`S.L,DM&W#5:#]W_X](Z@J_&&#T5P M1>@5DM7"UU)3>E^`K?NJD!HI-G-)X2:(HZJL$%KX7)=KF'=$E(!>J[6#W%(= MG=A\%M*JKK!$%KND886R16TK+@UDG&JP?J\+ZY81W<+*D@)/+,D`CVP.JB$8 M'4TFNI.(Z\E#.&DTEC#S5F3KR>3!$A,!O4.Y%IZ]0.Y-GFU@7NYN4*^2]V+_ ML8W)^<$5E$\,LF8N;AO(M."D-A+R!2`-B+MLFBP`:N3!)KRA3N?Q"XPJ`UB` M%,XVC>E8K:'LZ*^`RN]+P*=C%IP[$IHV87MB4LY(SJ8BR1SDR=0CG'-D<\UH M`36/X$>(:'\ZE,^#KBRD59,4UVG"*5CK+(F0A\;V6^XTM@;T65BW,@/MF$3O M5J%=4I&KU1C0UI[L*HQ1\F)Y?'%Y<7]Q=@>65Z?@[O[ZY#__>GUY>G9[]_57 M[S_\#,[^Z]/%_=_WC9[8;EN77WMT1FK4HK<: M>64JFEMVWK_WK;&U(&C@^K5NR69#_S%N#_;?S(7?4$KWJ) M1&3R2,RGC6]];#>[WXG?09A^\.7A^Y`2J$M;^?3R(R]^-W_TT,[,-%R-KX.G MS<^]]RI?IUD)P?>"\@M6FNN'$I7:12<.1F9->0JFJ6_Z$SG&6C(;8G](( M%O%C2NX0]G18@#\=OGU[A%;O.7BFMZZ^6[Q]^Q;_#Q3X`2,T'V[+-2YN#*,% M2+,4@K@H\`*()-=LRZ)$_T">V+WU2)#'R:&1P\YNL)6E6L;"DCH)JWK2\H*0 M+/7%1@P%YAC$#U*+>/?MXOV//RZ^>_>^_I6:Q\_XEW<_?+\X^J'YQ2MK$>&. M%W:)06=Q;RR*R%6@(+D)XN@B/0DV,5KUR7;&1"WL[XL)96=VEQI*@$E!G(** MV(-4G$%JX%S%`Z1&2(G=`U\!)&;_20=%]LS@/H=!L+]]_5$X9[S(M1TX>[ M"C+VD'X+RR!.850_J=FN\D#K/DB0K]/8NB5H:=2'6-UH_Z3LZTY-%-IPKHJ: MF@E8@S1KJQ%1*I>SV[PZV+1V?,24WI0PK%& MT^4_OCOZ0;ZQ.5&G:Q1CT1+_C*R+9^[O@9O)FC"G?2X#NMO-9/U-9`_.UKG9 MF7HG[8*FWF4=RT_AF^LX^(*.<]\_0!=J(DE/([.9P:?48HV#>PWDC7D*L'G1 MG4V*$16FT6UH^5E`#4V8^:UJ@\L@U4E8;7.1EK,9K8[6TP*CU,H&J&7MG0%M MZ'5?0#3#W4RF<2FIU&/2V!\3N915\E&9R>7L[TF-MA4M_43VHM3/"Z-A0*EM M.`)$CC">ZANWL(!(/5P6L%5`MOF)(9I5R"NZV@X MS-J?0,V.>NWJPF%6S':[4\M/V!D^1=43:RYC@"EV',=@.QSO/FX01+,TA8F1 MQQ"V45`VM[\XH->ECK*J2Q8DY/;BQ-TP;]YLN>GCJ;[F8@,F>;5S!\B(-LR=X MF16RFQ(].NO([\O)JT-#")UM$ M+?$<0QE:=S&#->_#KF8$*DZ`LL*[6W.@K.-<>!US%*REKSPX#5D%4BZV0`JA(P&ZK$!4ONT M+J#*R"L8\V-;:%4?RPT47`56.^=Q`X7WPK[XV.88F`S8%J^]H0Z%RY=8=H#0 MHK%_B:TE'Y-%@G\#O^-?/0@$F)YD;COQN]%Z:%CA[CJ_Q;M`S>8/#+.SF>G[9IF6\0'9*(B?8;.AO&IVF$E,#U_"9!NA+L&VA7_:;.DT@2DA76VI M=H<<1/YCS4FP3)C&EAP[E[,7F(=Q`6_R.(3-CXVL1Z8N1BH;>!^ZBY M`<*N1>.WQQC0"37-`CF#2N<-T=EWL]<%NI:QFZ'8CD?R:NXQ?%N3W,3[/#?EI^#/%*^:#W=-^Q?P9ZP?V3W$$C+@P?<%+3Y M@_8'<)JP^`LA7W&^[SH8IYK;I/("R6.$0X>`J>%(MTKID]FL:=J5DDG[1 M?P'\NS?+-5ZW,G7[A'UJ?_B5>_E]0F<0$.[AMT#@S?8]OWM%0)AXV_[^+&$ORS?)C5D8G?_U%1#YE+WYPS4#,`2WU`G M+.K:)0T3\J2D#V<$8Q5&(#D2:$?;N-R7':L<-1^PP=H\2;2QMF4[R``[>[DC MK,_>'/(K+'#UPCI_K5F^B!TZ/].4/8G=;'71DZ].A1CMPT8.YR M&C-8@(H%0#P<1QC3Z(MAB52]WN!&A89:5O<#S.'*K/B'8M4GHT1QQ01&V>+B MH5&V=1QJE'B!X#+98AIM>R:I5LHODV3`:FZ2`J0Z-\G][J!H<_!24N]G2N:^ M&+!9C^C;]9ZO8NOZTH>*.]/#1M-F!F/F"S"ERO_]0HZ[+M(;4O'SEUQ^O7F6 MKWTYQB;ML\FM;U'/40M`OX@OSM%OXK\XOU9LJ1M)ODJW)WRX`3.CX4WFG72M M[LMQ5^=9OH)QN46PKO69T5UQO_;%N2M^G\WIKEI?W/LLMV]^6.K$KK.J&L'H M38AO"N(DLB_?<4E,<&K'I;2_$>>!DC='I7<$U>WLGOIIZ&'T)*X/Q7;MZF3M M!$P7?627J84V5YFBP#`W>05 M*7I'F,]_;-,XRS'G.(PW`0X/NF\@RZU*N[E=8]/7J@\0VA)TFO8?Q_8%.89C MUP'4H(%S$!_^`K/'/-BLXS!(=&-$MHV[.)$C?Q]R;1+_XD71``AC1GGO6X00 M?.R+HXX;Q6WL0T@BOQQ"_H2+JB%@0*37_R/F.\0.YWJ%\FFM3V5W]F)DY&3G M$@+W4:(WHFH%B$II/QW>'3J>U/D`[P/ M7_6[>[/P1%`MH]"4U;%9<,'9L0H),NT%'?=QB2\P7J11_!Q'6V7,*J"W'FR( MY&;6SY@.WVS=4WH3LDK[GGG.7MWQ]E#S"XIP]GOSNQL42:=E<9YMT^@B7>7X MS]&G39;2VA(2.)DRLHXS8TV92!=?2VIQ6("*!R!,0,,%;!&;NJ"+VU27T4KO MJ])L:%OWQC8,LGTK'(/7$9'.IS2"!9HK\-&_R6Z7NIW=>$A##R;";37Q=5]+ M=W@ZT[_9V%B\%=Z1Y2;(KW.R51+]&B1;6)>DE?AT70;V;Y'K:L;<+N_"#KOP M'-?'H:T!:;ZO0>SRKL!T*FZ0BL^XD7O7;89(YH+]`#BZLC;Z;,1R6ZZS//ZG M]`$"54/'UL711`&Y^A64?1M_#,E>B*+;& M1E,W\L)@&@TTC872^V8HNEHL0"R1W[5E=-&D8Q4\*+FUB-:3.X9FT6GIA6UT M==$TD.O9GY8:;"5&^BS4CV2YMA<.UG2,1@@TBP5&2:W8H>L=K=;VBX=JZ<3+ M*\Y2[Y;7A&E3FX,O*10$BI1FX7;,PXN@M M6.3-W!N#/+3G6X0G*Y51NM3/+_BT5-&!F-)*/%BDW.7-F`H=M$&OWO`2X#"))6H4&(/WO2-^R8I>_E0E'D0EA*( M"UM8A[E8]CYF*"5H2,'O-;$'^4B*(>B#1ZO_+3XWANOC;E%H/14T<.$2A]*Q'K$D!I45KPXK:)=J--*`_2;$^6FK-U+VIY;8[_\@Q MSTY`.H"W/P-IS#P.9QR)WUZ`^ZP,DKGL#O/6G65X\39N#W+_YQC5W.)NLZ4@ M557.7G!Q(JU(2=S$P2:+4'IV4Z*HZN+4Q)[$4`8ZU"2.7]\S%_@G]X:H`CJ[ MW:.#$TX0.Z=@*;I,)>Y3.S&79AN M$)Y[$)9KA>,>+#0UY*8+3NAE(#Y07)=1N&[T[-0U\,Q1>=^YS1.MNBO M)LF-QIQ\\3T274=ZGXJSAX['0.>9E=!9]/@U4F< MVK?.D@B!G+X>KK%^T6SOKDJM0B_VH9HZWPZO35HMO_[J_8>?`6WO52Z>T0@* M2]OJ#Y\#;%)Q\%,Y64K>^]"LELQOYPZ+`CV8\U$*LCV=-W7HM$9$B#'U<-C# M5D\69?ED`;UU+(GD5F'(H]+)TJ[O@T>CWYW<05*^B\VA=7G;2%@UK7,3U8=' MK$V%=@]H(2PDEX7<5FY;1E&,=QV#Y":(HXOT)-C$:%&@!+6BG76`J_3HXV9/ M#W"#`UQPDS;Q`OK3J>/>*+0@UC<0`WPYNDZG-!$NM=OK=.(G@[K7Z7PP@2&" MNP>[!"+2BW2.7Z+1*R7@N'Z`XLJ]E3(!&_+$*EK(Y*4*P`IQC^%CG*;XE/,X M2/#;M^!U7&_(?S.K]&>IWEO`8MG/Z/&LMN!65Z8:%0U\*&.PC/YG2V^B%/>9 M8+KCOPY,'$;U_N\M1,NB(B[A'F]D-W*`2I#JN7#0$L7M\:2[_J9= M1=]:SP@;?+39L'?OCBR;.1M'.[!QFQO#2$CJQT^WN)0^E8S4,KN%19G'85E5 M#B2OIE_!\GK5>C-=NG<\EK6#[>71O<&W+\H34*:5]UG0XG[8/=6<*\=%>"\` MXHZ/^%K\W3JI&7H';N1<[-%X^B MT-G$B=2K-AH-/7"B(=:/S)M3-LZ=&';-C![$LV79<.O1="#ZIN/<9Q!?UPZP MSJJQE.Z^F//RQ5](]1T0^/^,7B) MG[9/RI'OT5D?^[Z<_=&O?O?@G45IS_81(.E6BQB(4ST,=.GL8Z`G)X,!^KM/ M&.#U+(,!<;=:/!?&2;U.,[,`<^801[QO'`K@Y%&G\+RXG)RNX\) MBZ66)9;2T-!AD7%#V=N;BD-V$S4.(D;K&V7A%J_8N/ODXX8+:(R7#4O7L9/. M\\Y:1N+D1M@)@LEYDGW6J?\H;^;R_A=/"^FU+]P`D!:^7O02#HSD?I=B5.P! M[`J66):;/'N.(Q@=[SZA=?=%>KV!N*A2^KA$4]LSF<4T8#>$F74P#M*X#U%\ M($:06;,!QSN`&>'THH85V//RI)+I),JW3!(;!E=?]Q8Z'-E]NQT+:WO6?`HW M.0QC,J'C^FA/65[&_U2=@TM;6;=/N0[,[?P6]0*@_TH@"3Q(O;M6TP6XRM)- MGD4T5O>@),IP/=W;E@;.^D:D#3++*?=&"2/>Y(1HIWT(4SJ(B#?$E&'@*Z?]?I#LOB%'G91;73V33$F$$:"<9K+!#U3[%#[B M)X555CA9)[RN.7T#HHH7[H1-U0EU?,L@?/,UF@S M<.D%EF&8;=.RN`EVP4."Q41_R;<(47'P$"H&:&ZC8 MT/V)%I3]AKL1XD'-[-$JD_"[+IN;-4H&BMT>W[:TIM7.S[VL\7M8 M_H0@C7#5)3F]QV6UF7@0:D@T%,ZI=>ON3G-3.<63/)$`F M,4.RGR@]*-5M#EQUC*"'6BE-V*;[>4",?Q5?DF\^2BU[58]?XR_C'+_&8RW$'EQG(FRY- M49>2IP;07U.=<,,#EV;+W"57Y2W8NO-E%7T)=Z)3=BDS7Y99JZM.N)Y'^(]MG$,D,_(ZY>X") M'T5"?R6O$TKLV(2)=?LUTK`/W+HQGO*JYJ!NOP"$PX(^+%8S\>(L9)3.]0*, M[&-&LF(;-HW3'*A]HQR*4A\GUTDF5:\G4_,]2]ZDXN^>I;[*G3`[;I3T>L]R M=NW\C`O&QP.>N9[S.`W0:F6:N%[*S!=7)-?8**YO6/FWK3")\OVHGJ>OM]:K M@6Q-*]:&M<6H/L]""*/B'/6&:6D(C;;V8W@-?9C0O6I#L>EAD9S;D9DVQ#,$]%8C?:(*(+>=%D'H1S:N'N)D!J2"FX\!YB2!I=9K/XV+957C:)?P`I0`M[AL:.S5ZB0>,LTPO^'-\*>@P1O MEM'*1OUC?8F)FK&Q_W:5F9;<)0_>[R7_:'%8U&74.U,=`F/F0:W!&+9GKM?Y8Y!6U\[0+%]D21S55])N$([J:@C7J\K' M!$ES:[LXC8LPR8IM#N_A2WF,Q/Q#8M+3?\JZV<_06WT;:7\"=+Y!+*7]%5P- MH/D.V'\([+\$?L??`N1CCD^`+??=HD['P:M:W'.7,;+!*"YW[IW+7$;7=T#S M6IS%9#N-"P(G]/*4+&_.A(O]%#@C'9ED*^U+-14/QV^S3*.LW]=F!J"62?\: M"EDO2\/=QV4"E6\9#V7HD:`UAYC9ZF4)W^@,^?R/9<>DC"F9*KP9T\B`?,9EG$*23\\Q1H.V]LN%:NC#*T99-:,[C^V&X'?8^.T/RECOEJL:8D_U'V8UU9=Y8:!'C3'=*[M$J9>!P,H^DCQE+BR=Q MZQBNSE[0JJF,GY&\JSB$N7*5(FUE_YQ-J@-[31I1@X8<5/2*!8VML-%,E_]` M'#=K<'<(;K(H2XH_8O?VHX$HY@Q,%T[V[**1YE?\:C`:\#A"DX_2,.3-K%N& M0@M.QE]E%+^2Q[KK!I[8AJ$VMUD*?HOA.H'NC4('3GVKT,?2B(4/OA:0(F(A MLKE4=AL*>YH?@KT&>[\!Y7(1KQQ$Y?_P[L;=L\*T>[VV? MM@F^D7@*T001E_0YM%/X#).,7*6[*P.-!\A,&;DXY#/3E'/T53,`%0<0T>=( M6SP`8>*):Y]#9_=>?QAF.>=[@P%KSS[_:QN@YSY>W=UU_]^.[HAY_! M^<75\NKD8GD)[NZ7]VPN?XX+D,#62%9SO M-CE,LDS%L0SMQLYC-&>W[B@OG%*X]R6%P$DXSRFTI7_C"CC=X/(P84K5[]<0 M(&)T0ZALT*: MR!M8S$8)US#:XOWILSS/\LHQXXUIDO2)=*`)Z*W*8CK)V^/8VL]U&=<+3&I, MQ0[CGS`$+8Y57C:VBNKR1KOTW>_W)$71NN(POI+]=1/%M**[J3_I,/*;O/=DL8_&9ISQ7ASYK@?[3',#4AQ#S8E&)_OG;>%5 M,E]*LE.G8^UR;WQH;\AVPCL6IV=GESXD44X-%LD6[@1(L3D;PC1`MG^#]Z"R M;9'L;LFV%(S4%VZ431W,3DIMV%F&-EF`?2-0M_+DC'>`6LMB@#YV9ST]X+&S MEPGJQJSR]U7-ZJ)F:)(,>7&>@M[R"EPL-X/]5FTZ`.NB=1M,[7))K*^`J-`> M7JQMD&QK7`DES)Z>T)_H[WCC'2_6%K2>V*S*ZBUQ)QDNYZM.A;%TUY!:EC(F M-:\HT'0<0IKM01>DYW%>B+-0]9I93MY3:L%D\U4M`&U2[^N01EYD^$VET9%2 M'WMI@'I8Z^8%F@#-7BQX"YNX=;]]HPP#I:VL1X!R'=ASZ?UB9D_N2=1GILI^ M)\X#RS!`5#^^TX;3Q//#'7[Q2;SHT6SG?H;HZ:'I4&DK7^>(83J]4RKD=)+@ M`4XY2XC1-K$YO,\'V$*KD7M#:&N@B1C4Q&?$,&.BA(M@0$Q#B@*&AX_9\YL( MQC2:0/_H!Q'H3W\_K18\]X@M!S'E$"3.J'?7-[FV?HDJZ>&Q'XJEV0D.,+]!?>89F4 MV@DJ6)F%N*"DU?$5)O8#&8)>YV%#VN5VT%'M8&CCHT/O$"%=N548J7?3?$,) MI_?%.!%V_5Q(.2.E.F[A8XQOIJ3E5?`DFECXI%;Q(9"6.7>@I5?V=``3N@6% MK*/;>%#W\KQ0.$%8S(/D(HW@RW_"G10+#*T#,+#R"M!0$0)""1"I#W@0]#8+ M"&E7SX6(*CEB/X7)(T\QN55<2*1F=F6K])AVF.%'#*KJ^C9"]/I]7K=Q'B
UDUE=(>G@N$-SG`2[C>;=[>LAX MK[AQ:*P.?%\^)MF<_@XH@=NQYO9E>Y0E'3ES;$!2-6C]:9R>45QORZ(,2`57 M>:`@;>@B:I!K(@HA:*H*:;8`M"%HM?3!1^B,$2>\T!Z@$0<9RS3*LY<@D9]< M]*GL'E4P,C);E16!+R<1_$[M'#W(>G3$<)X%>8K@@9]T(IC9/YERJ:HLK-74 M[L#K:<,XAJH5WGV@#J'S_-#E[-5W=G4!ZX;9=B]X3-.F.!6_[3CT08XJX!\4Z@47S>O/UJOVFL\C) MJEI9+MRNTH'W2B1NT+PSCJ_)=EX@=UK0?+`Z4)`4[3I'6`]DW>+E&@A#>E"] MD%G\@?X;_1?ZQT-00*+H_P)02P,$%`````@``F.G1G51;#H$(0``Z2X"`!4` M'`!R<')X+3(P,34P,S,Q7W!R92YX;6Q55`D``Z.12U6CD4M5=7@+``$$)0X` M``0Y`0``[5UM4^/(=OZ>JOP',O*]I_>] MJ[`('UD8_9[/ZN]U/G8^GNW!#X?'^U_"]_WN8>=D[[\.NS]UCG\Z/OSOO?_M M?_F_O<\/CWO[>]^_?_\80PM%V<+'*!ON[>_S[R0T_?TIS,D>="S-?_GP4A2C MGPX.>/FW)Y9\S-CS0??P\.A@5O##I.1/;SE=*OW]:%:V<_`?7VX?HAX?=3Z^Y?$'D,'>WL\L2\@]&>R5'?BI>!^17S[D=#A*>,?+W[TP,OCE`QNQ MMU+,AT>3^G^YRJ+QD*3%11I_3@M:O-^D@XP-RUY_V./M?KN_6>K^'UD:/I.4 MMBPC_?DE7*%N1OT&CY112Q,8D_OXU(FA/3'J[5--YEM"8SZJ? MPH1/30\OA!@KOTE##OI[QY[#E/Y14G0WXHL`_,!%SD%671!6W,J[Z\,&T>"$%C<+$V2!;:74K(Z[/ MLG@<%5?DE239B.M;GXX(-$JN2!'2Q-U@-/C25A!?Q/!?^&685'8DKL&J/[*] M^<@.EVVC6\?1V0B0SC:1.%`_)U_:U#RY^/[=8#$VFLR1LA;=KX=V-,@J.UX1 M+\,D&B>3N690_8-=;^V:=(S!@=*;-[>Q,XD#%'4:WNQ9Q@&HVJV[F8.$$T4I MZ)[ MQ4I_1XSD@*8L2L(R"">=9TWW\`*5UH)X9M)%BU])N'VR8SI!,1_ M$Z@^<&6NQZR:-8X_+A&Y;*U M=UKB8%0.T_WHA29S+1BP;%A#JM.^9&:@QCET+QM-YO(/>QF#J>.7#[!S!H@# MPAB);R<2DD(H^U^*L1FC@S!_*EL=Y_O/83B:T$J2(I_]9I7?Z:^#^5QQF83Y M;!:\>*.Y@&1MG>#T^-PGUSK"ENDUA"-FN;M3+%>1767#D*8*>M<+!ZLFF`1$WJ\`X0^0K,:`GF1 MX/0((V5+),AI6R`0$W6"F*@+`!!S$-=)^"QA:JD,`#W9/:H$$,1<]1!S-8/= M)XQFL-V+KV#1T(RNI;(`O+=[W"F@B#D\W0$.KVD.1V]NS+V&W^@6N972`/YT M=WD4@A$S>;8S3$Z4TYS+2GD0P-FNL[D&1\SG.6(^)\?G>_),^:DY+;Z&0]GD M*BH*L#&>$#4LRI%(3`"'Z!F\!`$P;H&.R=N_D7CAE;6B34^QQ9<<#?V3TJU6@D;/HPV-@-R6N:$'8).)XSIAZ02R4! M=7?W.)0"D="'V2[SR$(>UOWP/GS*$@EQ2V4`J5>;>#W*!!`D9&&VN4S7@6PX MS-+2)EAZS_.[<<'CUSE`]5JHJ`@RV4'[C"DN"==-S#8@HH-5Y]Z&G'ZFL>Q6 M_C\WQOE_'\.6D@[>0=+SOGVA>3[OU&4&PHT*$M^DTZ6O/!8*HIODSL7-?2PX M.3VQ'[H2UZEI^"\HP"=H]_?Y#S)_:NT&`997*]"F"5N>"%S(RI$[])6PIRPG MMUZFB=4+)1ZF`^A"-DYYY/,[]X5T":R<#2X"\)\#>VE2UH>QO7GD*4P MB2\"-O6#5U8EZ-98<3>#PF0,2NL$711+K%+,XJ&DAM2&E5!RB]##P%E,27># M:E_N2<*C'2^SO,A+$LK>PN1FNA=NUG#0/?,U"(T[_JG:<9.AVK#EH.O5NN^0 M6/&P=R&>-DP.JEN\'F8(17<6C!E,"%;M!$<=7^/?J)\FP]VNH>#(JZ&Y/DOB MP5P#_.[O@@VNM7L8P'/CPMU@;G#H9SG51,S;5`].#WT-UWGW9-'SXH+!J5?? MG+5PQ:-,@`E/W+RIT^"6/(?)Q%`NB8T7E`I.44R7`@+6G0"BKN,)?+?S[4@# MW%>+!*?>O7`BN1[_YY MY5>`^0$'_N'WFE_#I#SR%)G7@.UZZJ"*3)',?C^%<&4\A41H+#P MVI*[CL%1Z'V1%6'B>3QG(\**]WX23BZXPSQ6IA+[2M0#65XM.$-QW==X$==B M<16FCV70:D=K<(;"]F"Y#2M[[2H:W__(K(15@%*NYYWB53%$84QRH@`:C1`-V MT&C6G_6W1*PSG0M*!^=N;]N*T[DS3PF03GV"QI#BSFA?"YB^=.;A MZD*U;XL[%5R5TKA?$4,E>MXJ88>3]H.5Q,';G*2C%Q*/$\*32I2/G:TF>S:Y MIV3>2.`W[ZY[UB3SOYU`VG#GT.YER!]Y?&JDA?%VH7FASI\9R]BT[]-)OL0W M29UZ$?_/."^,;S,W:38XP1$$M2FB=?-*78EM;*IQD%VJ!KKY^TG:MRQAY6UTC@-]-Y4XYT*XL1 M_-V_:2]XB'O'LTX=^[M!OU@95CKW*&1R_;T%* M[(3?8*N8T^>4;Q&78QZ_D.$380+:C.H!9!2N9QD9`IN<&20\KT3ZRT?4P9$! MH\:,NX(!SW.1KL*TX61WQTJX<1D7-T\#+B?8K`$0&`I3G8Q*,?$VV%J3[6(9 M].2-FXMQ\9(Q^L?"CJ#5A-6*("44=SB::(`8DZL$&2B9O\GSL37KDTI!!X=C MN#GC53SMR9`A0JI^WOQAI4[2HOJ0&"P64]J\=T%4Q[ MLFI8/MUI4@U$A,NR5H_O-43MR:RQ=+=M@E;!M:`T"`2%Z(XEEUD@.>(('&B4OY?C@0$+8*XV(QM\I*AX[)G;PB;"%N\][!L)CG&X M!&OL2&J"]1LRT)1XZ7:D3C/!B5?O8$T"FVA!!;>C:`&W>C#O]K^\C[)GZ%E, M\Z%ZAE94"4Z\.@%K4R-@6(?2402`X]B\@C":DFOZQ#(:YQU-1)ZP='#BU87G MDD,%0%H09P=`]'P+$1)\M\RM#@\6ANZAYUSZMM02;W=7;6.MV*2]3CIQS63CC# M/81<88TN4_,GP&W9H;*'HXW M/3=%AN1X*9`!'KLLECQ\/2RO@JZ3I:%5#`6/_=9?'KX>EE=`E4Q)]G42.*TP M_LX$\A"1-(09T'345LN#.'!8?>U'[#J,5AAXIZB^I?F(1'1`X9"JM>O*Z@2G M'11+M8(SF5]4B:@-1MP9Q#Z#/78VSI/W>S+*&(_^T-EV=55!2#B6836+:NK5 MX!S9@#%89^[)?,NZ>.I'JP.*6B`A'"MV'?JUN%ID!6Z:@_7T$,?-*_NU>P6# MWXLTSH8QG"XC;D:LV).G+UFI![*\'@@3AT-60IQT#.L@.3*C8AC%EUE>WB.= M/5JF.EVM%`59X'#.6M$K1K$Y>^?V*?U*BILTRH:$OVJEX'.I'(@!APO6BDP! MA/:DQ]2\_:1@5E,3!(7"EV''M1$H5S=Y=LAOT?GAN*AA*S_W]WYR;<<%BOWR MIL@P=%Q(]]M_9L?%Z2$N0UF%+%O'10GEA^,B!4'@L(*IF3)V7)1P?C@N9M;C MTT,<1B[[$;L.XX?C8MU"B"*:3,&9O>/">QJO77! MTTOZZ?-%5-#7,KY5;0DU;`163UP1)RN42LVD5OA:$R8N`7Z3OL)\UU`[!(V` M]-`ZO*RU0XIO4\^/X;.P8DOJL>M6UQ./5M?YU3X=+F-8YFE"W'X2Q(CBG+$I M!9$=4#8IS5;9E)N%U"*Q)6^4;AL;5Z\M%FFW-J[>(6(;5T]NF]8@:H6)>H,V MKAZ2J#TUBS5M7#UY.-]NF;,K*8J8QDUJB:D4W+_ZL45SS64&Y=.=LY\+2.FQ4@>.P`FTU6VL&1!4%$P3)9TL[C M.9%O*CEIQV\Z`JGDUPE:[W8KCM$-_<0=9*D'I&-,AZ$-)^)[\DK2,3%Q?*P6 M!2%@]?F6],@VAB(4CLZ._CV[$^_D9!O-5_X;GBCB<%S8L+C<=T='M"(KP@35G5*#.5=6!22#*PS>:.Y5 MHW$4=H5A=&[BTG@71VB\FD/9>-8":TUHU:\D)2Q,>"K)>$A3RJ53T%>BIU]3 M$^2$8KM51P&,H&TJ?LK_1&\QP8,H4"0/J,.R&(NSB^?>U^]Z"02Z2-(V6:W4 M`@BNKI#[YW%S"02Z2'(T67%M!`K'BY!N^/\;H<\O@.P".A,^DZ]C'N1P-RC! MYW?C(B_"-.8!OOK]N6U3($P4B[B=AM1#B>.ERNVJ3#EV'.A+V0Z($84WOQ[] MS52I(@!7+V7ZWQ=*P$\GVC49V.N1K"40)(I=Y18T22T"B2XU-@%NT>D_?:%@ MMLGV>.W"XO4$@Z6T1FM!9R5FS@B\Y.WB1>#;^G=EOG^SBM!-%#'!M26\/`!M M0/]IX@;\AO_:4&(01R`/]VU5'('?--I2R>OB".2YLK<51U!C!E7%"IA7!O!> MC2GUQYDM1K^Q!1*"I[U6FO/EKTO9-@&"\&I-L:5,0+@U6@1Q"&KN^]!REJ8D ML:);4@LP>[6&N&-8";`U80=WQ0MA=1Z44U<$*7D]G393`QN,KD(9O&M"S5<% MI;+Q>A_!#?\:>*ZB&U:\)ULT/'!7T,Q':*J/[!HSEBU8]A8'.0 M50'*=N_"`8XL:VJ1BH>.",F?QG*`)#N:@`(#2X$\!5JK+`5=?#<.N@8W#KH_ M;AQ,5NTN+K>\=(SI,+3AQD&]*)I.%ZW?O&L815-"0'#`W[Q'?-6/:Q1;4Z]! MD"H*'[F=8C3!VAIKPN;"L#I=%-YN.YTP`K4A`X*G4R2V/().3Y!==Z[IU8]< MT3Q*LGS,B-(QK:D&743AEE:+4&!S-<*%Y_R(Y3643M>_C]J(.LV>6`P,SRG4 MW]LHG2-KH)HR3_6\A8J$B.+RL*P%!<"9")7.2YEJ%P=")M M%N.K9.F3!4V?5A&BL!M8\R2"T9J#YWV8/A/-(C@O`]C]>Y@;+'HK0!R=_?QF MG."0]`^*+$H%I\3.Y6\R[/,4UBF+AWRB,D)>^@9+]$T@_?3=^0:=8PZ$$-V[(CD^0\3&[FI%BAD.OL\R3_ M[*?W19DIAHOO(8O-'XAI^`T0%(HMJ`NZ)491MZ)J@]&\GX3IUW"H,Q%4BP%X M%+%SCMD4J\PZ\#:8SF>HM&;SY8)!YQB%R7R=%#5YU=ZCM)`_?L\>7[)Q'J8Q MSPB4\(Q^DVS]-VD$`J&OA&-1&V6M&@%AH+"JBR@2'%9K8$-A:WI&_1"H@.152?@$_)/MP66YO>#==BA[7.@7;,6P$)HHCOFOLJP@:\!%2B!K0><$ MA?4%MQ)+!>?*$U11XJT^7C<+ M=H#CKC-SG.++RBL$NGK0213G\QJ2%=CDS-#B<9)L^&;ZB?\`#C-&EJF48L'C MY]C81?43KP=CJ>37"5KO=JLNJL^>5#>]K%,M#^+P'X-79^`9H&K#!?89JF]I M/B(1'5`2:XW:TCH@%ASG.#EGLL@#)2*_'@N94_*%,MAAL^)=XW=<*0>04,21 M:&0N\C(*D;3F"KGC"Y(G_B](.IEWQ@HY%K@0VK@P!0Q'S(J!',R%;(6F%JG^GZKR1[9N'H MA49A8CI'K]8!L?C/">QDCA8C:X==FCRO(M1OD&5U0"XH+$P:XB1LJU%MP(#K M8.J&'G+'=J2>H9=+`1X4`1L:@0OF8Q$.9T_=N4_#?9TQ0I\U<9-+A0`2BF@) M>VH$,%P]0^?_Z/)("^[OOTEC^DKCL79)%)8'H>RVJ4B!RM7S<5Z7PC5\?Z/% M2WGM@WOV7NCH,=/8>&NV%)S@R`6C(-A0(TQPNGHBSN_9]H62P>H4KHX4IT8LO!MI(-W4WZ"MW-Y`-=4`I@H3@3.6!1BDY"FK59:R.D*;8\ MM[HL'"9U@Q,$N?KJ[.LL$4I(MC9P^=_._PKZO4#ZW@\+#O\Z&Z?Q33I@_-?Q MMU&63K)'*&9ONX9@)^75?6C)MW@&KP-9$LNQDUDU%/B_9H4S]1&W!>+TZMO< MM`:I4$N4:+=2:0#N/$MHS#,)S(V4,V?$2Y8`IGQRL=1'Z.2\1Z(.&81,&M4/ MNAU_"3%J/M?3[>`(*3"7K\:A48&%)T+2`:\34?#0[2PM)RA#UY6H'H@'1Z() M`6D:>N5P\(15-CAJ+Z/36N.$Y8,NLK>S<;T8+2(`\4=C1KEJ586A/9>1%%X^&X3(]V108THL75F!_B*N]G MPS)GD$C:KB&0(HHX!OMQ7P-FFW)0-'PAL(OLQ2CS??D*!K_!H*[(7+-]U/7I[?9[`LJ>TX(\$/;*/;@ENGL29<]I MV:)R"[^5'@!]N&QU1@JX5>%L+BFUI^5G,G`G>Z@)YM_"9$SN25XP&A736/TR M3<-74MP-*DD:=(M5@Z:#[M$N3H5.4+L*RD6L8I,U0SPH[;5*U1J(=`>GM-I` M784-(]:=H5&++]SW\61A]N.;`$$5Z'$_GEL;%!!DGN[L4%% MGDO;/AIX<@S_G,:[9T_!D5.[B3U%GEG;/D)81"3*^*U^*=874O"[`[(@LP'$F5I;,]F MM1X@1['2-J=S'96CN*RM\7G$:I`YKQ3T.B@.E1D0 M%BZ;L'8?M-+U-B3&J[QRK^-L%@*&(_?^"A<*PJK];D.8TY?PC0['0RUI2^4` M/@KKZAHC8N($?6]#3KLO-#6CKEH.X*-8\4RI6^][*[+378PC#N!+R'XGQ2+U M(HE@22_HU+/S`"L[T5D'+%L"&>*RNVK7R5H`/2>UV[J2E$DPM#:&>@T&1SA4 MII8B--:I-4&X"@'RG!V38_ND?Q"Q6@[PH[B7T(0]B4UR'::K:!T<)N?;>C<2 MCG!L%FH8EU
,[CI\C@,XUTG?1MXE^4F3(DQ6&B0V&.DLE>8,%0(L$0NB(A MK!)P,XNWZ3,:25^NDI4/>AT4!R@+RM10<&2\DPVS,'])2#X/D9HZ)J>!4]+1 MIJP5G.(X`ML,.@-`KN)2*O/D=J,88I*6P;?B<`8N@NLD^^[E`;^*8WS>#[MX MA;5J07?EZ8%="%/PFSS?7*QFT0F*A/F(WW2K]QA?%UD6_`H%RV1).X\GLF!3 MK^]U_>;`ETI^G:#U;KV?M*"KXX]%GV2F$G\NG] M&VPN;M*[$6'EHSD744%?2YN#P4)NWQ@($NO)KJ18K!!U<;8F)4S-&PM^DZ@V M94^J"ZL06Y,=YHI`CR,Z(2B-+X89*^@?NGN2BEI!]Q3%<'>K`EK`CB(?_"N$ M_9U9R6W1TQ;.!"JLC@(I_&L`S'4\*1:Y(I-_;](^(Z.0\G1()8[/;QPZ@7%P M5[P0=I'GI%`M$?4:#+IG*`YJ;C6HB2R:QGN<3S0LA9--0?Q>MEH7PT449>.T MR/OA.]^L\TDVBM@8^DG#)YJ4`K;2,9,&0:XHG(&;UC%S6;@*3/$_C9G+U,EQ M!\2'XLSK?.MKA=]5R$J1%6&")2?3URR-0`CEF?$QXQE[TH@F9.E8\)BY.V-O M^M.P7T$1L.I65;3 M,"U@*\OO'95I>14*8]X("!#%;=6ZU(L5R19_X_`E1&=-#@`3Y-4U#V"ZX6;@4C8$XV[-P:7&Z"MWRO[T&Z!$A<7X-DK3- M"Z>M"\+"O$AI:98L4F:P764KPJ4C_-$]1I_&L%I.SP*&"K)>$<2$XAKQYK1# MAKD]KZ":R\[):A,<'6(VA-=4&5O\KIY"];]IX;#Y^Y_P#]_9OX8)W_U/LBRL M6B$4"F33#(@0Q;[7;J-BC]#54Z=8E>0"Q@QC[S`\RJR^UMJQ4A^$MH/[5PMH M$GVPM@AC>8QB6UJ!(CQD,UHAS_YF;;KUG%+SCCV'Z330:6JKA@TYR."6@@!B M3T\A5WNUN"4S"!3(#84,X-#'1!/)IL1G*-;/,;OL/]\P,$]P>ZH9.S_`5!+ M`P04````"``"8Z=&6JQ&USL*``#Y80``$0`<`')P'-D M550)``.CD4M5HY%+575X"P`!!"4.```$.0$``.UX^_QQ_Y^$B)_O#]:N&C1R(DY>RRU3DZ;B'"7.Y1]G#9^CRY=MZWT/?? M??W5AS\X#OJ!,")P0#PT?48]'.")P.X7F>BCSE'GZ#V"B^,SYQ8_.R?'G;?H M'\I3]F5+ M>C45?B)_VE;%4RQ)(JY*O6"MD!9^VXX*UZ*^Q>Y/`S"<-DHMPI3)`#-W`V(' M=.QBY_S\O*U+$]%0.@\8+]?",RRG6C0N4`UWYAQWG'737;@\9(%XWO91$O?H M@3^VXT*E=II1"X6`[F?2BTMSZO,(S=>!@AQQLG+G^?*J)$>!LD(V"#D@101U MUWK[E6(%B"`(?<",<0@M$)+TO7JR7%(VX_$M/%#]^T(!GH`Z4A>?[V^,D4%[ MUN-NJ"),EWE]%M#@^08LBH6NIX4H-(Y58EUW4KM'9I11C;)SW(&8F*BG+\$4 MBFRAE+$/[:R%K[_*F@\E\8;L.WT-_$FPIG55T(CU8Q&[[J:2LIHN]MW0-U8: MJ[6WJ$B9K,+1%6<>85`#7$CN4T_UVH_85Y%O/"3L?)T`26-H4!(3 M=C6\Z_7OQOV>NAH/!S>][@1N/G8'W;NK/AI_ZO-W<^[DQL0:"@U4YI+S#C@[IOX7U/_[YYO)SPVI!Y.:'Y`K*=OI?G3O*W58+T57?\"5T/AC\V0=I$Z%`\8$9_UW5N9DQ85`PH M#$1O'9P+R-D)?*\6+52Z/I>A('"3MOAGM+&),*QHUE8;X@S$W9-'JO;4AK.1 MH%S\3+"0UY1!;DNQOQEA$7M%A>T4GF,;&G_`I1P1,9Y##A"U_-83>[-W MLLVN=!$H(ZW=-+JAT77.IS:](358J`Z:VB8SE-F).,D2H:TX'Y49E+;34&), M[A8+&NA`#1,[9&P!92#@4K+.YLP"=G)V-D\VEO1\OV6K(:ARLC;!4S]AJ["T MG;JS:HD;>A-9;]92!V9P:4K+J=AYS>Z2E$[F&H9+9G5I)O.+[(QE-SJR"5Y# M2)E,+\U&SG,[%=_:L[Z&B<.GLI'@7N@&/?)(?+Y477Y$EP2J(CT28.H7GN7V M&[)S77'G`KV)*T:IFE%2]3?H35Q[TT>J]Y&NYVEGL)]Z]UVR>UAMV'O&SH9( MT9ZQJ3/]TK[I$R^6-&WU@9(Z5LY/=K99*N1-#L;/!5*%'I`(_;0+_`6NI+>X-978Z3_?MES>DE%I/76VJ M'\[2!5M4E=*P$[BS,95=@Z7LJR&Z7=R,N7+T[H_`A:7MM+[=1VN3/%?E,_^] MRGYF*^C9.7Y7]%U-PW9UMBUO:_937E79SOO.MIGU/5!#?MJ@^J/&X#V9(7WZ MYD(=;+AL2;I8^NK4CGXV%V1VV5*GF)SDM-(OX/31:N$G(JH&RSD@W7>R[117 MG)B(SW+83P>!$;XD(@`FVPGX%FJ_H&/`2%G'MDFLIUL^GI9U"U2(7U^/8`"4 M]2@S9E[6KVB\I<_\P%WZ3)!^!&YQ$2"6>\;0='@N.IXXX*XV95%1=TZBYZA' M3N?$.>TD2[2$])=-1%A0%K/T1PH+P)R$*MJEH(QU*7K4"$*FG5 M4I`F4NY-M)X7BOA;5$9]7WW'D$D5NRF!*1.!2=CK_P^`)3]KH>Y8$RX!\)3GR?K&J#/0O(C%M] MK2&'8DS$(W6)'!.7,P^+YRL(\P]<&%1P&M>M]TL^-?&>"' MNM_3%-:#UW*(#9ZOM3X]+_D#9]BC*9H!8F6%_ID.(O?5P\HGE*?JETN_='I_V)J MFH.F<,,IR4Q-!B\6<( M5WKC(Y/4+J"'!#`GE.JPT5YCL.ML)#J-?ACELN4*XM&@>!N4\L+>$B,B)`1$ MXO^_.6\$;IH1L?=?/*Q?BM5N#.^%:DRK!`R"'[$0T.ZUF?1R45D]^%A/ M%[*P##Y,GOADSD.)F:=6HSZ,3!;]Q,8-]'=8G#Z2$73]VCA7$J_!:\O;Z]J- MK_U83=3.J?!&6`3/]6%O!Y(!^U]#1KE0DM2E2ZQ<'@DR(Q`U/?TM2&U<*HS4 MN&.U@(R.NK5Q*`O(@/N:"T(?ZA,8,GA,*T;F$0EB:E^^IAUJ/T1+4.-,2_*E MJD5/Q]DD6#][Y86,$5GY\%RCW+X82H.+-PPFKH"+VG2[+"`#[J(GC&'-^M$' MOM<7&1>#Y/DK=\4#\.]=B?:%X.**PWAU%0S5*W0E(^U!U_LUE%%W6?^HE9[` MZ]9$+^F0J)_`%!+`0(>`Q0` M```(``)CIT:]0$[4&#T``!@^`P`1`!@```````$```"D@0````!R<')X+3(P M,34P,S,Q+GAM;%54!0`#HY%+575X"P`!!"4.```$.0$``%!+`0(>`Q0````( M``)CIT:.RU!G\P4``"Q"```5`!@```````$```"D@6,]``!R<')X+3(P,34P M,S,Q7V-A;"YX;6Q55`4``Z.12U5U>`L``00E#@``!#D!``!02P$"'@,4```` M"``"8Z=&MH^&(S0>``"XVP$`%0`8```````!````I(&E0P``"TR,#$U M,#,S,5]D968N>&UL550%``.CD4M5=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@``F.G1JV/[N7N*@``]E<"`!4`&````````0```*2!*&(``')P`Q0` M```(``)CIT9U46PZ!"$``.DN`@`5`!@```````$```"D@66-``!R<')X+3(P M,34P,S,Q7W!R92YX;6Q55`4``Z.12U5U>`L``00E#@``!#D!``!02P$"'@,4 M````"``"8Z=&6JQ&USL*``#Y80``$0`8```````!````I(&XK@``"TR M,#$U,#,S,2YX`L``00E#@``!#D!``!02P4&``````8` ,!@`:`@``/KD````` ` end XML 27 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9

Document And Entity Information
3 Months Ended

Mar. 31, 2015

May 01, 2015

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q1

Entity Registrant Name REPROS THERAPEUTICS INC.

Entity Central Index Key 0000897075

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Trading Symbol RPRX

Entity Common Stock, Shares Outstanding 24,276,173dei_EntityCommonStockSharesOutstanding

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 28 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9

Organization, Operations and Liquidity (Product Development Pipeline) (Details)
3 Months Ended

Mar. 31, 2015

Enclomiphene [Member] | Secondary Hypogonadism [Member]

Product Information [Line Items]

Status NDA accepted and under review

Next Expected Milestone(s) PDUFA date of November 30, 2015

Proellex [Member] | Uterine Fibroids 1 [Member]

Product Information [Line Items]

Status Phase 2

Next Expected Milestone(s) Complete first course of treatment in a Phase 2B study (oral delivery) (YE 2015) Complete first course of treatment in a Phase 2B study (vaginal delivery) (YE 2015)

Proellex [Member] | Endometriosis [Member]

Product Information [Line Items]

Status Phase 2

Next Expected Milestone(s) Fully enroll Phase 2 study (oral delivery) (YE 2015)

X

- Definition

Product Next Expected Milestone

+ References

No definition available.

+ Details

Name: rprx_ProductNextExpectedMilestone

Namespace Prefix: rprx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Product Status

+ References

No definition available.

+ Details

Name: rprx_ProductStatus

Namespace Prefix: rprx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ProductInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ProductOrServiceAxis=rprx_EnclomipheneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=rprx_ProellexMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Revenues and other income

Interest income $ 1us-gaap_InvestmentIncomeInterest $ 2us-gaap_InvestmentIncomeInterest

Total revenues and other income 1us-gaap_Revenues 2us-gaap_Revenues

Expenses

Research and development 7,321us-gaap_ResearchAndDevelopmentExpense 7,569us-gaap_ResearchAndDevelopmentExpense

General and administrative 1,205us-gaap_GeneralAndAdministrativeExpense 1,226us-gaap_GeneralAndAdministrativeExpense

Total expenses 8,526us-gaap_CostsAndExpenses 8,795us-gaap_CostsAndExpenses

Net loss $ (8,525)us-gaap_NetIncomeLoss $ (8,793)us-gaap_NetIncomeLoss

Loss per share - basic and diluted $ (0.35)us-gaap_EarningsPerShareBasicAndDiluted $ (0.38)us-gaap_EarningsPerShareBasicAndDiluted

Shares used in loss per share calculation:

Basic 24,276 23,033

Diluted 24,276 23,033

X

- Definition

Total costs of sales and operating expenses for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 30 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock-Based Compensation
3 Months Ended

Mar. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

NOTE 5 – Stock-Based Compensation

During the three month period ended March 31, 2015, the Compensation Committee of the Company’s Board of Directors approved grants of options to purchase 369,000 shares of our common stock to certain employees and directors under the 2011 Equity Incentive Plan. All of these options vest in equal annual installments on the first three year anniversaries of the date of grant. Additionally, during the three month period ended March 31, 2015, 5,000 options either expired or were forfeited.

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9

Loss Per Share
3 Months Ended

Mar. 31, 2015

Earnings Per Share [Abstract]

Loss Per Share

NOTE 4 — Loss Per Share

Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed using the average share price for the period and applying the treasury stock method to potentially dilutive outstanding options. In all applicable periods, all potential common stock equivalents were anti-dilutive and, accordingly, were not included in the computation of diluted loss per share.

The following table presents information necessary to calculate loss per share for the three month periods ended March 31, 2015 and 2014 (in thousands, except per share amounts):

Three Months Ended March 31,

2015

2014

Net loss

$

(8,525)

$

(8,793)

Average common shares outstanding

24,276

23,033

Basic and diluted loss per share

$

(0.35)

$

(0.38)

Potential common stock of 3,274,157 and 4,086,885 common shares underlying stock options and warrants for the periods ended March 31, 2015 and 2014, respectively, were excluded from the above calculation of diluted loss per share because they were anti-dilutive. Other potential common stock at March 31, 2015 includes Series A Warrants to purchase 39,595 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 429,704 shares of our common stock at an exercise price of $2.49 issued in our February 8, 2011 public offering. Other potential common stock at March 31, 2014 includes Series A Warrants to purchase 877,137 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 809,805 shares of our common stock at an exercise price of $2.49 issued in our February 8, 2011 public offering.

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9

Accrued Expenses (Details) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2015

Dec. 31, 2014

Schedule Of Accrued Liabilities [Line Items]

Research and development costs $ 654 $ 284

Personnel related costs 63rprx_AccruedPersonnelExpenseCurrent 458rprx_AccruedPersonnelExpenseCurrent

Other 76us-gaap_OtherAccruedLiabilitiesCurrent 92us-gaap_OtherAccruedLiabilitiesCurrent

Total $ 793us-gaap_AccruedLiabilitiesCurrent $ 834us-gaap_AccruedLiabilitiesCurrent

X

- Definition

Accrued Personnel Expense Current

+ References

No definition available.

+ Details

Name: rprx_AccruedPersonnelExpenseCurrent

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accrued Research and Development Expense, Current

+ References

No definition available.

+ Details

Name: rprx_AccruedResearchAndDevelopmentExpenseCurrent

Namespace Prefix: rprx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: rprx_ScheduleOfAccruedLiabilitiesLineItems

Namespace Prefix: rprx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 33 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9

Organization, Operations and Liquidity (Additional Information) (Details) (USD $)

Mar. 31, 2015

Dec. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Product Information [Line Items]

Deficit accumulated during the development stage $ 281,600,000

Cash and cash equivalents 37,875,000 46,620,000 68,012,000 75,807,000

Accounts payable and accrued expenses $ 2,000,000

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_ProductInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9

Revision of Prior Years' Financial Statements (Tables)
3 Months Ended

Mar. 31, 2015

Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements [Abstract]

Schedule of Error Corrections and Prior Period Adjustments

The effects of the error correction on the consolidated statements of operations for the three month period ended March 31, 2014 are as follows (in thousands):

Three months ended March 31, 2014

As previously
reported

Correction

As revised

Research and development

$

7,325

$

244

$

7,569

Total expenses

8,551

244

8,795

Net loss

(8,549)

(244)

(8,793)

Loss per share – basic and diluted

(0.37)

(0.01)

(0.38)

Schedule Of Error Corrections And Prior Period Adjustments Cash flows

The effects of the error correction on the consolidated statements of cash flows for the three month period ended March 31, 2014 are as follows (in thousands):

Three months ended March 31, 2014

As previously
reported

Correction

As revised

Net cash used in operating activities

$

(7,614)

$

(285)

$

(7,899)

Net cash used in investing activities

(285)

285

(0)

X

- Definition

Tabular disclosure of prior period adjustments to Consolidated statement of cash flows.

+ References

No definition available.

+ Details

Name: rprx_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsCashFlowsTableTextBlock

Namespace Prefix: rprx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_QuantifyingPriorYearMisstatementsCorrectedInCurrentYearFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22644-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22663-107794

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22658-107794

+ Details

Name: us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9

Commitments and Contingencies
3 Months Ended

Mar. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 6 — Commitments and Contingencies

Therapeutic uses of our enclomiphene product candidate are covered in the United States by nine issued U.S. patents and nine pending patent applications. Foreign coverage of therapeutic uses of our enclomiphene product candidate includes 76 issued foreign patents and 99 foreign pending patent applications. The issued patents and pending applications relate to methods for treating certain conditions including the treatment of testosterone deficiency in men, the treatment of diabetes mellitus Type 2, the treatment of metabolic syndrome and conditions associated therewith, and the treatment of infertility in hypogonadal men. Enclomiphene (the trans-isomer of clomiphene) is purified from clomiphene citrate. A third party individual holds two issued patents related to the use of anti-estrogen such as clomiphene citrate and others for use in the treatment of androgen deficiency and disorders related thereto. We requested re-examination of one of these patents by the U.S. Patent and Trademark Office (“PTO”) based on prior art. The patent holder amended the claims in the re-examination proceedings, which led the PTO to determine that the amended claims were patentable in view of those publications under consideration and a re-examination certificate was issued. We subsequently filed a second request for re-examination by the PTO in light of a number of additional publications. The request was granted and all of the claims were finally rejected by the PTO in the re-examination. The patent holder appealed the rejections to the PTO Board of Patent Appeals and Interferences (the “PTO Board”) which ultimately reversed the rejections of several dependent claims in view of those publications under consideration. The patent holder filed a Notice of Appeal to the Federal Circuit on September 28, 2010 contesting the rejections maintained by the PTO Board. A decision was rendered by the Court of Appeals for the Federal Circuit on December 12, 2011, affirming the rejection of the appealed claims. The PTO issued an Ex Parte Reexamination Certificate on April 29, 2013, canceling the rejected claims and confirming the patentability of the remaining claims. Nevertheless, we believe that our development of enclomiphene does not infringe any of the remaining claims and that all of the remaining claims are invalid on various grounds including additional prior art publications. We also believe that the second of these two patents is invalid in view of published prior art not considered by the PTO. If necessary, we intend to vigorously defend any and all claims that may be brought by the holder of such patents in a court of competent jurisdiction in order to develop enclomiphene further. Adverse determinations in litigation proceedings could require us to seek licenses which may not be available on commercially reasonable terms, or at all, or subject us to significant liabilities, in which case we may not be able to successfully commercialize or out-license enclomiphene until such patents expire or are otherwise no longer in force.

On July 19, 2013, we received a letter from Dr. Harry Fisch threatening to file a lawsuit against us and two of our executive officers (Joseph S. Podolski, President and Chief Executive Officer and Ron Wiehle, Executive Vice President), seeking addition of Dr. Harry Fisch as an inventor on three of our patents, U.S. Patent Nos. 7,173,064, 7,737,185 and 7,759,360, covering therapeutic uses of enclomiphene. We believe that these allegations are without merit and on August 2, 2013, we commenced a lawsuit against Dr. Fisch in the U.S. District Court for the Southern District of Texas seeking a declaratory judgment that he should not be added as inventor to any of these patents. On October 2, 2013, Dr. Fisch filed counterclaims to our complaint seeking correction of inventorship of the three patents at issue to name Dr. Fisch as a co-inventor of the applications leading to these patents. Dr. Fisch subsequently stipulated that he does not claim to be a co-inventor of U.S. Patent No. 7,173,064. The court granted summary judgment in favor of the Company on separate equitable and legal grounds, and entered judgment on December 23, 2014. Our request for attorney’s fees was denied. On February 9, 2015, Dr. Fisch filed a notice of appeal of the summary judgment rulings to the United States Court of Appeals for the Federal Circuit.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9

Organization, Operations and Liquidity (Tables)
3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Product Development Pipeline

Our product development pipeline, with dates as expected as of the date of this report, is summarized in the table below:

Product Candidate (Indication)

Enclomiphene

Status

Next Expected Milestone(s)

Secondary Hypogonadism

NDA accepted and under review

PDUFA date of November 30, 2015

Proellex®

Uterine Fibroids

Phase 2

Complete first course of treatment in a Phase 2B study (oral delivery) (YE 2015)

Complete first course of treatment in a Phase 2B study (vaginal delivery) (YE 2015)

Endometriosis

Phase 2

Fully enroll Phase 2 study (oral delivery) (YE 2015)

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of product information that are included in the discussion of the nature of an entity's operations.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfProductInformationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9

Accrued Expenses (Tables)
3 Months Ended

Mar. 31, 2015

Accrued Expenses [Abstract]

Accrued Expenses

Accrued expenses consist of the following (in thousands):

March 31, 2015

December 31, 2014

Research and development costs

$

654

$

284

Personnel related costs

63

458

Other

76

92

Total

$

793

$

834

X

- Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9

Revision of Prior Years' Financial Statements (Details 1) (USD $)
In Thousands, unless otherwise specified
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Net cash used in operating activities $ (8,847) $ (7,899)

Net cash used in investing activities 0 0

As Previously Reported [Member]

Net cash used in operating activities (7,614)

Net cash used in investing activities (285)

Correction [Member]

Net cash used in operating activities (285)

Net cash used in investing activities $ 285

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock-Based Compensation (Additional Information) (Details) (2011 Equity Incentive Plan Member)
3 Months Ended

Mar. 31, 2015

2011 Equity Incentive Plan Member

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 369,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 5,000

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 40 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)
In Thousands, except Share data

Total

Common Stock

Additional Paid-in Capital

Treasury Stock

Accumulated Deficit

Beginning Balance at Dec. 31, 2013 $ 72,519us-gaap_StockholdersEquity $ 23 $ 314,405 $ (1,380) $ (240,529)

Beginning Balance (in shares) at Dec. 31, 2013 23,125,565 112,350

Stock based option compensation 920 0 920 0 0

Issuance of 69,197 shares of common stock for the cashless exercise of 91,664 stock options 0 0 0 0 0

Issuance of 69,197 shares of common stock for the cashless exercise of 91,664 stock options (in shares) 69,197 0

Exercise of stock options to purchase common stock stock for cash ($1.56 to $9.60 per share) 104 0 104 0 0

Exercise of stock options to purchase common stock stock for cash ($1.56 to $9.60 per share) (in shares) 15,000 0

Net loss (8,793)us-gaap_NetIncomeLoss 0 0 0 (8,793)

Ending Balance at Mar. 31, 2014 64,750us-gaap_StockholdersEquity 23 315,429 (1,380) (249,322)

Ending Balance (in shares) at Mar. 31, 2014 23,209,762 112,350

Beginning Balance at Dec. 31, 2014 44,017us-gaap_StockholdersEquity 24 318,437 (1,380) (273,064)

Beginning Balance (in shares) at Dec. 31, 2014 24,388,523 112,350

Stock based option compensation 1,022 0 1,022 0 0

Net loss (8,525)us-gaap_NetIncomeLoss 0 0 0 (8,525)

Ending Balance at Mar. 31, 2015 $ 36,514us-gaap_StockholdersEquity $ 24 $ 319,459 $ (1,380) $ (281,589)

Ending Balance (in shares) at Mar. 31, 2015 24,388,523 112,350

X

- Definition

This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).

+ References

No definition available.

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock issued as a result of the exercise of stock options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 41 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9

Accrued Expenses
3 Months Ended

Mar. 31, 2015

Accrued Expenses [Abstract]

Accrued Expenses

NOTE 3 — Accrued Expenses

Accrued expenses consist of the following (in thousands):

March 31, 2015

December 31, 2014

Research and development costs

$

654

$

284

Personnel related costs

63

458

Other

76

92

Total

$

793

$

834

X

- Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9

Commitments and Contingencies (Additional Information) (Details)
3 Months Ended

Mar. 31, 2015

Domestic [Member]

Commitments and Contingencies [Line Items]

Number of patents 9

Number of pending patent applications 9

Foreign [Member]

Commitments and Contingencies [Line Items]

Number of patents 76

Number of pending patent applications 99

Third Party [Member]

Commitments and Contingencies [Line Items]

Number of patents 2

X

- Details

Name: rprx_CommitmentsAndContingenciesLineItems

Namespace Prefix: rprx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of entity's patents that another entity was found to have infringed.

+ References

No definition available.

+ Details

Name: us-gaap_GainContingencyPatentsFoundInfringedUponNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of entity's patents that another entity was found not to have infringed.

+ References

No definition available.

+ Details

Name: us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementGeographicalAxis=rprx_DomesticMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=rprx_ForeignMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=rprx_ThirdPartyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 51 90 1 false 20 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.zonagen.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.zonagen.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.zonagen.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.zonagen.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 105 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.zonagen.com/role/ConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY false false R6.htm 106 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.zonagen.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) false false R7.htm 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.zonagen.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R8.htm 108 - Disclosure - Organization, Operations and Liquidity Sheet http://www.zonagen.com/role/OrganizationOperationsAndLiquidity Organization, Operations and Liquidity false false R9.htm 109 - Disclosure - Revision of Prior Years' Financial Statements Sheet http://www.zonagen.com/role/RevisionOfPriorYearsFinancialStatements Revision of Prior Years' Financial Statements false false R10.htm 110 - Disclosure - Accrued Expenses Sheet http://www.zonagen.com/role/AccruedExpenses Accrued Expenses false false R11.htm 111 - Disclosure - Loss Per Share Sheet http://www.zonagen.com/role/LossPerShare Loss Per Share false false R12.htm 112 - Disclosure - Stock-Based Compensation Sheet http://www.zonagen.com/role/StockbasedCompensation Stock-Based Compensation false false R13.htm 113 - Statement - Commitments and Contingencies Sheet http://www.zonagen.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R14.htm 114 - Disclosure - Organization, Operations and Liquidity (Tables) Sheet http://www.zonagen.com/role/OrganizationOperationsAndLiquidityTables Organization, Operations and Liquidity (Tables) false false R15.htm 115 - Statement - Revision of Prior Years' Financial Statements (Tables) Sheet http://www.zonagen.com/role/RevisionOfPriorYearsFinancialStatementsTables Revision of Prior Years' Financial Statements (Tables) false false R16.htm 116 - Statement - Accrued Expenses (Tables) Sheet http://www.zonagen.com/role/AccruedExpensesTables Accrued Expenses (Tables) false false R17.htm 117 - Disclosure - Loss Per Share (Tables) Sheet http://www.zonagen.com/role/LossPerShareTables Loss Per Share (Tables) false false R18.htm 118 - Disclosure - Organization, Operations and Liquidity (Product Development Pipeline) (Details) Sheet http://www.zonagen.com/role/OrganizationOperationsAndLiquidityProductDevelopmentPipelineDetails Organization, Operations and Liquidity (Product Development Pipeline) (Details) false false R19.htm 119 - Disclosure - Organization, Operations and Liquidity (Additional Information) (Details) Sheet http://www.zonagen.com/role/OrganizationOperationsAndLiquidityAdditionalInformationDetails Organization, Operations and Liquidity (Additional Information) (Details) false false R20.htm 120 - Disclosure - Revision of Prior Years' Financial Statements (Details) Sheet http://www.zonagen.com/role/RevisionOfPriorYearsFinancialStatementsDetails Revision of Prior Years' Financial Statements (Details) false false R21.htm 121 - Disclosure - Revision of Prior Years' Financial Statements (Details 1) Sheet http://www.zonagen.com/role/RevisionOfPriorYearsFinancialStatementsDetails1 Revision of Prior Years' Financial Statements (Details 1) false false R22.htm 122 - Disclosure - Revision of Prior Years' Financial Statements (Additional information) (Details) Sheet http://www.zonagen.com/role/RevisionOfPriorYearsFinancialStatementsAdditionalInformationDetails Revision of Prior Years' Financial Statements (Additional information) (Details) false false R23.htm 123 - Disclosure - Accrued Expenses (Details) Sheet http://www.zonagen.com/role/AccruedExpensesDetails Accrued Expenses (Details) false false R24.htm 124 - Disclosure - Loss Per Share (Calculation of Loss Per Share) (Details) Sheet http://www.zonagen.com/role/LossPerShareCalculationOfLossPerShareDetails Loss Per Share (Calculation of Loss Per Share) (Details) false false R25.htm 125 - Disclosure - Loss Per Share (Additional Information) (Details) Sheet http://www.zonagen.com/role/LossPerShareAdditionalInformationDetails Loss Per Share (Additional Information) (Details) false false R26.htm 126 - Disclosure - Stock-Based Compensation (Additional Information) (Details) Sheet http://www.zonagen.com/role/StockbasedCompensationAdditionalInformationDetails Stock-Based Compensation (Additional Information) (Details) false false R27.htm 127 - Disclosure - Commitments and Contingencies (Additional Information) (Details) Sheet http://www.zonagen.com/role/CommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies (Additional Information) (Details) false false All Reports Book All Reports 'Monetary' elements on report '119 - Disclosure - Organization, Operations and Liquidity (Additional Information) (Details)' had a mix of different decimal attribute values. Process Flow-Through: 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Mar. 31, 2014' Process Flow-Through: Removing column 'Dec. 31, 2013' Process Flow-Through: 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 106 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Process Flow-Through: 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Process Flow-Through: 113 - Statement - Commitments and Contingencies Process Flow-Through: 115 - Statement - Revision of Prior Years' Financial Statements (Tables) Process Flow-Through: 116 - Statement - Accrued Expenses (Tables) rprx-20150331.xml rprx-20150331.xsd rprx-20150331_cal.xml rprx-20150331_def.xml rprx-20150331_lab.xml rprx-20150331_pre.xml true true XML 44 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9

Revision of Prior Years' Financial Statements (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Research and development $ 7,321us-gaap_ResearchAndDevelopmentExpense $ 7,569us-gaap_ResearchAndDevelopmentExpense

Total expenses 8,526us-gaap_CostsAndExpenses 8,795us-gaap_CostsAndExpenses

Net loss (8,525)us-gaap_NetIncomeLoss (8,793)us-gaap_NetIncomeLoss

Loss per share - basic and diluted $ (0.35)us-gaap_EarningsPerShareBasicAndDiluted $ (0.38)us-gaap_EarningsPerShareBasicAndDiluted

As Previously Reported [Member]

Research and development 7,325

Total expenses 8,551

Net loss (8,549)

Loss per share - basic and diluted $ (0.37)

Correction [Member]

Research and development 244

Total expenses 244

Net loss $ (244)

Loss per share - basic and diluted $ (0.01)

X

- Definition

Total costs of sales and operating expenses for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Document And Entity Information	3 Months Ended
Document And Entity Information	Mar. 31, 2015	May 01, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	REPROS THERAPEUTICS INC.
Entity Central Index Key	0000897075
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	RPRX
Entity Common Stock, Shares Outstanding		24,276,173dei_EntityCommonStockSharesOutstanding

Organization, Operations and Liquidity (Product Development Pipeline) (Details)	3 Months Ended
	Mar. 31, 2015
Enclomiphene [Member] \| Secondary Hypogonadism [Member]
Product Information [Line Items]
Status	NDA accepted and under review
Next Expected Milestone(s)	PDUFA date of November 30, 2015
Proellex [Member] \| Uterine Fibroids 1 [Member]
Product Information [Line Items]
Status	Phase 2
Next Expected Milestone(s)	Complete first course of treatment in a Phase 2B study (oral delivery) (YE 2015) Complete first course of treatment in a Phase 2B study (vaginal delivery) (YE 2015)
Proellex [Member] \| Endometriosis [Member]
Product Information [Line Items]
Status	Phase 2
Next Expected Milestone(s)	Fully enroll Phase 2 study (oral delivery) (YE 2015)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenues and other income
Interest income	$ 1us-gaap_InvestmentIncomeInterest	$ 2us-gaap_InvestmentIncomeInterest
Total revenues and other income	1us-gaap_Revenues	2us-gaap_Revenues
Expenses
Research and development	7,321us-gaap_ResearchAndDevelopmentExpense	7,569us-gaap_ResearchAndDevelopmentExpense
General and administrative	1,205us-gaap_GeneralAndAdministrativeExpense	1,226us-gaap_GeneralAndAdministrativeExpense
Total expenses	8,526us-gaap_CostsAndExpenses	8,795us-gaap_CostsAndExpenses
Net loss	$ (8,525)us-gaap_NetIncomeLoss	$ (8,793)us-gaap_NetIncomeLoss
Loss per share - basic and diluted	$ (0.35)us-gaap_EarningsPerShareBasicAndDiluted	$ (0.38)us-gaap_EarningsPerShareBasicAndDiluted
Shares used in loss per share calculation:
Basic	24,276	23,033
Diluted	24,276	23,033

Accrued Expenses (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Schedule Of Accrued Liabilities [Line Items]
Research and development costs	$ 654	$ 284
Personnel related costs	63rprx_AccruedPersonnelExpenseCurrent	458rprx_AccruedPersonnelExpenseCurrent
Other	76us-gaap_OtherAccruedLiabilitiesCurrent	92us-gaap_OtherAccruedLiabilitiesCurrent
Total	$ 793us-gaap_AccruedLiabilitiesCurrent	$ 834us-gaap_AccruedLiabilitiesCurrent

Organization, Operations and Liquidity (Additional Information) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
Product Information [Line Items]
Deficit accumulated during the development stage	$ 281,600,000
Cash and cash equivalents	37,875,000	46,620,000	68,012,000	75,807,000
Accounts payable and accrued expenses	$ 2,000,000

Stock-Based Compensation (Additional Information) (Details) (2011 Equity Incentive Plan Member)	3 Months Ended
	Mar. 31, 2015
2011 Equity Incentive Plan Member
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	369,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	5,000

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $) In Thousands, except Share data	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit
Beginning Balance at Dec. 31, 2013	$ 72,519us-gaap_StockholdersEquity	$ 23	$ 314,405	$ (1,380)	$ (240,529)
Beginning Balance (in shares) at Dec. 31, 2013		23,125,565		112,350
Stock based option compensation	920	0	920	0	0
Issuance of 69,197 shares of common stock for the cashless exercise of 91,664 stock options	0	0	0	0	0
Issuance of 69,197 shares of common stock for the cashless exercise of 91,664 stock options (in shares)		69,197		0
Exercise of stock options to purchase common stock stock for cash ($1.56 to $9.60 per share)	104	0	104	0	0
Exercise of stock options to purchase common stock stock for cash ($1.56 to $9.60 per share) (in shares)		15,000		0
Net loss	(8,793)us-gaap_NetIncomeLoss	0	0	0	(8,793)
Ending Balance at Mar. 31, 2014	64,750us-gaap_StockholdersEquity	23	315,429	(1,380)	(249,322)
Ending Balance (in shares) at Mar. 31, 2014		23,209,762		112,350
Beginning Balance at Dec. 31, 2014	44,017us-gaap_StockholdersEquity	24	318,437	(1,380)	(273,064)
Beginning Balance (in shares) at Dec. 31, 2014		24,388,523		112,350
Stock based option compensation	1,022	0	1,022	0	0
Net loss	(8,525)us-gaap_NetIncomeLoss	0	0	0	(8,525)
Ending Balance at Mar. 31, 2015	$ 36,514us-gaap_StockholdersEquity	$ 24	$ 319,459	$ (1,380)	$ (281,589)
Ending Balance (in shares) at Mar. 31, 2015		24,388,523		112,350

Commitments and Contingencies (Additional Information) (Details)	3 Months Ended
	Mar. 31, 2015
Domestic [Member]
Commitments and Contingencies [Line Items]
Number of patents	9
Number of pending patent applications	9
Foreign [Member]
Commitments and Contingencies [Line Items]
Number of patents	76
Number of pending patent applications	99
Third Party [Member]
Commitments and Contingencies [Line Items]
Number of patents	2